Affiliation Disclosure & Disclaimer:

The managing principal of Ridire Research is affiliated with a private investment fund that holds long positions in the securities discussed herein (LXP Industrial Trust, LXP), which could influence the views expressed. This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

1. Why This Story Is Different

2. Start With What Already Works

3. The Real Story Is the Development Spread

4. Phoenix Is the Bridge From Optionality to Reported Earnings

5. Why This Deserves More Credit Than a Typical Land Narrative

6. The Balance Sheet Makes the Optionality Actionable

7. What Has to Happen for the Stock to Work

8. What Would Break It

9. Bottom Line

Why This Story Is Different

LXP is not a direct AI stock. But it may be an indirect AI and MAGA/protectionist winner: its Phoenix land bank sits in the path of semiconductor reshoring, advanced manufacturing migration, and a broader policy push to localize strategic supply chains.

Most REITs are not transformation stories rather they are cash-flow vehicles. Investors buy current income, modest rent growth, balance-sheet discipline, and some NAV accretion over time. LXP is more interesting because it may no longer fit neatly inside that box.

The company today looks like a credible, stabilized industrial landlord. But inside that stabilized portfolio sits something more valuable than “extra land.” It sits on a development pipeline that could convert dormant carrying value into future NOI, NAV creation, and a better growth profile than a standard industrial REIT screen implies.

There is also a timely macro layer here that makes the story more relevant than a normal land-bank pitch. LXP is not an AI stock in the conventional sense, but it is arguably an indirect beneficiary of the same capex cycle. Management has pointed to advanced manufacturing tailwinds tied to TSMC and semiconductor supply-chain migration into Phoenix.

That makes LXP a second-order AI infrastructure and domestic industrial-policy beneficiary because it owns land in a market that may increasingly absorb the warehousing, logistics, and supplier footprint created by semiconductor reshoring and protectionist supply-chain realignment. This is not really a “land story.” It is a land-to-NOI conversion story with a potentially favorable macro backdrop.

Start With What Already Works

• As of year-end 2025, the company owned 108 properties totaling 52.7 million square feet. Roughly 92.6% of square footage was Class A. The portfolio was 97.1% leased with a weighted-average lease term of 4.8 years. It also controlled 514 acres of developable land. The stock does not require a heroic view on development to be investable. The base business is already a modern industrial platform with solid occupancy and a reasonably clean portfolio.

• The internal earnings bridge also looks better than a simple REIT screen may suggest. Management’s fourth-quarter presentation notes that leases expiring through 2030 carry an estimated current mark-to-market of roughly 16%, enough to increase initial annual cash rent by about $29 million, or roughly $0.48 per share, equal to about 15% of FFO. The same presentation says LXP has 1.5 million square feet available for lease, which could add another roughly $16 million of initial annual cash rent, or about $0.28 per share. Layer in average annual rental escalations of 2.8%, with 2025 signed leases carrying average annual escalations of 3.2%, and the existing portfolio already has credible internal growth. Even before the development pipeline contributes meaningfully, LXP has a clear path to higher rents, better occupancy, and incremental earnings.

The Real Story Is the Development Spread

The market usually values REITs by capitalizing current or near-term NOI. That works well for stabilized portfolios. It works poorly when part of the asset base is held in land that generates little current income but can be developed into higher-value industrial product. In those cases, book value can be a misleading anchor. The relevant economic question is not what the land is worth sitting still. It is what the company can earn by building on it.

LXP’s filings show land held for development at roughly $82.97 million on the consolidated balance sheet, with another $11.47 million in non-consolidated land projects. The consolidated land table shows 315 acres in Phoenix carried at about $75.4 million. But the heart of the thesis is whether LXP can convert that land into stabilized industrial product at returns above what the market will ultimately pay for those assets.

If LXP can consistently develop industrial assets at 7%-plus stabilized cash yields and the market values comparable stabilized product at materially tighter cap rates, the value creation is mechanical. The land bank becomes a pipeline of future NAV accretion rather than a passive balance-sheet line item.

Phoenix Is the Bridge From Optionality to Reported Earnings

Phoenix is the clearest expression of that mechanism.

In its 2025 annual letter, management says the company’s 514-acre land bank includes 315 acres in Phoenix. It has already broken ground on a 1.2 million square foot speculative development project there with projected completion in the first half of 2027, an estimated budget of $120 million, and a stabilized cash yield expected in a range of 7.0% to 7.5%. More importantly, management says the remaining 240 acres at the site can support up to four million square feet of industrial development.

This is a multi-year inventory of future NOI.

Phoenix matters for another reason: it is where the macro overlay meets the financial model. Management notes that construction costs are about $20 per square foot below peak levels and points to advanced manufacturing tailwinds tied to TSMC and semiconductor supply-chain migration into Phoenix. That makes the project more than a generic Sun Belt warehouse build. It potentially places LXP inside a broader reshoring and industrial-policy current that has both AI and protectionist characteristics. AI does not only require chips and data centers. It also requires domestic manufacturing ecosystems, supplier networks, and logistics infrastructure. Phoenix is becoming one of those ecosystems.

The key point is not that every macro tailwind must fire perfectly. It is that LXP appears to control land in a market where large-box industrial demand may remain strategically supported, and where the economics of building today look better than they did at peak cost.

As long as land remains land, upside stays abstract. Once the first building is delivered, leased, and stabilized, the market has to stop treating the site as dormant optionality and start treating it as an earnings pipeline. Optionality only rerates when it becomes legible in reported results.

Why This Deserves More Credit Than a Typical Land Narrative

Many companies can point to undeveloped acreage. Far fewer can show an operating history of converting land into value. That is why LXP’s execution record matters so much here.

Management says it has constructed 15 facilities since 2019 at a 7.1% weighted-average stabilized yield on first-generation leases and generated $91 million of sales proceeds in excess of cost basis. It also says that in 2025 it sold the Indianapolis and Ocala development properties for $175 million to a user buyer at an implied 5% capitalization rate and a 20% premium to initial cost basis:

That is a highly important proof point. It suggests the upside is not merely “Phoenix land is probably worth more than book.” The stronger claim is that LXP has already shown it can build at one yield and monetize at another. That spread is what turns development from a story into a capital-allocation engine. In other words, the bull case is essentially repeated spread capture.

The Balance Sheet Makes the Optionality Actionable

Optionality in REITs is useless if the balance sheet cannot support it. LXP looks more interesting now because that constraint appears to be easing.

At year-end 2025, the company reported net debt to Adjusted EBITDA of 4.9x after selling assets, repaying debt, and reducing exposure to non-target markets. In the annual letter, management explicitly says that with its key 2025 objectives achieved, 2026 capital allocation priorities will focus on development opportunities, primarily within the existing land bank, while still leaving room for opportunistic buybacks.

That statement is more important than it sounds. It marks a shift from portfolio repair and simplification toward deliberate capital deployment. The thesis strengthens materially once investors believe LXP has both the land and the financial flexibility to start converting it. The distinction here matters:

• A land bank on a stressed balance sheet is deferred optionality.

• A land bank on a repaired balance sheet is potential growth inventory.

What Has to Happen for the Stock to Work

The mechanism is straightforward:

• First, the existing portfolio continues to compound through rent mark-to-market, escalators, and lease-up. That supports earnings growth even without any heroic development assumptions.

• Second, the cleaner balance sheet allows capital to move toward development inside the land bank, especially Phoenix.

• Third, development starts become delivered buildings, delivered buildings become leased buildings, and leased buildings become stabilized NOI. At that point, the market no longer has to value those acres as dormant land.

• Fourth, as the contribution becomes visible, LXP can begin to look less like a plain industrial landlord and more like an industrial REIT with an internal development engine. That is the point where the valuation framework can shift.

That chain is the entire thesis:A sequence of conversion from land to buildings to NOI to NAV.

What Would Break It

The biggest risk is that the spread never gets realized:

• If industrial demand softens, speculative leasing stalls, construction costs re-accelerate, or capital becomes less available, the land bank can remain underutilized for longer than bulls expect. In that outcome, the acreage still exists, but the timing of value realization stretches materially.

• There is also clear concentration in the upside case. Phoenix is the crown jewel. If Phoenix performs, the thesis becomes more obvious. If Phoenix disappoints, the stock may still work as a decent industrial REIT, but the argument for material upside weakens.

Finally, rerating is not automatic. A REIT can create real value and still trade as if it were only a current-income vehicle for longer than investors expect. The market often requires repeated proof before it changes the box it puts a company in.

Bottom Line

LXP is a stabilized industrial REIT whose current earnings base may understate the value of a real internal development pipeline.

• The existing portfolio already supports ownership through rent growth, lease-up, and a healthier balance sheet.

• The Phoenix land bank is what adds asymmetry. And that asymmetry is not happening in a vacuum: Phoenix is also exposed to semiconductor reshoring, advanced manufacturing buildout, and a more protectionist domestic supply-chain regime, which makes LXP an indirect beneficiary of both the AI capex cycle and the political push to localize strategic production.

• If management keeps converting low-carry-value land into 7%-plus stabilized industrial product, and if the market continues to value finished assets at materially tighter cap rates, then LXP has a credible path to create more NAV and more future NOI than a standard REIT multiple implies today.

In short LXP is a landlord with a visible path to turn land into earnings in a market increasingly shaped by AI infrastructure demand and industrial reshoring.

Affiliation Disclosure & Disclaimer:

The managing principal of Ridire Research is affiliated with a private investment fund that holds long positions in the securities discussed herein (AerSale Corp, ASLE), which could influence the views expressed. This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• Executive Summary

• Company Overview

• The Setup

• Causal Mechanism

• Timeline

• Key Risks

• Conclusion

Executive Summary

AerSale (ASLE) is in the middle of a business-quality transition: from a volatile “asset trader” (whole aircraft/engine sales) toward a more recurring, higher-margin aviation aftermarket platform where TechOps (MRO + proprietary engineered solutions) becomes the primary earnings driver. The inflection is already visible in reported results: in Q3’25, the company delivered no aircraft or engine sales yet still expanded profitability, with management explicitly citing TechOps margin expansion from 13.6% (Q3’24) to 25.3% (Q3’25) as the segment mix and work scope shifted toward higher-margin opportunities.

• The near-to-medium term forcing function is AerSafe, a proprietary, FAA-STC-backed engineered solution tied to an FAA compliance deadline in Q4 2026. As aircraft rotate through maintenance windows, AerSafe deliveries are positioned to remain elevated into 2026.

• Simultaneously, AerSale is coming off a multi-year facilities buildout: management states construction is complete on expansion projects and guided (on the Q3’25 call) to ~$25M of revenue and ~$4–5M of EBITDA contribution in 2026 from the three expansion projects as they ramp into production.

What must be proven for the thesis to compound:

• TechOps margins remain structurally higher even when whole-asset sales are muted .

• Engineered solutions scale without pulling forward all demand into a single “deadline quarter”.

• The company converts its substantial inventory base into cash flow as the model becomes more capital-light.

Company Overview

AerSale is an integrated aviation aftermarket provider organized into two reportable segments:

• Asset Management Solutions: acquires flight equipment and monetizes it through leasing, trading, or disassembly into used serviceable material (USM).

• TechOps: provides MRO (aircraft/component maintenance, landing gear, thrust reversers, aerostructures, modifications/cargo conversions, storage) and sells internally developed engineered solutions permitted by FAA Supplemental Type Certificates (STCs) (proprietary, non-OEM solutions to airworthiness directives/technical challenges).

In Q3’25, AerSale reported total revenue of $71.2M, split between $39.2M Asset Management Solutions and $32.0M TechOps. The quarter also highlighted the company’s deliberate pivot away from pure trading volatility: no aircraft or engines were sold in Q3’25, versus five engines in the prior-year quarter.

The Setup

• “Quality of revenue” is improving even as headline revenue remains volatile.
  While reported revenue can fluctuate with the timing of aircraft and engine transactions, the company’s recurring businesses, USM parts, leasing, MRO services, and proprietary engineered solutions, are becoming a larger share of activity, supporting a more stable earnings profile over time.

• TechOps is the margin inflection point, already happening.
  Management attributed the step-change in TechOps profitability to refocusing MRO facilities on higher-margin work and to engineered solutions volume/mix. Operationally, Roswell has been repositioned toward teardown/decommissioning work (higher-margin scope), while other shops (aerostructures/landing gear) and AerSafe helped offset softer services at certain facilities.

• Capacity expansion is shifting from “build” to “harvest.”
  Management stated construction is complete on expansion projects and the company is transitioning into operations. Separately, AerSale opened a new ~90,000 sq ft aerostructures MRO facility in Hialeah Gardens, FL, described as ~3× larger than the prior location, with upgraded equipment supporting larger widebody structures (B777 nacelles/thrust reversers, GE90/Trent platforms).

• Capital allocation has already cleared the private equity overhang.
  In March 2025, AerSale repurchased ~6.4 million shares at $7.00 per share (~$45M) from its former sponsor, Leonard Green & Partners, and immediately retired them. The transaction effectively completed the sponsor’s exit and removed a recurring technical headwind that often weighs on asset-heavy businesses with private equity ownership. While not an operational catalyst, the removal of a large financial sponsor reduces potential share supply and clarifies the company’s transition into a fully public shareholder base.

Causal Mechanism

The thesis is a stacked mechanism where multiple moving parts reinforce each other:

Mechanism A: Regulatory-driven engineered solutions + maintenance cycles → accelerating high-margin TechOps mix.

• AerSale stated it saw a strong increase in AerSafe deliveries YoY and expects volume to remain elevated through 2026 as the company approaches an FAA airworthiness directive compliance deadline (satisfied by AerSafe installation). At quarter-end, management disclosed that 2025 AerSafe deliveries + backlog totaled >$22M. Management also stated AerSafe should support results through the regulatory compliance deadline in Q4 2026.

• Because engineered solutions are proprietary products sold under FAA STCs, the incremental margin profile is structurally better than labor-heavy commodity MRO (and requires meaningfully less incremental capex once certification and tooling are in place).

Mechanism B: “Build is done” facilities expansion → capacity + capability unlock in 2026.

• In Q&A, management quantified the expansion projects: ~$25M of revenue and ~$4–5M of EBITDA in 2026, stepping toward a higher run-rate at full capacity.

• This contribution is powerful because it is incremental to the pre-expansion base and intended to be more recurring than whole-asset sales, reducing consolidated earnings volatility.

Mechanism C: Leasing + USM monetization → smoother revenue and better operating leverage.

• The company is explicitly shifting its deployment strategy toward assets on lease to create more stable quarter-to-quarter performance (leasing additional converted freighters/engines).

• The financial statements show this operationally: AerSale disclosed reclassification of inventory to equipment held for lease (a signal that inventory is being pushed into recurring lease-earning assets rather than one-time sales).

Mechanism D: Capex taper (post-buildout) + working-capital discipline → potential inflection in free cash flow.

• Cash-flow disclosures are directionally consistent with capex moderating as major buildouts complete. Management has also framed working-capital optimization as part of building a “more resilient business model,” but the proof will be in reported operating cash flow as inventory turns into USM sales, lease revenue, and TechOps throughput.

Timeline

Near-term: FY2025 results (March 5, 2026).
AerSale announced it will report Q4 and full-year 2025 results on March 5, 2026 (after market close), with a conference call the same day. This is the first opportunity for investors to pressure-test whether Q3’s margin profile persists and whether 2026 ramp commentary holds.

2026: “Harvest year” for expansions + AerSafe pre-deadline acceleration.
Key 2026 checkpoints:

• H1 2026: early evidence of expansion project ramp, utilization, and whether TechOps margins remain elevated. (Management’s quantified expectation for 2026 contribution is a direct benchmark.)

• H2 2026: engineered solutions should remain strong as operators work through compliance timelines; management has explicitly anchored AerSafe support through Q4 2026.

Post-deadline (2027 setup): durability question.
After the compliance deadline, the debate becomes: is AerSafe predominantly pull-forward (a “one-time compliance wave”) or does it settle into a multi-year annuity-like stream (replacement/maintenance + broader adoption)? The company’s longer-term narrative also depends on whether AerAware converts from “engineering asset” to “commercial product” via a launch order.

Key Risks

• Used-serviceable material supply loosens faster than demand.
  If OEM delivery rates and retirements normalize faster than expected, USM pricing and demand intensity can soften, pressuring the Asset Management segment and lowering returns on acquired feedstock. This matters because AerSale’s balance sheet is heavily inventory-weighted.

• AerSafe “demand cliff” after the Q4’26 compliance deadline.
  Management is clear that AerSafe is tied to an FAA compliance window through Q4’26. If demand collapses post-deadline and AerSale does not scale additional engineered solutions, TechOps margins could revert toward historical (lower) levels and the “recurring, high-margin TechOps” narrative weakens.

• Whole-asset sales remain structurally lumpy (earnings optics risk).
  AerSale repeatedly emphasizes that whole-asset sales drive quarter-to-quarter volatility; Q3’25 is a reminder that reported revenue can swing materially depending on whether aircraft/engine sales occur. Even if the long-term shift toward leasing/TechOps works, near-term results can look noisy.

• Working capital / inventory monetization risk.
  The company disclosed $371.1M of inventory and cash used in operations year-to-date of $34.3M, reflecting inventory investment. If inventory turns slow (or pricing deteriorates), leverage rises and cash conversion can disappoint.

Conclusion

AerSale’s thesis is best framed as a margin + mix + cash-conversion transition. The company has already demonstrated that profitability can improve even in a quarter with zero whole-asset sales, driven by higher TechOps margins and a pivot toward leasing/USM monetization. The next 12–18 months are about validating durability: AerSafe demand into the Q4’26 compliance deadline, the 2026 ramp of expansion projects (with disclosed revenue/EBITDA expectations), and tangible improvement in operating cash flow as inventory is monetized.

A secondary dimension of the story is AerSale’s position as a sub-scale but integrated platform in a consolidating aviation aftermarket industry. The company combines aircraft and engine feedstock sourcing, USM parts distribution, MRO capabilities, and proprietary engineered solutions, capabilities that are increasingly being assembled into larger platforms by strategic buyers. While not required for the thesis, the company’s integrated capabilities and regulatory certifications create potential strategic value if consolidation in the aerospace aftermarket continues and could potentially be an acquisition target.

Affiliation Disclosure & Disclaimer:

The managing principal of Ridire Research is affiliated with a private investment fund that holds long positions in the securities discussed herein (Kioxia Holdings, 285A JP), which could influence the views expressed. This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• Executive Summary – A Different NAND Cycle
  Mix shift, improved earnings quality, and balance sheet repair within a tight supply backdrop.

• Company Overview – Enterprise-Weighted Model
  Revenue composition, manufacturing control, and the Gen8 transition.

• The Setup – Operating Leverage and Cash Conversion
  Price and volume strength, inventory discipline, and revised JV economics.

• Causal Mechanism – Earnings Path Upgrade
  Enterprise mix expansion, supply discipline, node transition, JV compensation, and cash compounding.

• Timeline
  JV extension, Gen8 production crossover, enterprise SSD qualification, and CY2026 supply outlook.

• Key Risks
  Cycle normalization, AI demand variability, consumer weakness, execution, accounting transition, and FX.

• Conclusion – Structural De-Risking
  Less about peak margins, more about sustained earnings quality and capital structure improvement.

• Special Note:
  KIOXIA perpetual contract expected to launch.

Executive Summary

Kioxia (285A JP) is operating from a position of strength in a genuinely tight NAND backdrop. Pricing is firm, bit shipments are expanding, and the operating leverage is translating directly into cash. Q3 FY2025 revenue reached a record ¥543.6bn, non-GAAP operating income was ¥144.7bn (27% margin), and free cash flow was +¥85.7bn, the eighth consecutive quarter of positive FCF. Net debt-to-equity has been reduced to ~80%, materially improving the balance sheet profile. But the more important point isn’t really that “NAND is strong.” It’s more what Kioxia is doing with the strength and how it could exit this cycle.

Two things stand out:

1. Enterprise SSD is now the center of gravity. In SSD & storage, management described the mix as roughly ~60% data center/enterprise and ~40% PCs/other, with data center/enterprise volume and revenue both at record highs (AI server demand plus higher unit prices).

   

2. The SanDisk JV economics have been rewritten in Kioxia’s favor. Kioxia will receive $1.165bn in cash consideration over 2026–2029 (about $290m/year on average) and recognizes ~$131m/year of additional revenue from Feb 2026–Dec 2034 and management explicitly said this revenue contributes directly to operating profit. Historically, ~¥200bn/year of SanDisk-related revenue was effectively booked “at cost.” Simply put this changes the quality of earnings.

   

Guidance is aggressive and importantly specific. For Q4, revenue is guided to ¥845–935bn and non‑GAAP operating profit to ¥440–530bn, with unit pricing expected to increase significantly across applications, total shipments down, and data center/enterprise SSD mix up. Full-year FY2025 guidance calls for record revenue (¥2.1798–2.2698tn) and record non‑GAAP operating income (¥717–807bn). The trade is simple to state: if the company is right that CY2026 stays tight, then Kioxia is easily upgrading mix, upgrading earnings quality, and de‑risking the balance sheet at the same time.

Company Overview

Kioxia is a NAND manufacturer with three practical revenue buckets: Smart devices, SSD & storage, and Other (which includes B2C products like SD cards and revenue from sales to SanDisk recorded via the manufacturing JVs). Management noted all three categories delivered record revenue in Q3.

In Q3 FY2025:

• Smart devices (smartphones/tablets): ¥186.3bn, 34% of total revenue, up 18.4% QoQ, helped by the Gen8 BiCS FLASH transition that “began in earnest” in Q2 and continued through Q3.

• SSD & storage: ¥300.4bn, 55% of total revenue, up 22.8% QoQ. Within this, management pegged the split at roughly 60% data center/enterprise / 40% PCs & other.

That 60/40 call matters because it’s management telling you what’s driving the margin profile: the incremental bit demand is moving toward enterprise sockets (qualification, endurance, performance-per-watt, controller/firmware tuning), not just consumer clearing prices.

On operations, they’re making a point of control: Kioxia says it controls 100% of wafer manufacturing at the Yokkaichi and Kitakami plants and independently manages procurement, automation optimization, cycle-time reduction, lead-time reduction, and yield management. That’s the “why” behind the confidence in investment efficiency and manufacturing competitiveness.

The Setup

• In Q3 both price and volume moved higher. Unit pricing firmed again sequentially, but just as importantly, gigabyte shipments expanded, led by data center and enterprise demand. In memory, simultaneous price and volume strength is usually a signal of genuine supply tightness rather than short-term channel behavior.

• Free cash flow remained solidly positive, leverage continued to decline, and the balance sheet is materially stronger than it was a year ago. Inventory trends tell a similar story. Days declined meaningfully, consistent with demand running ahead of supply and disciplined production execution.

• Layered on top of the operating momentum is the revision to the SanDisk joint venture. What had historically been revenue recognized largely at cost now incorporates explicit consideration and margin-accretive recognition over time.

• Guidance maintains the same posture: firm pricing, improving enterprise mix, and further profitability expansion.

Causal Mechanism

• The first mechanical shift is mix. AI workloads are pulling NAND demand toward enterprise and data center sockets, where qualification cycles are longer, density requirements are higher, and product selection is less price-elastic. Management’s view is straightforward: data center and enterprise demand for AI applications is driving NAND growth, and near-term demand is expected to exceed supply into CY2026.

• Importantly, the demand base is not singular. Enterprise growth is supported by three overlapping vectors: ongoing conventional server replacement, sustained AI inference deployment, and supply constraints in nearline HDD that encourage substitution into high-capacity QLC SSDs. Even if AI sentiment cools tactically, HDD availability and density economics can continue to shift bits toward enterprise SSD adoption. The demand story is therefore broader than a single AI capex cycle.

• Demand alone, however, does not create earnings durability. Supply discipline does. The company expects market bit growth to remain in the mid-teens this year and upper-teens next year, while acknowledging ongoing capacity constraints. The implication is that the industry is not responding with aggressive capacity additions that would immediately compress pricing. Tightness converts mix into margin.

• Overlay the product cycle. The transition to 8th-generation BiCS FLASH is progressing, with Gen8 expected to become the mainstay production node by fiscal year-end, while investment in subsequent generations continues. That sequencing is critical. Cost reductions and competitive positioning are advancing during the upcycle, not deferred to a downturn. It provides margin defense when pricing inevitably moderates.

• Then there is the structural revision to the SanDisk joint venture. The shift toward explicit consideration and margin-accretive recognition through 2034 reframes part of what had historically been throughput economics. Management positions this as reflecting the strategic and technological value embedded in Kioxia’s manufacturing and development capabilities.

• The practical result is improved cash visibility and higher-quality earnings. Higher-quality earnings compound through the balance sheet. Net D/E has already compressed meaningfully over the past several quarters, driven by sustained free cash flow and retained profitability. In prior cycles, leverage amplified volatility when conditions softened. Today, improving capital structure reduces the reflexive downside that has historically characterized memory equities.

The mechanism, therefore, is layered and put simply what changes the earnings path is:

Enterprise mix expansion → tight supply backdrop → node transition supporting cost structure → improved JV economics → sustained cash generation → balance sheet repair.

Timeline

• Jan 30, 2026: Yokkaichi JV extended through end‑2034; $1.165bn consideration over 2026–2029; revenue recognition Feb 2026–Dec 2034 (~$131m/year).

• End of CY2025: shipment of 122TB and 245TB SSD models for customer qualification (high‑capacity 2Tb QLC on Gen8 BiCS FLASH).

• End‑March 2026: Gen8 expected to surpass Gen5 in production ratio and become the mainstay product.

• Q4 FY2025: IFRS requires lump-sum recording of ¥12bn in property taxes for the full year (recorded in Q4); management says profit growth is expected to “significantly” exceed that headwind.

• CY2026 (company view): NAND supply/demand expected to be very tight in the near term, driven by data center demand.

Key Risks

The NAND cycle risk doesn’t go away.
This is still a commodity industry at the core. The real risk is supply responding faster than expected (or demand pulling forward so hard that you get a digestion pocket). Management’s own strength in Q4 guidance implicitly raises the question: is this a peak quarter? Obviously not our view but still a reasonable question.

AI inference demand can wobble.
Kioxia is leaning on sustained AI inference and AI server demand as a driver for record data center/enterprise results. If hyperscalers pause deployments, or storage attach rates disappoint, enterprise SSD mix can normalize faster than investors expect.

Consumer sets are a real watch item.
Management flagged that in smartphones and PCs, there’s a shift toward higher-end AI models, but total sets may decline due to rising costs. If that turns into outright unit weakness, it can still pressure the broader NAND pricing umbrella.

Execution on Gen8 ramp.
The company expects Gen8 to become the mainstay product by end‑March 2026. Any yield, utilization, or transition inefficiency shows up quickly in gross margin, especially if ASP momentum decelerates.

JV optics / accounting noise.
Moving from “revenue at cost” toward explicit compensation improves economics, but it can create reporting quirks and confusion for generalist investors. The risk is the market misreads the income statement during the transition period.

FX and financing sensitivity.
Q3 benefited from FX tailwinds (JPY 153/USD vs 147 in Q2), and refinancing reduced interest cost. Both can reverse.

Conclusion

The easy take is “NAND upcycle.” The better take is that Kioxia is using the upcycle to change its shape.

• Enterprise SSD is becoming the profit engine (and management is talking in enterprise terms: qualification, high-capacity QLC, data center sockets).

• The SanDisk JV revision adds a contractual layer of cash consideration and margin-accretive revenue recognition that should make earnings less purely spot-driven over time.

• Cash generation is not a slide-deck claim anymore, eight straight quarters of positive FCF and a net D/E ratio down to ~80% is a tangible de-risking path.

What needs to stay true for the thesis to work is also clear: pricing can’t roll over immediately, enterprise mix needs to hold, and Gen8 needs to ramp cleanly into mainstay production by fiscal year-end. If those three hold while the JV cash begins flowing (2026–2029), Kioxia exits this phase with a materially improved balance sheet and a higher-quality earnings base, exactly the combination that changes how cyclicals get valued.

Special Note:

Trade.xyz secured the KIOXIA listing via the HIP-3 auction, committing 515.64 HYPE (~$24k USD), which is burned upon settlement. At current pricing, this is a non-trivial expenditure for a single ticker, particularly with the perpetual not yet live.

Affiliation Disclosure:

The managing principal of Ridire Research is affiliated with a private investment fund that holds long positions in the securities discussed herein, which could influence the views expressed.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

1. Executive Summary

2. View

3. Why Look at This Now

4. What Long Rates Reflect

5. Productivity and Uncertainty

6. Why Short-Term Inflation Noise Matters Less

7. Why Duration Is the Correct Expression

8. Basket Expression

9. Optional Convexity

10. Why This Framework Exists

11. When This Would Change

12. Closing

Executive Summary

Markets appear to be pricing long-run inflation uncertainty and term premium too pessimistically at a time when productivity pressures, first visible in software and increasingly across services, are beginning to stabilize costs. Long-dated Treasuries are the cleanest way to express a repricing of that uncertainty, benefiting from term-premium compression even without deflation or near-term inflation relief.

View

The market may be overpricing long-run inflation and term premium in an environment where productivity is gradually improving. This note is not about near-term inflation prints or calling a macro inflection point. It’s about how long-dated assets are priced relative to plausible long-run outcomes, and whether that pricing still reflects the direction of underlying cost pressures.

Why look at this now

Inflation debates have become largely binary: either inflation is structurally higher forever, or it is about to collapse. Markets do not require that level of certainty to reprice. They move when the range of plausible outcomes narrows. What has changed recently is not inflation data, but where productivity pressure is becoming visible.

Markets have begun to recognize that AI is already pressuring software and digital services pricing. What initially looked like a margin expansion story is increasingly showing up as:

• higher output per employee,

• slower headcount growth,

• rising competition within services categories,

• and, in some cases, explicit pricing pressure.

That recognition matters because software and services have been among the most inflation-resilient parts of the economy over the past decade. Long-duration assets are especially sensitive to shifts in long-run uncertainty like this. Their pricing depends less on the next year and more on how investors assess cost stability over the next decade or two.

The question is straightforward: is the market still demanding too much compensation for long-run inflation and duration risk given these developments?

Chart 1: Long-run inflation expectations vs realized inflation (US 5y5y breakeven, 10y breakeven, and CPI YoY)

The chart below shows market-implied long-run inflation expectations alongside realized CPI. Despite large swings in headline inflation over the past two years, forward breakeven rates have remained contained, oscillating within a relatively narrow range. This matters because long-duration assets are priced off expectations about the next decade, not the last twelve months. The stability of long-run breakevens suggests that, while near-term inflation noise has been elevated, the market has not materially revised its view of long-run inflation. To the extent term premium has risen alongside nominal yields, it reflects uncertainty pricing rather than a clear shift in long-run inflation beliefs.

What long rates reflect

A long-dated Treasury yield embeds three components:

• expected future short-term rates

• expected long-run inflation

• term premium, which compensates investors for uncertainty over time

Most macro commentary focuses on the first two. This allocation is focused on the third. Term premium tends to rise when inflation outcomes feel unstable and cost structures feel fragile. It tends to compress when investors gain confidence that the long-run environment is more predictable, even if growth is uneven.

Chart 2: U.S. 10-Year Treasury Term Premium (Adrian-Crump-Moench model)

With long-run inflation expectations largely stable, elevated long-end yields increasingly reflect a higher term premium, compensation for uncertainty rather than a repricing of the inflation path.

Chart 3: U.S. 10-Year Real Yield (TIPS)

With real yields already elevated, changes in long-end pricing increasingly reflect shifts in term premium rather than expectations for stronger real growth.

The remaining question, then, is what could plausibly reduce this uncertainty over time?

Productivity and uncertainty

Productivity matters here not because it guarantees lower prices, but because it affects the stability of the system.

Incremental productivity improvements can:

• reduce marginal cost pressure,

• weaken pricing power over time,

• limit the persistence of wage-price feedback,

• narrow the range of long-run inflation outcomes.

Importantly, this process does not stop at software.

If digital services are the first place where productivity gains are visible, physical services are the logical next step as automation, robotics, and humanoid labor systems mature. Even partial substitution in labor-intensive services can materially change long-run cost dynamics without eliminating jobs outright.

None of this requires deflation. It does not require immediate or universal adoption. It requires only that the long-run cost structure of services becomes modestly easier than currently assumed. If that occurs, long-run inflation expectations and term premium can drift lower without any dramatic macro event. That is sufficient for long duration to reprice.

Chart 5: Software and IT Services Operating Margins (S&P 500 Software vs IT Services)

Operating margins in software and IT services have essentially stopped expanding despite continued demand. This is consistent with productivity gains translating into competitive and pricing pressure rather than sustained margin capture. Given software’s historical inflation resilience, early margin pressure here increases the likelihood that productivity effects eventually extend into broader services.

Chart 6: Services inflation: official vs real-time

The chart compares official measures of services inflation with a real-time price index. While the two series differ in construction and volatility, both suggest that services inflation has stopped accelerating. This matters because services inflation has been the most persistent component of CPI. Even modest stabilization here reduces the risk that elevated inflation persists indefinitely, supporting a narrower range of long-run inflation outcomes.

Chart 7: Unit labor costs

Despite elevated wage growth, unit labor costs have moderated as productivity improves, lowering the probability that services inflation remains structurally high.

Chart 8: Labor productivity

Measured productivity growth narrows the range of plausible long-run inflation outcomes by lowering marginal costs and weakening wage–price persistence. One of the largest productivity shocks of the past decade coincided with the shift to remote work, a reminder that removing hours of low-value activity can matter more for output than most incremental technological upgrades. For long-dated assets, the level of inflation matters less than the stability of the cost structure that produces it, which is why productivity primarily acts through term-premium compression well before it appears in inflation data.

Why short-term inflation noise matters less

Near-term inflation is influenced by tariffs, supply chains, fiscal dynamics, and labor constraints, effects that are primarily reflected in short-dated rates. Long-duration assets are priced on longer horizons and respond to changes in confidence about long-run stability rather than transitory volatility. The thesis only fails if policy or structural forces permanently re-anchor long-run inflation expectations or sustain elevated term premium.

Chart 4: Treasury total return by maturity (Bloomberg US Treasury Total Return Indices)

Longer-duration Treasuries exhibit disproportionate total return sensitivity to changes in long-end pricing, making them the most direct way to express a view on term-premium compression.

Basket Expression

AI Productivity Duration Basket allocation:

• TLT — 62.50%

• EDV — 18.75%

• ZROZ — 18.75%

TLT provides liquid exposure to long-duration Treasuries. EDV and ZROZ increase effective duration and sensitivity to changes in term premium. This allocation is intended to be held as a structural position rather than traded tactically.

Optional convexity

In addition to the structural duration sleeve, an optional options overlay could be used to introduce convexity. This overlay is focused primarily on long-dated calls on TLT, with a smaller exposure to long-dated EDV calls, and ZROZ options included only where liquidity allows and sized so a full loss would be immaterial. The purpose is to benefit from a faster-than-expected repricing of long-run inflation or term premium, while keeping downside strictly limited to the premium paid.

Why this framework exists

Long-dated rates currently embed a high degree of caution about the future. That caution may ultimately prove justified. It may also prove excessive if productivity gains continue to show up in services pricing and cost structures.

The asymmetry is the point: a modest reduction in long-run inflation uncertainty can have a meaningful impact on duration pricing, while the downside of a limited allocation remains manageable.

When this would change

This sleeve would be reduced or removed if:

• long-run inflation expectations rise persistently,

• term premium increases structurally due to sustained fiscal pressure,

• productivity improvements fail to extend beyond narrow or isolated use cases.

Absent those developments, long duration remains a reasonable hedge against the possibility that long-run inflation risk is priced too aggressively.

Closing

This is a measured macro bet based on a simple observation: The future may be somewhat more stable, and less cost-intensive, than the market currently assumes. That alone can be enough for duration to work.

One final point, this framework is explicitly about long-run inflation uncertainty and term premium, not about near-term price levels or cyclical reflation. For that reason, several common “inflation hedges” are deliberately excluded.

• Inflation-linked bonds and commodities primarily benefit from rising realized inflation, which is not the view being expressed.

• Financials tend to benefit from elevated term premium and steeper curves, making them a poor fit for a compression thesis.

• Traditional value exposures are similarly sensitive to inflation persistence and higher discount rates.

• However, these could all still work for reasons not mentioned in the scope of this article.

Our framework is designed to benefit from uncertainty repricing rather than inflation acceleration.

Affiliation Disclosure:

The managing principal of Ridire Research is affiliated with a private investment fund that holds long positions in the securities discussed herein, which could influence the views expressed.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• Executive Summary

• Company Overview

• The Setup

• Causal Mechanism

• Timeline

• Key Risks

• Conclusion

• Special Mentions (Not Covered In Detail)

Executive Summary

Anthropic’s recent move into legal workflow tooling is a useful stress test for every “AI will eat SaaS” thesis. The headline isn’t that Claude got better at answering questions rather it’s that Anthropic is publishing workflow plugins that can execute real clerical/legal ops tasks, document review, NDA triage, compliance tracking, pushing the company up-stack from model supplier toward workflow owner.

That matters because it clarifies the shape of disruption:

• The most vulnerable incumbents are those whose moats are primarily UI, seats, and workflow convenience, especially where outputs are “good enough,” iteration is cheap, and switching costs are low.

• The least vulnerable incumbents are those embedded in deterministic, audited, regulated, or counterparty-mandated workflows, where an error cascades into lawsuits, regulator attention, or operational shutdown, and where “system-of-record” status matters more than model quality.

This piece is a nuanced response to the deterministic vs probabilistic framing that is becoming popular. The framing is directionally right, but incomplete. The real dividing line is not “AI can’t do deterministic tasks.” It’s that deterministic workflows have external accountability (auditability, provenance, liability, certification, and integration into other systems). In those contexts, AI becomes a feature and an accelerant rather than a wholesale replacement.

That’s the lens behind Don’t Get Fired Software, illustrated through two case studies here and supplemented by broader, well-covered examples at the end.

• Trend Micro (4704 JP): a cybersecurity control plane. The moat is embedded deployment, operational integration, and career risk, the security stack you don’t casually rip out when the downside of a bad transition is a breach and a board interrogation.

• ReposiTrak (TRAK): a compliance/traceability system-of-record in food supply chains. The moat is not “better UX.” It is mandatory network effects, retailers and wholesalers can force suppliers to comply through a particular rail, making participation a cost of doing business.

The implication is practical: AI lowers the cost of building software and compresses margins in “probabilistic productivity” layers, but it does not eliminate the willingness to pay for guardrails where the alternative is reputational and legal catastrophe.

Company Overview

Trend Micro (4704 JP): Cybersecurity as a Control Plane (and a Career Hedge)

Trend Micro is an incumbent cybersecurity vendor that has deliberately repositioned from “point products” into a platform control plane, unifying detection/response, exposure management, and multi-surface security operations. Its investor communications explicitly emphasize platform consolidation and platform-led growth, in other words: selling an operating layer rather than a single tool.

Why it qualifies as “don’t get fired” software:

• Security is not a normal ROI purchase. It is risk transfer. The buyer (CISO/CIO) is protecting the firm and themselves from tail outcomes. That changes switching behavior: transitions are slow, painful, and politically loaded.

• “Deterministic vs probabilistic” is a false binary in security. Threat detection is probabilistic by nature, but the workflow is deterministic: response playbooks, auditability, control coverage, and incident reporting expectations. It’s the workflow that buyers cannot risk breaking.

• AI is additive, not substitutive. AI can reduce analyst load and speed triage, but it also expands the attack surface and increases governance expectations (the organization must prove it is managing cyber risk, not merely buying tools).

Trend Micro also benefits from being a credible consolidator in a market where CISOs increasingly want fewer vendors and a tighter operational loop (alerts → response → reporting). This is exactly the category of software that tends to survive pricing model shifts (seats → usage/outcomes): you can change the meter, but you can’t opt out of the underlying need.

ReposiTrak (TRAK): Compliance and Traceability as a System-of-Record Network

ReposiTrak sits in a different, and arguably cleaner, “don’t get fired” lane: regulated compliance + counterparty mandates in food supply chains. It operates a traceability/compliance platform that functions as a system of record across retailers, wholesalers, and suppliers, where documentation, data standards, and audit readiness are the product.

Why it qualifies as “don’t get fired” software:

• It is compliance infrastructure, rather than discretionary workflow. The job is to produce clean, auditable traceability and compliance data that stands up under scrutiny.

• The moat is forced participation + network effects. Retailers are increasingly requiring traceability across broader sets of foods and earlier timelines than the government baseline meaning suppliers adopt because access to distribution depends on it. ReposiTrak’s own SEC filing explicitly describes retailer requirements like expanded traceability scope (“all foods”), additional electronic data elements, and accelerated deadlines.

• AI assistants don’t replace the rail. An LLM can draft an email or summarize a document; it cannot by itself create a trusted, standardized interchange between thousands of counterparties with data validation, audit trails, and operational integration.

ReposiTrak also leans into a practical reality: suppliers need interoperability (EDI compatibility, standardized capture, and translation of formats across trading partners). That’s “plumbing” work and it tends to be sticky.

The Setup

1) Anthropic’s legal plugin

The market reaction to Anthropic’s legal plugin is less important than the product direction. Anthropic is shipping workflow plugins (including legal) that handle tasks like contract review and compliance tracking, tools that historically lived inside vertical software suites or services-heavy platforms.

This is the broader pattern: foundation model providers are moving from model access to workflow ownership, because workflow ownership captures:

• distribution (where the user lives),

• data context (what the model can pull from),

• and economic rent (the part of value that is billable).

The “legal tech fray” is simply where the first public repricing happened.

2) Deterministic vs probabilistic is useful, but the better lens is external accountability

The deterministic/probabilistic split is a good first approximation:

• Probabilistic outputs (marketing, sales enablement, support, content, planning) allow iteration and tolerate “good enough.”

• Deterministic workflows (payroll, clinical, grid, compliance) punish errors.

But the nuance is this: many workflows are hybrids, probabilistic assistance inside deterministic guardrails. Security is the obvious example. Legal is another: a model can triage NDAs, but the organization still needs provenance, audit trails, and defensibility.

So the practical question for disruption isn’t “Can AI do the task?” It’s:

• Can AI own the system-of-record?

• Can it meet auditability and provenance requirements?

• Can it offer reliability and liability posture that enterprises will accept?

• Can it integrate into existing counterparty and regulator expectations?

Where those answers are “no,” disruption becomes feature-ization instead.

3) Cost of building software is falling, but distribution and trust are not

AI-assisted coding and agentic workflows are compressing the marginal cost of producing software and automating white-collar tasks. That pressure naturally flows into pricing. Seat-based pricing is already under strain, and consumption/outcome-based models are spreading, especially where AI automates away “seats.”

However, “software gets cheaper” is not the same as “customers stop paying.” In risk control planes, what customers are paying for is assurance: uptime, auditability, incident defensibility, and reduced tail risk. Those are not free simply because code is cheaper.

4) The regulatory floor moved, but counterparty enforcement is the ceiling

This is the most underappreciated nuance in ReposiTrak’s story.

The FDA’s Food Traceability Rule originally pointed toward a nearer-term compliance date, but FDA has proposed a compliance-date extension and Congress directed FDA not to enforce the rule prior to the extended date.

If you stop there, you might conclude the urgency is gone. But suppliers don’t work for the FDA; they work for their customers. Retailers and wholesalers can, and do, set requirements beyond the FDA baseline, including broader coverage (“all foods”) and earlier timelines. This is why ReposiTrak is “don’t get fired” software: the enforcement mechanism is commercial, not merely governmental.

5) Cybersecurity governance is now formal disclosure territory

In cybersecurity, the regulatory vector is not “install product X.” It’s that public companies must treat cyber risk as governance risk. The SEC’s rules require disclosure of material cybersecurity incidents (Form 8‑K Item 1.05) and disclosure around cybersecurity risk management and oversight. That drives demand for platforms that make risk observable, operational, and reportable. Again, control planes.

Causal Mechanism

The mechanism is the same in both names, but it expresses differently.

Shared mechanism: “Don’t get fired” budgets behave differently

• In discretionary SaaS, the buyer asks: “What’s the ROI?”

• In risk control planes, the buyer asks: “What’s the downside if this fails, and who gets blamed?”

That second question creates three structural advantages:

1. Budget priority: security/compliance survives cuts because the downside is existential.

2. Vendor stickiness: switching introduces new risk; incumbents become the “safe choice.”

3. Outcome defensibility: even if pricing shifts away from seats, vendors that can demonstrate risk reduction or audit readiness retain pricing power.

Trend Micro mechanism: threat velocity + governance pressure → platform consolidation

• Threat velocity is rising, and the operational burden on security teams is not linear. That pushes enterprises toward platform consolidation, fewer vendors, integrated telemetry, consistent policy and response.

• Governance expectations are rising (disclosure, board oversight), so security becomes more than detection; it becomes auditability and reporting.

• The “AI era” increases rather than reduces the need for security control planes, because AI expands software footprints, data flows, and attack surfaces.

• In fact Claude Code has become a cyber weapon itself:

Anthropic-style disruption here is constrained: an LLM can assist triage, but it does not replace endpoint telemetry, cloud workload coverage, policy enforcement, or response integration. In practice, AI becomes an embedded layer inside the incumbent platform, meaning the vendor that already owns the control plane is well positioned to capture the uplift. Trend Micro’s communications emphasize platform momentum and integration (the direction that matters for survivability under AI pressure).

ReposiTrak mechanism: counterparty mandates + regulatory complexity → forced network adoption

• The traceability/compliance problem is structurally a network problem. It only works when multiple parties exchange standardized data.

• Retailers are increasingly setting requirements that exceed the regulatory baseline (broader scope and earlier deadlines), creating forced adoption dynamics.

• ReposiTrak positions itself as the interchange layer: capture once, normalize/validate, deliver in the format each trading partner requires, in other words the “plumbing” that makes compliance operational.

Anthropic-style disruption is limited here too: an LLM can help interpret requirements or draft responses, but it does not replace the compliance system-of-record, the audit trail, or the counterparty rail. If anything, AI may accelerate adoption by making onboarding and exception handling cheaper, again benefiting the incumbent rail.

Timeline

1) Near-term: AI moves up-stack, markets reprice “workflow incumbents”

Anthropic’s workflow push is already prompting investors to ask which SaaS categories are “workflow wrappers” versus “systems-of-record with teeth.”

This repricing is often indiscriminate at first. That creates opportunities: “don’t get fired” names can get hit with the same multiple compression narrative even when their fundamentals are structurally protected. The investor job is to separate workflow convenience from operational control planes.

2) Cybersecurity: disclosure regime + consolidation cycle

SEC cyber disclosure and governance requirements increase the premium on platforms that support incident readiness, documentation, and defensibility. Concurrently, the market continues to push security consolidation. This favors vendors that can credibly offer a unified control plane and integrate AI capabilities without breaking reliability expectations.

3) Food traceability: the enforcement date may shift, but retailer enforcement persists

The FDA timeline has shifted in terms of enforcement posture. But retailer and wholesaler requirements are already pushing suppliers to operationalize traceability sooner, and often across broader product sets than the FDA’s list.

This creates a two-speed timeline:

• Commercial enforcement (retailers/wholesalers) drives adoption now.

• Regulatory enforcement extends the long tail and increases the “late majority” cohort later.

4) Pricing model shifts: seats → consumption/outcomes, and who wins

As AI automates labor, seats become a weaker billing unit. Consumption-based and outcome-based pricing becomes more common, and vendors must show value in concrete terms.

“Don’t get fired” vendors can adapt because they sell outcomes customers already care about:

• risk reduction,

• compliance readiness,

• auditability,

• faster incident containment,

• fewer recalls/exceptions.

Key Risks

Theme-level risks

1. Pricing pressure is real even for mission-critical software.
   AI lowers switching costs at the margin by making integration, customization, and migration easier. It also shifts procurement toward outcomes. “Never cut” doesn’t mean “never negotiate.”

2. AI-native workflows can commoditize layers around the system-of-record.
   Even if the core rail is sticky, some value can migrate to orchestration layers. The winner is often whoever controls distribution and the interface where decisions are made.

Trend Micro risks

• Platform competition intensifies. Large vendors can bundle security into broader suites and compress stand-alone pricing. Even with strong product positioning, the market can treat incumbents as “legacy” if they fail to anchor the platform narrative.

• AI changes the threat environment faster than vendor roadmaps. If attackers outpace defenses materially, buyer behavior can shift and procurement can rotate to perceived leaders.

• Perception risk. Cyber is a narrative sector. The market can punish “steady” names and reward “story” names even when fundamentals diverge.

(Note these are not unique to Trend Micro; they are endemic to cybersecurity as a market structure.)

ReposiTrak risks

• Regulatory slack can slow urgency at the margins. Even if retailer mandates drive adoption, some suppliers will procrastinate if enforcement is perceived as distant.

• Standards fragmentation. If the industry fractures into multiple incompatible traceability rails, network effects weaken. The counterpoint is that fragmentation is operationally painful, which is why consolidation is the natural endpoint.

• Execution and service risk. The “system-of-record” claim carries expectations: uptime, data integrity, onboarding throughput, and support quality. If the network is perceived as unreliable, it invites alternatives.

Conclusion

Anthropic’s legal plugin is a reminder that the application layer is no longer sacred. When a model provider can ship a workflow that does meaningful work review, triage, track compliance, incumbents built on interface convenience and seat economics should expect pressure.

But the right conclusion is not “AI eats all SaaS.” The right conclusion is:

• Probabilistic productivity layers (where iteration is cheap, switching is easy, and “good enough” works) will be commoditized fastest.

• Deterministic, externally accountable control planes (where auditability, provenance, integration, and liability dominate) will be disrupted differently: AI will be absorbed as a feature, and the system-of-record will remain sticky.

Trend Micro and ReposiTrak sit in that second category. They are don’t get fired software: the security stack you don’t casually replace, and the compliance rail you can’t opt out of when counterparties set the rules. Their moats are not code. Their moats are embeddedness, accountability, and the cost of being wrong. That’s the nuance response to the Anthropic moment: AI is absolutely compressing the marginal cost of software and reshaping pricing models, but it is not erasing the premium enterprises pay for guardrails when the downside is existential.

Special Mentions (Not Covered in Detail)

A few other companies clearly fit the “Don’t Get Fired Software” framework and reinforce the core nuance of this theme. We’re not covering them in depth here for a simple reason: they are already widely covered by the market or have been covered previously by us.

• Microsoft (MSFT)
  Microsoft’s security stack (Defender, Entra, Purview) has effectively become a default enterprise security control plane through bundling, distribution, and governance integration. This is well understood and heavily trafficked territory. AI enhances Microsoft’s position, but does not change the underlying control-plane logic.

• Palo Alto Networks (PANW)
  Palo Alto is the most obvious public-market example of the thesis: premium pricing justified by auditability, platform consolidation, and board-level defensibility. The market already treats PANW as a “safe” security incumbent.

• Digital Arts (2326 JP)
  Digital Arts represents the same dynamic in the Japanese market: deterministic security infrastructure embedded in regulated enterprises, education systems, and public institutions. Its durability stems from trust, certification, and institutional deployment depth. This name has been discussed previously here

Why they’re excluded here:
This piece is not meant to catalogue every beneficiary of the theme. The purpose is to clarify the mechanism:

AI disrupts probabilistic workflows first. It struggles to displace control planes where errors create legal, regulatory, or career-ending consequences.

MSFT, PANW, and Digital Arts already sit squarely in that category, and are priced, discussed, and understood as such. The incremental insight lies in identifying less obvious expressions of the same structural truth (TRAK, TrendMicro), not re-litigating the best-known examples.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• Executive Summary

• Company Overview

• The Setup

• Casual Mechanism

• Timeline

• Key Risks

• Conclusion

Executive Summary

LGI Homes (LGIH) is a business driven more by monthly affordability than headline pricing.

As financing conditions ease, entry-level buyers can return quickly, homes sell faster, and existing inventory begins to move which is enough to improve earnings even before profits per home recover. What it does not do immediately is lift margins. Keeping payments affordable often requires incentives and working through higher-cost inventory, which can hold margins down in the short term.

The opportunity is recognizing that the early phase of improvement shows up first in volume and operating leverage, with margin recovery coming later.

Company Overview

LGI Homes is a U.S. homebuilder focused on attainable, entry-level housing. The business is built around a standardized product, fast inventory turnover, and a sales process designed to convert renters into first-time buyers. What matters for this thesis comes down to how the company creates demand and how it manages risk when demand softens. Two structural features matter for this thesis:

• Affordability is the product: LGI does not compete on design or customization, it competes on the monthly payment. Management explicitly frames the sales process around getting buyers to a payment they can qualify for, which makes demand highly sensitive to financing conditions and borrowing costs.

• Wholesale acts as a pressure valve: Alongside retail sales, LGI sells a portion of homes in bulk to institutional buyers, primarily single-family rental operators. This channel helps keep construction moving and inventory from backing up when retail demand slows, but it typically comes with lower margins than traditional home sales.

It is worth noting that LGI also operates mortgage and insurance businesses through joint ventures. These help improve buyer conversion and enable financing incentives.

The Setup: Demand Improves First, Margins Lag

Easier financing tends to bring buyers back quickly, especially at the entry level. As borrowing conditions improve, more households qualify, traffic picks up, and homes begin to sell at a faster pace. That early demand response is real and usually shows up before anything else.

Where things get less intuitive is on profitability. For LGI Homes, supporting affordability has historically meant relying on incentives, adjusting sales mix, and working through higher-cost inventory accumulated during tougher periods. Those actions help move homes and stabilize the business, but they can keep margins under pressure even as demand improves.

That tension is the core of the setup: falling rates can clearly help volumes and sales momentum, while profitability per home takes longer to recover. The early benefit shows up in activity and cost absorption, not immediately in cleaner margins.

Causal Mechanism

• Easier payments bring buyers back first: LGI Homes sells to buyers who sit right on the edge of affordability. For this group, a small improvement in financing can be the difference between qualifying for a mortgage or remaining renters. When that line is crossed, demand responds quickly. This shows up first in sales activity, more orders, a growing backlog, and faster inventory turnover, well before it shows up in profitability.

• Why margins don’t snap back right away: Even as demand improves, profits per home can lag. Keeping homes affordable often requires continued incentives, preferred financing programs, and selective discounting. At the same time, the company may lean more on wholesale sales to keep construction moving when retail demand is still rebuilding. Finally, there is a timing issue: homes being sold today were often built when land, labor, or financing costs were higher. All of this can keep margins under pressure even as the business itself is clearly improving.

• Where earnings actually improve first: The early earnings lift comes from operating leverage, not pricing. As more homes are sold, fixed costs are spread across a larger base, improving overall profitability even if margins per home remain constrained. This cost absorption is typically the first clear financial signal that conditions are turning.

In the early stages of easier financing, the stock can work because volumes recover and costs are better absorbed, even while margins remain capped, earnings can improve simply by selling more homes through the same cost structure. In simplest terms margins are about making more per house; earnings are about selling more houses and right now the machine just needs to run faster, not get better.

Timeline

• Near term: The next earnings update is the first real checkpoint. What matters is not precision guidance, but tone and direction, whether management signals improving demand without leaning harder on incentives, and whether wholesale remains a tactical tool rather than a growing crutch.

• Over the next few quarters: The story becomes clearer as operating data accumulates. A sustained pickup in backlog and sales pace without an obvious step-up in incentives would confirm that demand is returning organically. At the same time, a gradual reduction in wholesale activity would signal that retail demand is strong enough to stand on its own. Improving cost absorption as volumes rise would be the clearest evidence that earnings power is rebuilding, even if margins per home remain constrained.

• On the macro side: This setup works best if financing conditions continue to ease and stay supportive. Stable or improving affordability, paired with steady buyer activity, would reinforce the idea that volume recovery can carry results forward before margins fully normalize.

Key Risks

• Rates don’t fall (or re-accelerate): The buyer cohort is payment-constrained; higher-for-longer would extend the incentive war.

• Incentive arms race intensifies: LGIH ran marketing-heavy promotions (a year-end savings event with price reductions and preferred-lender rate options), which can be necessary to drive pace but pressures margin.

• Wholesale becomes structural: If wholesale remains mid-teens as a % of closings, it may signal retail fragility and keep margins capped.

Conclusion

This is a case where improvement shows up before it looks pretty. LGI Homes does not need higher margins to start working as a stock it just needs buyers to come back. As financing eases, demand can recover quickly at the entry level, inventories can move, and earnings can improve through volume and cost absorption alone.

Margin recovery matters, but it is not the first signal, and waiting for it risks missing the earlier inflection. The stock works if affordability improves enough to sustain pace without escalating incentives, allowing operating leverage to do the heavy lifting. In that sense, this is less a bet on pricing power and more a bet on timing, recognizing that the business stabilizes and earnings recover before margins fully normalize.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• Executive Summary

  • Key Thesis Points

  • Theme Basket Overview & Expression

• Nuclear Medicine Overview

  • Casual Mechanism & Tipping Point

• Competitive Advantages & Structural Edges

• Ecosystem Landscape

• Valuation & Implied Expectations

• Capital Cycle, Policy & Capital Allocation

• Key Risks

Executive Summary

Nuclear medicine, the use of radioactive isotopes for imaging and treating disease, is emerging from niche status to become a frontline modality in cancer care. Our thesis is that recent breakthroughs in radiopharmaceutical therapies and supply-chain infrastructure have brought this field to a tipping point. We identify a long basket of select radiopharmaceutical developers and “picks-and-shovels” suppliers to capture this theme’s multi-faceted upside while mitigating single-name risk.

Figure 1: The global nuclear medicine market is projected to grow significantly, supporting the investment thesis that the field is at a tipping point. This growth is driven by the introduction of new therapies and expanding applications.

Key Thesis Points:

• Demonstrated Efficacy: Targeted radiotherapies have shown compelling clinical results in hard-to-treat cancers (Novartis’s radioligand drugs prolong survival in neuroendocrine tumors and prostate cancer). This validates nuclear medicine as a powerful therapeutic approach.

• Technology & Infrastructure Advances: Improvements in isotope production, targeting molecules, and safety protocols have lowered historical barriers. Modern “theranostic” platforms pair imaging and therapy, ensuring patients get the right isotopic treatment at the right time. Meanwhile, specialized suppliers are scaling up isotope manufacturing and distribution networks.

• Big Pharma Endorsement: Large pharmaceutical companies are making major investments in radiopharma. Recent acquisitions (Bristol Myers buying RayzeBio, AstraZeneca acquiring Fusion Pharma, Lilly acquiring POINT Biopharma) signal a long-term commitment to build radiotherapeutics franchises, bringing deep capital and expertise into the field.

  

  Figure 2: A wave of multi-billion dollar acquisitions by major pharmaceutical companies helps validate the long-term potential of the radiopharmaceutical sector.

• Broad Optionality: Radiopharmaceuticals represent a platform, not a single drug. The same core technologies (radioisotopes + targeting ligands) can be applied across multiple cancer types and even other diseases. This gives the sector numerous “shots on goal”, success in one indication can open the door to many others, delivering outsized growth for the leaders.

• Structural Tailwinds: We see a favorable capital cycle: years of underinvestment in nuclear med are reversing as demand rises. Regulatory agencies and governments are supporting domestic isotope supply and fast-tracking novel radiopharmas. This backdrop creates a supportive environment for the theme to play out over the next 3–5+ years.

Theme Basket Overview:

• We express this theme with a basket of equities spanning the value chain – from drug development to isotope supply. This includes established leaders with commercial products (to provide stability and cash flow), late-stage innovators nearing the market, emerging platform players (for high-upside optionality), and infrastructure providers that profit from broader industry growth.

• The basket balances current revenue generators (Novartis, Telix) with pipeline-dependent biotechs (Actinium, Clarity, Alpha Tau). It also adds lower-volatility “picks and shovels” names (BWX Technologies, Eckert & Ziegler) that benefit from rising isotope demand regardless of which drug wins. This mix is designed to capture the theme’s upside while reducing single-name binary risk.

• By including both growth-oriented biotech and cash-flowing industrials, the basket is positioned to weather different market conditions. In a bull case where multiple radiotherapies succeed, the pure-play biotechs could soar. In a scenario where progress is slower, the infrastructure names and diversified pharma exposure help preserve value.

Thematic Basket Expression

We express the nuclear medicine theme through a diversified long-only basket spanning Revenue Anchors, Infrastructure (Picks & Shovels), and Pipeline Optionality. The construction is designed to capture upside across the full value chain while reducing single-asset binary risk.

Revenue Anchors — 40%

Novartis (NVS) and Telix (TLX AU / TLPPF) anchor the basket with commercial scale, proven execution, and near-term revenue visibility. These positions provide durability and ensure exposure to radiopharma adoption even if pipeline outcomes vary.

• NVS — 20%

• TLX AU / TLPPF — 20%

Infrastructure (Picks & Shovels) — 30%

BWX Technologies (BWXT) and Eckert & Ziegler (EUZ GY) represent the isotope supply and manufacturing backbone of nuclear medicine. These positions benefit from rising sector activity regardless of which specific therapies ultimately dominate.

• BWXT — 15%

• EUZ GY — 15%

Pipeline Optionality — 30%

Actinium (ATNM), Clarity (CLRPF), Perspective (CATX), and Alpha Tau (DRTS) provide asymmetric upside through differentiated radiotherapy approaches. These are intentionally sized smaller to reflect clinical and regulatory risk, with the expectation that only one or two successes are required to materially lift basket returns.

• ATNM — 10%

• CLRPF — 8%

• CATX — 6%

• DRTS — 6%

Nuclear Medicine Overview

Nuclear Medicine is an interdisciplinary field at the intersection of nuclear physics and medicine, encompassing the use of radioactive isotopes for diagnosis and therapy. In practice, this ranges from imaging procedures, for example, PET and SPECT scans where radioactive tracers illuminate biological processes, to radiopharmaceutical therapies that deliver lethal radiation doses directly to disease sites. For decades, nuclear medicine was largely confined to diagnostics (think of cardiac stress tests or FDG PET scans in oncology) and a few niche treatments (like radioactive iodine for thyroid disease). Today, however, a new generation of radiopharmaceutical “theranostics”, pairings of diagnostic scans and targeted radioisotope treatments, is poised to move the field from the fringes of oncology into the mainstream.

Nuclear medicine occupies a unique niche in healthcare, sitting between traditional pharmaceuticals and the world of nuclear technology. It requires a tight integration of science and infrastructure: advanced chemistry to link radioactive atoms with targeting molecules (like antibodies or peptides), as well as specialized facilities to produce, transport, and safely administer these compounds. Historically, this complexity kept radiopharmaceuticals as a backwater in pharma – a bit too “nuclear” for biotech investors, and a bit too biotech for the nuclear industry. That is now changing. The convergence of better molecular targeting (from biotech) and improved isotope production techniques (from nuclear engineering) has created the conditions for a renaissance in nuclear medicine.

Figure 4: Theranostics allows clinicians to "see what they treat" by pairing a diagnostic agent with a therapeutic agent.

Two landmark therapies illustrate this turning point:

• Lutathera (Lutetium-177 dotatate) was approved in 2018 for certain neuroendocrine tumors, becoming one of the first modern radioligand therapies to show a survival benefit in solid tumors.

Figure 5: The mechanism of PRRT, the technology behind Lutathera, which targets neuroendocrine tumors.

• Then in 2022, Pluvicto (Lutetium-177 PSMA-617) was approved for advanced prostate cancer, after dramatically reducing tumor progression in trials.

Figure 6: The mechanism of action for PSMA-targeted radioligand therapy, where the drug binds to and is internalized by prostate cancer cells, delivering a lethal dose of radiation.

• These drugs proved that by combining a radioactive payload with a targeting vehicle (such as a peptide that seeks tumor cells), one can attack cancers that are otherwise incurable, with manageable safety profiles. The success of Lutathera and Pluvicto provided a clinic-ready template for others to follow, sparking intense R&D activity and investment across the sector.

Causal Mechanism & Tipping Point

Why Now? The core mechanism driving this theme is straightforward: targeted radiotherapy works. By delivering ionizing radiation from within the body, right at the cancer cell, radiopharmaceuticals can destroy tumors that evade surgery, external radiation, or conventional drugs. The concept isn’t new, earlier attempts date back to radio-immunotherapy drugs in the early 2000s, but the tipping point came from improvements in precision and proof. Unlike older agents, today’s radiopharmas use more selective targeting ligands (for example, PSMA in prostate cancer is a highly specific marker) and often pair therapy with diagnostic scans to confirm that the drug will hone in on a patient’s tumors. This greatly increases the chances of success and builds physician confidence.

Figure 7: The radiopharmaceuticals market is forecasted to experience steady growth, driven by the clinical success of new therapies.

Several converging factors created the tipping point we’re now witnessing:

• Clinical validation: The strong trial results and real-world outcomes from Lutathera and Pluvicto in the late 2010s and early 2020s gave physicians and investors tangible proof that radiopharmaceuticals can extend and improve lives. After decades of being viewed as experimental, nuclear medicine suddenly had credible champions and published data in top journals showing meaningful survival benefits. This changed the narrative from skepticism (“too toxic, too complicated”) to optimism (“a new pillar of cancer therapy”).

• Supply chain maturation: A therapy is only as good as its ability to reach patients. Historically, one of nuclear medicine’s Achilles’ heels was the fragile supply chain for isotopes. Many medical isotopes are produced in only a handful of aging nuclear reactors worldwide, leading to chronic shortages (for instance, the well-known molybdenum-99 supply crises affecting diagnostic scans). However, the past few years have seen major initiatives to modernize and expand isotope production: new reactor projects and particle accelerators dedicated to medical isotopes, government funding (in the US, EU, and others) to localize supply, and companies like BWXT and Eckert & Ziegler ramping up commercial production lines. These efforts mean the infrastructure is finally catching up to the science, reducing the risk that a breakthrough drug languishes due to lack of material.

• Better targeting & safety: Early radio-drugs sometimes faltered because they either hit unwanted tissues or caused collateral damage. Advances in biochemistry (e.g. more stable chelators that securely hold radioactive metals, and more specific targeting agents) have improved the therapeutic index of radiopharmas. For example, modern radioligands can target antigens almost exclusive to tumors (like PSMA or SSTR2) and clear quickly from the bloodstream, limiting radiation to just the cancer. Moreover, supportive care protocols (such as amino acid infusions to protect kidneys during Lutetium treatments) have evolved to mitigate side effects. The result is a tipping point where the benefits now clearly outweigh the risks in many indications, which was not the case 20 years ago.

Figure 10: The development of different types of radioisotopes, such as alpha and beta emitters, provides a range of therapeutic options with distinct properties for targeting various cancers.

• External pressures in oncology: It’s worth noting the broader context that oncology is hungry for new modalities. Many cancers (prostate, lung, brain metastases, etc.) still have poor outcomes in advanced stages. As immunotherapies and targeted pills plateau in some settings, doctors are looking for the next leap. Radiopharmaceuticals offer a fundamentally different mode of attack, physical cell destruction, that can complement or overcome resistance to other treatments. This has created an openness among oncologists and regulators to try novel approaches, paving the way for radiotherapeutics to get a fair shot where previously they might have been dismissed as too unorthodox.

• Chain Reaction of Adoption: Success breeds success. As initial patients responded well and word spread, more clinical trials launched, drawing in more investment. We’re now seeing a classic feedback loop: positive data → more funding and partnerships → more trials → broader proof-of-concept → increased big pharma interest → even more funding.

Competitive Advantages / Structural Edges

Nuclear medicine exhibits unusually strong structural moats driven by technical complexity, regulatory friction, and supply-chain constraints. The same factors that historically limited adoption now favor incumbents that have already built the required capabilities.

• High barriers to entry: Radiopharma is capital-intensive and operationally complex. Production requires radiation-safe facilities, licensed handling of isotopes, and regulatory approvals that are slow to replicate. On the supply side, companies like BWXT and Eckert & Ziegler have spent decades building nuclear and isotope expertise that newcomers cannot quickly duplicate. On the therapy side, platforms such as Telix and Actinium have accumulated proprietary know-how, chelators, targeting ligands, and manufacturing processes, that compound over time.

A hot cell facility at the Saskatchewan Centre for Cyclotron Sciences, showing the specialized radiation-safe infrastructure required for radiopharmaceutical production.

• Integrated infrastructure and first-mover advantage: Early leaders were forced to integrate vertically to succeed, and that integration is now a competitive edge. Scaled manufacturing, logistics, and hospital relationships allow faster and more reliable delivery than new entrants starting from zero. First-mover adoption also creates operational stickiness: once hospitals integrate a radiopharma workflow, they are more likely to expand usage with the same suppliers.

• Theranostic Model – Patient Selection and Loyalty: Radiopharma companies benefit from a theranostic approach: they often develop a diagnostic scan alongside the therapeutic. This is a competitive advantage because it creates a built-in funnel for their therapy. For example, if a Telix or Clarity Pharmaceuticals provides an imaging agent that identifies patients with a certain tumor target, those patients (and their doctors) are naturally led to consider the corresponding therapy from the same company. It’s a seamless pipeline from diagnosis to treatment that competitors without a paired diagnostic can’t easily replicate. This model also potentially speeds adoption – by demonstrating with a scan that a patient’s cancer is lighting up (i.e. has the target), you give physicians confidence that treating with the radiopharmaceutical will be worthwhile. As a result, companies following this theranostic playbook can gain physician mindshare and patient loyalty that others might struggle to chip away.

A detailed workflow diagram showing the theranostic approach from pre-therapy imaging through post-therapy imaging and treatment.

• Concentrated supply and sticky relationships: Key isotopes are produced by a small number of qualified facilities, creating de-facto oligopolies. Switching suppliers is non-trivial due to quality control, regulatory re-validation, and logistics. Once long-term supply contracts are in place, they tend to be durable, supporting pricing power and stable demand for infrastructure providers.

• Convexity through M&A interest: One could argue another “advantage” for investors in this space is the heightened probability of takeover at premium valuations. Big Pharma’s growing interest means each successful smaller player has multiple suitors. This isn’t a traditional competitive advantage in product terms, but it is a structural feature of the industry now: if a small cap radiopharma shows positive phase 2 data, the odds are higher than in many biotech sub-fields that it gets snapped up (given the current arms race for radiotherapy pipelines). For our theme, this dynamic provides upside optionality, even if a company might not succeed as a standalone long-term, investors could benefit from a buyout at a rewarding price.

In summary, nuclear medicine rewards companies that solve the hard problems: isotope access, manufacturing, logistics, and workflow integration. These structural edges favor entrenched platforms and infrastructure providers, aligning with a basket approach that owns both the therapies and the system that makes them scalable.

Ecosystem Landscape

The nuclear medicine ecosystem has matured into a vertically interdependent value chain, spanning large pharmaceutical platforms, specialist radiopharma developers, and a constrained isotope supply base. Our basket is constructed to capture value at each layer.

Large Pharma Anchor

• Novartis (NVS). Novartis remains the category leader and reference point for radioligand therapy. It was the first large pharmaceutical company to build an integrated radiopharma franchise, combining drug assets with global manufacturing and distribution. Its continued investment and commercialization establish radiopharma as a durable therapeutic category rather than an experimental niche. Novartis serves as both a stabilizing anchor and a benchmark for what scaled success looks like in the sector.

Specialist Radiopharma Biotechs:

• Telix Pharmaceuticals (TLX.AX) – A global leader among pure-plays, Telix already commercialized an imaging agent (Illuccix for prostate cancer PET scans) and is advancing a broad pipeline of therapeutic candidates (targeting renal cancer, brain cancer, etc.). Telix’s success with Illuccix (achieved significant sales within its first year of launch) underscores its strong execution ability. It’s carving out a role as a full-spectrum radiopharma company (diagnostics + therapeutics), somewhat akin to a mini-AAA/Novartis but independent. We consider Telix a bellwether for investor sentiment in this sector – and a potential mid-term acquisition target for a larger pharma given its head start.

• Actinium Pharmaceuticals (ATNM) – A US-based biotech focusing on alpha and beta emitting therapies for hematologic cancers. Its lead program, Iomab-B (using radioiodine to condition bone marrow prior to transplant in leukemia patients), has completed Phase 3 with positive results. Actinium also has collaborations to use Actinium-225 labeled antibodies in combination with other drugs for leukemia. If approved, Iomab-B would open a new niche (radiation conditioning for bone marrow transplant) with little competition, effectively creating a new market category. Actinium’s expertise in antibody radioconjugates gives it a platform it can potentially extend to other blood cancers or even solid tumors. We include it for its late-stage status and unique focus – though we acknowledge regulatory uncertainty around the approval path is a current overhang.

• Clarity Pharmaceuticals (CLRPF) – An emerging platform out of Australia, Clarity is championing copper-based radiopharmaceuticals (Copper-64 for imaging, Copper-67 for therapy). The idea is that copper isotopes have ideal properties for theranostics (Cu-64’s half-life allows centralized manufacture and distribution to imaging sites, and Cu-67 can be produced without a reactor, theoretically easing supply issues). Clarity has multiple drugs in early clinical development, including targets in prostate cancer and neuroblastoma. We include Clarity as a representative of the “next wave” of platform biotechs, it offers exposure to potentially more scalable technology (if copper can be produced via cyclotrons, that’s a game-changer for supply) and has attracted partnerships and government support. It’s still in trials, so it’s a higher-risk, higher-reward piece of the basket.

• Perspective Therapeutics (CATX) – Formed via the merger of Isoray and Viewpoint Molecular Targeting, Perspective combines a legacy brachytherapy business (Cesium-131 implants for treating prostate cancer, which Isoray had sold for years) with new targeted alpha therapies from Viewpoint. Their pipeline includes lead-212 conjugated molecules (Lead-212 is an alpha emitter) for cancers such as melanoma and neuroendocrine tumors. Perspective brings an interesting angle: they have experience in localized radiation (brachytherapy) and are now translating that into systemic targeted therapy. With isotopes like lead-212, they can create tumor-seeking radiopharmaceuticals. This company is early-stage, but it’s a play on alpha-particle therapy, an area that could leapfrog beta emitters in potency if challenges are solved. We include CATX for diversification into alpha therapeutics and to capture upside from any progress in their novel pipeline.

• Alpha Tau Medical (DRTS) – A bit different from others, Alpha Tau’s approach (Alpha DaRT) straddles the line between device and drug. They insert tiny seeds imbued with Radium-224 directly into tumors, which then emit alpha particles that kill the tumor from within over a few weeks. It’s a localized therapy (unlike the systemic injections of other radiopharmas) and is being tested in indications like skin cancers, breast tumors, and glioblastoma. Alpha Tau’s technology showed promising early results in a pilot skin cancer study. If it proves out in larger trials, it could become a new modality for solid tumors that can be accessed by a needle or minor surgery. We added Alpha Tau to the basket to reflect the diversity of approaches in nuclear medicine – it’s a more targeted “procedure-based” therapy that could complement systemic radioligands. It also exemplifies how the nuclear medicine toolbox is expanding (not just injections, but implants too). The company has risk (still in mid-stage trials, and adoption would require training surgeons/radiation oncologists on a new technique), but its upside is high as a potential disrupter of certain surgical or external radiation procedures.

There are other specialist radiopharma companies outside our basket for various reasons, for instance, Lantheus (LNTH) which is a commercial leader in diagnostics (they market Pylarify, an F-18 PET agent for prostate cancer). We chose not to include Lantheus mainly because its radiotherapeutic exposure is indirect (though it has licensed rights to some of POINT’s therapeutic candidates, Lantheus is still primarily an imaging and contrast agent company, and its valuation already reflects the huge success of Pylarify). Similarly, smaller biotechs exist but are either not easily investable for generalists or too early-stage to fit this memo. Our basket focuses on a representative set that covers both the current leaders and the promising newcomers in a balanced way.

Infrastructure & Isotope Supply

• BWX Technologies (BWXT) – A U.S. company with a long history in nuclear reactors (for submarines, power, etc.), BWXT has a growing medical segment. They are working on producing Molybdenum-99 (the source of Technetium-99m, used in millions of scans annually) using innovative reactor technology that doesn’t rely on weapons-grade uranium, a significant advancement in securing domestic supply. They also have initiatives for manufacturing Actinium-225 at scale in partnership with national labs, and are involved in producing other isotopes like Yttrium-90 and Strontium-89. BWXT’s advantage is it has the engineering muscle and capital to build complex facilities, something few pure biotechs can do. It also generates steady revenue from its core defense contracts, giving it financial stability. In our theme, BWXT represents the “macro” infrastructure bet, if nuclear medicine demand skyrockets, BWXT will likely see large, long-term contracts and government support to produce isotopes, boosting its medical segment earnings.

BWXT Medical's Tc-99m generator facility.

• Eckert & Ziegler (EZJ.DE) – A German company that has quietly become a global leader in radioisotope products and services. E&Z provides everything from radioactive source materials (Germanium-68 generators for Gallium-68 production, Cobalt sources for industrial and medical use, etc.) to contract development and manufacturing (CDMO) services specifically for radiopharmaceuticals. For example, if a biotech needs to build a production line for a Lu-177 drug, they might partner with E&Z to design and supply the hot cells and handling systems, or even have E&Z produce it for them. E&Z also produces small quantities of high-purity isotopes for trials. Essentially, it’s the one-stop shop for any company entering nuclear medicine that doesn’t have in-house manufacturing – a picks-and-shovels pure-play. We include E&Z in the basket because its profits rise with the entire sector: as more radiopharma trials commence and products commercialize, E&Z sees increased orders, service contracts, and sales of generators and equipment. It’s more Europe-focused (which is where a lot of isotope R&D happens), nicely complementing BWXT’s North American emphasis.

Eckert & Ziegler's radionuclide production equipment.

Healthcare Providers and Distributors: Another part of the ecosystem (not in our basket, but worth noting) are the nuclear pharmacies and hospital networks. In the US, companies like Cardinal Health and GE HealthCare’s pharmacy network are crucial for last-mile delivery – they take isotopes from producers and compound patient-ready doses daily. While we haven’t included these as positions (Cardinal is a broad healthcare company, GEHC is large imaging modality player), their role indicates that distribution channels are in place. It means scaling a new drug might be easier now because these networks can be tapped rather than built from scratch. Additionally, large hospital systems are investing in theranostic centers (for instance, some academic centers have opened dedicated radioligand therapy clinics). This increasing provider-side investment is a positive sign for the ecosystem’s maturity.

Competition and Landscape Summary:

• Novartis competes mainly with itself (it set the bar).

• Telix competes with Lantheus in imaging and will compete with big pharma radioligand programs in therapy (Novartis, Lilly’s POINT programs) but has a broad pipeline to differentiate.

• Actinium is fairly unique in bone marrow conditioning; its other programs (like CD33 targeting in leukemia) compete conceptually with CAR-T or antibody therapies for leukemia, not with another radiopharma per se.

• Clarity will inevitably compete with whoever is in the same indication (if their copper prostate therapy advances, it would compete vs Novartis’s Pluvicto and Lilly/POINT’s candidate). But Clarity’s bet is that a different isotope and improved targeting can carve a niche or even surpass incumbents.

• Perspective and Alpha Tau are in early stages where the “competition” is more status quo treatments (standard brachytherapy or surgery) rather than another similar company.

• BWXT’s competition is limited (mostly government-run reactors or a couple of smaller firms like Nordion in Canada or NorthStar in the US).

• Eckert & Ziegler similarly is one of few in its space; other players include ITM (a private German company focusing on Lutetium supply and therapies) and maybe Cardinal’s radiopharmacy division in the US. But E&Z has international reach and deep expertise that give it a solid position.

One can see that collaboration is as prevalent as competition, many of these companies will likely partner (a biotech partnering with BWXT for supply, or a big pharma licensing a smaller company’s compound). Our basket essentially picks those we think have strong individual prospects and also strategic value to others in the ecosystem.

Valuation & Implied Expectations

Traditional valuation frameworks are poorly suited to nuclear medicine. Instead of focusing on multiples, the relevant question is whether market expectations for the modality and its infrastructure are too low relative to the likely scale of adoption.

• Large Pharma (NVS): Radioligand therapy is still treated as a non-core option within a diversified pharma model. Expectations appear conservative, shaped more by manufacturing constraints than demand. Upside comes from indication expansion and scale, which would reframe radiopharma as a durable growth engine rather than a niche line item.

• Pure-Play Leaders (TLX): The market prices in at least one successful therapeutic transition beyond diagnostics, but does not fully price the platform nature of theranostics. Success in a single additional program could materially re-rate expectations; success across multiple programs would reframe the company entirely.

• Late-Stage / Platform Biotech (ATNM): Market expectations are low, reflecting regulatory uncertainty and narrow initial indications. This creates asymmetry: approval or partnership would force a rapid re-underwriting, while failure is partially mitigated by diversified basket exposure.

• Early Platforms (CATX, DRTS): Valuations imply a low probability of success. The market assumes most early programs fail. The basket thesis does not require broad success, one meaningful clinical win is sufficient to justify inclusion.

• Infrastructure (BWXT, EUZ GY): These names are valued as steady industrial or nuclear businesses, with medical isotopes treated as incremental. If radiopharma activity accelerates, medical exposure could drive earnings surprises and multiple expansion not currently reflected.

Capital Cycle, Policy & Capital Allocation

• Early speculative funding enabled proof-of-concept and late-stage trials. The current phase is dominated by strategic capital (large pharma M&A, partnerships, and long-term manufacturing investment), which is stickier and less cyclical.

• Capital is being allocated toward manufacturing capacity, isotope access, and platform build-out, not just clinical experimentation. This signals confidence in durability rather than short-term option value.

• Governments view medical isotopes as strategic infrastructure. Funding, regulatory alignment, and reimbursement frameworks have reduced non-scientific friction to adoption. This lowers the risk that effective therapies fail due to logistics or payment issues.

• Overfunding and thematic crowding remain possible, but leaders with scale, differentiated technology, or infrastructure positioning are more likely to consolidate rather than be displaced.

Key Risks

• Isotope Supply Crunch: If the ramp-up in isotope production does not keep pace with demand, the growth of radiotherapies will hit a hard ceiling. Many radiopharmaceuticals use exotic isotopes that are currently produced in gram or millicurie quantities worldwide. For example, Actinium-225 (an alpha emitter powering several next-gen therapies) is in extremely short supply, global production can meet only a fraction of potential patient demand. Efforts are underway to scale production (new reactors, particle accelerators, even projects to extract Actinium from Thorium stockpiles), but success is not guaranteed. Any setback, a reactor project running years late, technical difficulties in isotope extraction, or geopolitical issues (some isotopes come from reactors in Russia or Europe that could face disruptions), could leave eager patients and drug developers empty-handed. This would significantly slow adoption and could cause investors to lose faith if revenue ramps are bottlenecked by supply constraints rather than science.

• Logistical and Clinical Adoption Barriers: Even with supply in hand, operational logistics pose a risk. Radiopharmaceuticals have very short half-lives (hours to days), meaning the whole chain from production to patient is time-sensitive. Hospitals need special facilities (hot labs, radiation shielding, trained nuclear medicine physicians) to receive and administer these drugs. In areas without established nuclear medicine departments, adoption might lag simply due to infrastructure. Training and staffing are another issue, nuclear medicine specialists are not as common as, say, medical oncologists or surgeons. If healthcare systems are slow to invest in the necessary facilities or if there is resistance among physicians (some oncologists might be unfamiliar or uncomfortable with radiopharma initially), the rollout of new therapies could be slower than forecast. Essentially, the risk is delivery: many patients might benefit, but getting the product to them reliably is non-trivial. This could translate into lower sales than expected for novel drugs in their first few years, disappointing the market.

• Emerging Competing Therapies: The oncology landscape is highly competitive and dynamic. A risk to radiopharma is that some of the same targets being pursued (PSMA for prostate, somatostatin receptors for neuroendocrine tumors, etc.) are also being targeted by other therapeutic modalities. For instance, there are antibody-drug conjugates (ADCs) and bispecific antibodies in development for prostate cancer that target PSMA as well, these deliver a toxin or engage the immune system to kill tumor cells, rather than radiation. It’s possible that one of these approaches yields similar efficacy without the complexity of handling radioactivity. If an easier-to-administer, equally effective therapy emerges for the same patient population, it could cap the market for the radiopharmaceutical alternative. Additionally, conventional external beam radiation technology isn’t standing still, new techniques like proton therapy or targeted intraoperative radiation could address some tumors that radiopharmaceuticals target. While we believe radiopharma will often combine well with other treatments (not just compete), it’s a risk that, in some cases, it may lose out to a more convenient competitor.

Figure 12: While radiopharmaceuticals show great promise, they must compete with existing treatment modalities on both efficacy and safety.

• Regulatory and Perception Risks: Using radioactive materials in medicine naturally attracts regulatory scrutiny. Radiopharma trials have to navigate not just the FDA’s usual hurdles for drugs, but also radiation safety regulations from nuclear agencies. A risk factor is that regulatory requirements could become onerous, for example, requiring additional long-term safety monitoring or complex handling protocols that slow down trials and approvals. Furthermore, any safety scare could taint public and physician perception. If, hypothetically, a late-stage trial of a radiotherapy revealed an unexpected side effect (say, higher rates of secondary cancers years later, or severe organ toxicity in some patients), it could cast a pall over the whole field. Because radiation fears have a visceral element (the word “nuclear” can alarm people), a single high-profile incident might have outsized impact on sentiment. It’s worth noting that one of the companies in our basket, Actinium Pharmaceuticals, encountered an FDA request for more evidence of survival benefit despite meeting its trial endpoints – highlighting that regulators are cautious and want clear proof that benefits outweigh risks. Such hurdles could delay approvals or require costly additional studies.

• Financing & Execution Challenges for Smaller Players: The innovative biotechs driving this theme (aside from the big pharmaceutical anchors) are mostly pre-profit companies that rely on investor funding or partnerships. If the biotech funding environment deteriorates (for instance, due to rising interest rates or a broad risk-off sentiment), these companies might struggle to raise the capital needed for Phase 3 trials, manufacturing build-out, or commercialization. A prolonged capital winter could force dilutive financings or even shelve certain programs, stunting the theme’s progress. Additionally, executing in this field is harder than in traditional biotech – it’s a marriage of pharma and nuclear engineering. There could be unexpected setbacks in scaling production or in quality control (e.g., a manufacturing batch failing to meet purity standards could halt a trial). Companies might find it challenging to recruit enough specialized talent (radiochemists, medical physicists) to support their programs as they grow. In short, the road from promising Phase 1 data to a marketed product is long and fraught with operational hurdles; not all current players will make it to the finish line. For our basket, that’s why diversification is key – but it’s a risk that a couple of the smaller names could falter or even fail along the way, which would hurt the basket’s overall performance if not offset by others succeeding.

• Macro and Geopolitical Risks: Given the global nature of the supply chain (isotopes, equipment, and even patients for trials often cross borders), broader macro risks apply. Trade restrictions or geopolitical tensions could impact isotope supply (for example, some isotopes come from Russia or require Russian enrichment services; sanctions or conflict could cut that off). Currency fluctuations and inflation can affect the cost of building new production facilities or running trials across multiple countries. While these are not core to the thesis, they could create headwinds or volatility in timelines and costs.

Table of Contents

1. Introduction

2. Top 5 Ideas of the Year

3. Worst 5 Ideas of the Year

4. Biggest Fades

5. What This Year Reinforced

Introduction:

This year some ideas worked exceptionally well. Others didn’t. Both outcomes matter.

What follows is a transparent review of the top 5 performing ideas and worst 5 performing ideas published this year, measured from publication to end of year. All links are included so readers can review the previous articles.

A dedicated section for Biggest Fades sits at the bottom, ideas I watched work in real time without ever stepping in. In many ways, these missed opportunities are more painful than the ideas that didn’t work.

Top 5 Ideas of the Year

These ideas shared a common thread: structural tailwinds + mispriced narratives + asymmetric setups.

1. January 26 Calls on LC US +342.1%

This idea focused on a perceived valuation and classification mismatch rather than a directional macro call. The central observation was that LendingClub continued to be valued like a traditional regional lender, despite already operating as a profitable, AI-enabled digital bank with scale.

At the time of publication, LendingClub was originating more than $2 billion in loans per quarter, growing volumes at a double-digit rate, yet trading near tangible book value. The market largely overlooked the company’s underwriting infrastructure, which leverages one of the deepest consumer credit datasets in the industry: over 15 years of labeled outcomes and more than 100 billion data points. Incremental AI capability was being added through small, targeted acquisitions, improving credit performance and operating efficiency.

These advantages were already visible in reported results. Credit losses declined materially year over year, whole-loan sale pricing improved, and margins expanded, even as peers faced deteriorating credit trends. The company’s strong capital position further supported the durability of the business model.

The idea ultimately benefited from the market beginning to reassess LendingClub as a “second-derivative” AI credit platform, one where artificial intelligence was not a speculative future initiative, but a system already embedded in underwriting and economics. As that recognition improved, valuation followed.

In hindsight, the strength of this idea came from focusing on what was already working in the data, rather than what management hoped to build, and identifying where market perception lagged operational reality.

2. The Moat That Closes With Every Mortgage +75.7%

This was not a simple call on falling rates or a housing rebound. The core thesis was that Rocket Companies was being mispriced as a cyclical mortgage originator, when in reality it is in the process of becoming a vertically integrated, end-to-end housing platform.

The acquisitions of Redfin and Mr. Cooper, alongside the simplification of Rocket’s Up-C structure, materially changed the company’s earnings durability and strategic optionality. Redfin added top-of-funnel traffic and a national brokerage footprint, while Mr. Cooper brought scale servicing, recurring cash flow, and customer lifetime value. Together, they create a flywheel for retention, cross-sell, and structurally lower customer acquisition costs, something the market was slow to appreciate.

Operationally, Rocket continued to execute. AI-driven automation improved productivity and lowered costs, market share was gained even in a weak housing environment, and the balance sheet remained fortress-like. Importantly, the thesis also acknowledged macro uncertainty: servicing income and a flexible cost base helped offset higher-for-longer rate risk.

To further balance rate exposure, the idea was paired with copper producers (ERO CN and CS CN), a deliberate hedge against re-accelerating inflation or rising rates. This created a more robust expression across both rate-sensitive and inflation-sensitive regimes, rather than a one-way macro bet.

In hindsight, the strength of the idea came from treating Rocket as an emerging housing ecosystem, not a levered duration trade, and from structuring the idea to survive multiple macro outcomes.

3. Tariff to Table (LS) +74.6%

This idea examined the U.S.–U.K. Economic Prosperity Deal (EPD) as a rare, discrete policy catalyst capable of reshaping cross-Atlantic flows in both agricultural commodities and digital services. Rather than treating the agreement as a headline geopolitical event, the research focused on how specific quota creation, tariff removal, and regulatory harmonization would create winners and losers across adjacent industries.

The framework centered on expressing the downstream effects of regulatory clarity, where new access, cost advantages, or competitive pressure were likely to emerge, while contrasting businesses positioned to benefit from the agreement with those facing incremental margin or valuation risk.

U.S. Agricultural Export Beneficiaries
The EPD introduced a preferential duty-free ethanol quota for U.S. producers and removed tariffs on U.S. beef exports into the U.K. This materially altered export economics for select U.S. agricultural firms. The idea highlighted companies with modern production assets, export readiness, and scale advantages, where incremental international demand could flow directly into margins. Management commentary at the time reinforced that regulatory-aligned international demand was becoming a more meaningful earnings driver.

U.K. Domestic Protein Pressure
On the other side of the trade, the agreement increased competitive pressure on U.K.-centric protein producers. The introduction of tariff-free U.S. beef created the risk of import-driven price competition in a market already facing cost inflation. Businesses with limited geographic diversification and exposure to domestic fresh-protein pricing were identified as structurally more vulnerable to margin compression as supply dynamics shifted.

Digitized Trade Enablement vs. Consumer SaaS
Beyond physical goods, the EPD placed explicit emphasis on digital trade provisions, including paperless customs processes and harmonized digital standards. The research differentiated between platforms that directly enable cross-border commerce, through tariff calculation, VAT handling, and compliance workflows, and consumer-facing software businesses with limited linkage to trade infrastructure. The former stood to benefit from increased cross-border activity and regulatory normalization, while the latter faced the risk of relative multiple compression as capital rotated toward policy-aligned platforms.

In hindsight, the strength of this idea came from treating the EPD not as a macro headline, but as a microeconomic shock that reallocated value across supply chains and software layers. By focusing on second-order effects, who gains access, who absorbs competition, and who enables the system, the framework captured dispersion that broad market narratives missed.

4. Bandwidth Wars (LS) +58.8%

This idea examined the growing bifurcation within the global connectivity ecosystem. While “networking” is often discussed as a single sector, the research argued that the market was increasingly splitting into two distinct camps: companies enabling the next wave of bandwidth expansion and convergence, and legacy vendors tied to slower-growth, increasingly commoditized segments.

Rather than making a directional call on technology or equity markets broadly, the work focused on relative fundamentals inside the connectivity stack, who is positioned to benefit from secular demand for bandwidth, and who faces structural headwinds as architectures evolve.

Enablers of the Bandwidth Expansion
The research highlighted companies supplying critical technology for modern connectivity buildouts, including virtualized broadband access, optical transport, and high-speed datacenter interconnect. These businesses sit directly in the path of several durable trends: DOCSIS 4.0 and fiber upgrades, hyperscale cloud and AI datacenter expansion, and the shift toward software-defined, higher-capacity networks.

Across this group, common characteristics emerged: exposure to customer capex that is strategic rather than discretionary, improving product mix, and demand driven by physics (speed, power, latency) rather than refresh cycles. Product roadmaps centered on next-generation technologies such as virtualized access platforms, 800G+ optical links, and high-speed electrical interconnects designed for AI clusters. In many cases, fundamentals reflected this positioning through stronger growth, margin expansion, and improving balance sheet profiles.

Legacy Connectivity and Structural Pressure
In contrast, the research identified connectivity vendors whose core exposure remains tied to mature or saturated markets such as consumer Wi-Fi hardware, SMB networking, or traditional enterprise campus networks. While some of these businesses are well run and profitable, their end markets face slower growth, heightened competition, and increasing commoditization.

These companies tend to rely on incremental product updates, cyclical refresh demand, or cost discipline rather than participation in the fastest-growing areas of network spending. As customer budgets increasingly prioritize broadband infrastructure, cloud interconnect, and AI-driven capacity expansion, legacy segments risk being deprioritized.

Why Dispersion Matters
The central insight of this idea was that connectivity demand is simply reallocating. Bandwidth requirements continue to rise from the last mile to the core, but value accrues unevenly depending on where a company sits in the architecture. Firms enabling convergence, virtualization, and scale stand to benefit disproportionately, while those anchored to box-based or fragmented niches face relative erosion.

By focusing on this internal dispersion rather than the sector as a whole, the idea captured performance differences driven by technology relevance, customer mix, and capital allocation priorities, rather than broad market direction.

In hindsight, the success of this idea came from recognizing that the future of connectivity belongs to those enabling greater bandwidth, efficiency, and integration, and that legacy hardware models, while often optically cheap or operationally stable, remain structurally disadvantaged as the connectivity cycle evolves.

5. The Skeleton Crew +48.7%

This idea focused on a simple but non-consensus observation: the next wave of automation would not be led by abstract AI models alone, but by physical robots, increasingly humanoid in design, enabled by mature sensors, compute, and motion control systems. The value was expected to accrue not to any single robot form factor, but to the upstream suppliers providing the indispensable “bones and guts” of every robotic system.

Rather than speculating on which humanoid platform might win, the research emphasized infrastructure inevitability. Every general-purpose robot, regardless of brand or design, requires dense edge compute, high-reliability power management, precise sensing, motion control, and rigorous semiconductor testing. These needs exist independently of marketing narratives or end-user hype.

Why the Timing Mattered
The work argued that several forces had converged to push robotics out of the lab and into commercial deployment: persistent labor shortages, rising wages in logistics and manufacturing, improvements in real-time AI inference, and declining hardware costs. Together, these factors created a tipping point where general-purpose robots became economically viable rather than experimental.

Upstream Enablers Over End Products
The core insight was that the most durable value would likely accrue to companies supplying:

• Edge AI compute and robotics software stacks

• Analog, power, and sensing components embedded in every joint and actuator

• Semiconductor test, packaging, and inspection tools required to manufacture advanced robotics chips

• Optical and display technologies that support perception, interaction, and monitoring

These layers benefit regardless of which OEM ultimately dominates humanoid deployment.

Early Identification of the Robotics–Test Nexus
Notably, this research highlighted Teradyne’s dual exposure to robotics well before it became widely discussed. The analysis connected Teradyne’s ownership of Universal Robots and MiR, among the most widely deployed collaborative automation platforms, with its dominant position in semiconductor test. As robot intelligence increases, so does chip complexity, and every advanced processor, sensor, and memory component must be validated. This “picks-and-shovels” exposure to both physical automation and the silicon underneath it was identified early, ahead of broader commentary elsewhere (wink wink).

A Stack, Not a Bet
The strength of the idea lay in treating robotics as a stack. Compute providers, analog leaders, packaging specialists, optical equipment makers, and test vendors all occupy chokepoints with high switching costs and long design cycles. Many of these businesses already generate revenue from adjacent markets (cloud, automotive, industrial), giving them resilience while robotics adoption scales.

In hindsight, the effectiveness of this idea came from separating inevitability from uncertainty. The exact shape of humanoid robots remains fluid. The need for compute, power, sensing, testing, and integration does not. By focusing on the latter, the research captured exposure to the automation inflection without relying on speculative end-state winners.

Worst 5 Ideas of the Year

These ideas failed for different reasons: regime mismatch, narrative persistence, or being right too early (also called being wrong until further notice). Each one highlighted a weakness worth addressing.

1. LS Cash Flow Cosmetics (LS) -18.5%

This idea examined a structural divergence in global beauty, contrasting digital-first, science-led operators with diversified geography against a legacy prestige player reliant on travel retail and wholesale distribution.

The core thesis remains intact, but the idea proved too early. While channel pressure in travel retail and capital allocation constraints were correctly identified, the market proved willing to look through near-term disruption, restructuring, and China uncertainty for longer than expected.

Digital-native and IP-driven brands continue to deepen moats through data, proprietary formulations, and embedded distribution, while legacy prestige models face slower channel recovery and rising competition. The disconnect lies in timing of recognition, not in the underlying analysis.

This was a reminder that structural edges can take longer to surface in consumer sectors, and that patience, not conviction, was the missing ingredient here.

2. Hot vs Cold Storage (LS) -24.1%

This idea focused on a structural shift in data infrastructure: AI workloads increasingly favor low-latency, high-throughput storage over traditional hard-disk–based capacity. The analysis correctly identified flash, high-bandwidth memory, and modern networking as long-term beneficiaries, while legacy disk-centric models faced rising relevance risk.

The issue was timing and relative scale. Hyperscalers proved more willing than expected to extend HDD lifecycles for deep-archive and cold tiers, delaying the point at which latency economics fully dominated procurement decisions. At the same time, early AI-driven storage demand was simply too small, relative to the massive installed HDD base, to force immediate displacement. Capacity roadmaps and pricing discipline from disk vendors further slowed near-term disruption.

That said, the underlying physics have not changed. AI clusters remain constrained by data movement, not raw capacity, and capital spending continues to migrate toward flash, NVMe fabrics, and high-speed networking. This was a case where the destination appears right, but the path is unfolding more slowly and unevenly than anticipated.

3. Rare by Design (LS) -28.1%

This idea was built around a clear structural view: cash-generative, orphan-focused biopharma businesses with pricing power and execution discipline should outperform a broad biotech index dominated by speculative, pre-revenue names. Fundamentally, that view held, many rare-disease companies continued to grow revenue, expand margins, and raise guidance.

The problem was the hedge. In practice, biotech performance over the period was driven less by fundamentals and more by macro flows, sentiment shifts, and risk-on/risk-off positioning. Broad biotech beta moved in ways that overwhelmed relative dispersion, blunting the intended offset and compressing spreads.

In short, the selection was largely right, but the pairing failed in a regime where capital flows mattered more than cash flows. This was a reminder that even well-founded relative frameworks can struggle when sector-wide sentiment dominates fundamentals.

4. A Payments Trifecta -47.3%

This idea centered on high-quality payments infrastructure businesses with strong moats, recurring revenue, and durable compounding characteristics across processing, point-of-sale hardware, and cross-border rails. Fundamentally, the businesses continued to execute.

The primary issue was valuation, not quality. These companies entered the period priced for near-perfection, leaving little margin for error as rates stayed higher for longer and investors rotated away from premium compounders. Even solid execution failed to offset multiple compression.

In hindsight, the key lesson was clear: great businesses can still be poor ideas if paid for at the wrong price. This was not a breakdown in fundamentals, but a reminder that quality does not immunize against valuation gravity.

5. TRUECALLER AB-B -72.2%

This idea was based on Truecaller’s unusually strong engagement (utility-level DAU/MAU), improving mix toward recurring revenue (subscriptions + business), and a belief that a negative earnings reaction was more optics than fundamentals.

What went wrong was not that engagement disappeared, it was that the stock proved far more sensitive to non-fundamental overhangs than expected:

• Reporting optics and incentive-cost noise mattered more than anticipated. Even if economically non-cash, share-price-linked compensation and GAAP volatility created persistent confusion and kept investor confidence fragile.

• Macro/FX sensitivity hit perception. With meaningful exposure to India/MENA/Africa and SEK reporting, currency and risk sentiment became a bigger headwind than the thesis underweighted.

• “Quality” wasn’t enough without a clear near-term re-rating catalyst. The business continued to evolve, but the market didn’t reward the transition fast enough, and multiple compression did the rest.

Biggest Fades

This section captures a different kind of miss. These were not ideas that failed on analysis or fundamentals, but opportunities observed repeatedly without acting on them. In many cases, the thesis was clear and the setup unfolded as expected, but conviction lagged execution.

In hindsight, these tend to be more painful than ideas that didn’t work, because the cost is invisible: no loss, just foregone participation.

They are included here not as self-criticism, but as a reminder that restraint has a price, and that process risk includes when not to act as much as when to step in.

Presented without commentary. Consider what might have been…

The Recession Food Pair Trade (DLTR / SG):

Long/Short Behavioral Health (TALK/ACHC):

Long/Short GLP1 Related Procedures (ESTA + AIRS) / (INSP + TFX):

Long Bitcoin / Short Cardano:

Long/Short Freelance (UPWK / FVRR):

What This Year Reinforced

• Structure and timing are as important as thesis quality.

• Narrative persistence can overpower valuation for longer than expected.

• Long/short frameworks tend to be most effective in policy-driven, volatile regimes.

• Publishing losing ideas publicly is essential to maintaining a disciplined research process.

Thank you for reading, for thinking alongside me this year, and for sticking with the process. Wishing you all a healthy, focused, and rewarding 2026.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• 1. Investment Thesis

• 2. Catalysts & Narrative

• 3. Risks

• 4. Conclusion

Thesis Summary:

DNOW: The “Made in America” supply-chain utility hiding in plain sight. DNOW is evolving from “oilfield distributor” into a scaled, digitally-enabled industrial supply-chain utility, levered to U.S. re-industrialization, energy security capex, and AI-driven infrastructure buildouts, while the MRC Global combination turns its network density and category breadth into a harder-to-replicate moat.

1. Investment Thesis

Intro: A Primer on The Cost of Downtime

In industrial systems, downtime is not simply an inconvenience, it is a financial event with direct and indirect consequences. Downtime refers to any period in which a machine, facility, or system is unavailable for production. It can be planned (maintenance, turnarounds) or unplanned (equipment failure, logistics breakdowns, human error). The distinction matters operationally, but economically the outcome is the same: lost output at precisely the wrong moment.

Critically, the cost of downtime is not limited to the value of foregone production. It compounds across multiple dimensions:

• Idle labor and overtime to recover schedules.

• Missed deliveries and contractual penalties.

• Safety and regulatory exposure.

• Reputational damage with customers.

• Cascading disruptions across dependent systems.

In other words, downtime costs are non-linear. Once a system fails, every additional minute becomes more expensive than the last.

Recent research underscores how severe this has become. According to Siemens’ True Cost of Downtime study, unplanned downtime now costs Fortune Global 500 companies roughly 11% of annual revenue, nearly $1.5 trillion globally, up sharply from pre-2020 levels. At the facility level, large industrial plants now lose over $100 million per year on average to downtime. The cost of a single lost hour ranges from tens of thousands of dollars to well over $2 million, depending on industry and criticality. The key takeaway is not the exact figures, but the direction: downtime is becoming more expensive, not less, as industrial systems grow more capital-intensive, more regulated, and less tolerant of failure.

This reality changes procurement behavior. When the cost of failure dwarfs the cost of parts, purchasing decisions shift away from unit price and toward availability, specification accuracy, logistics reliability, and response time. The economic value migrates to whoever can ensure that the right component is in the right place at the exact moment failure becomes intolerable.

Manufacturers increasingly respond by investing in predictive maintenance, inventory buffering, supplier consolidation, and digital monitoring because it is cheaper than being wrong. Siemens’ research shows these strategies can materially reduce unplanned downtime, but they also raise the strategic importance of partners embedded directly in maintenance workflows.

For readers interested in the full data and methodology, Siemens’ True Cost of Downtime report provides a comprehensive breakdown across industries and geographies. Linked HERE

Where Downtime Economics Meet the Physical Supply Chain: DNOW

The correct way to underwrite DNOW is as a monetizer of downtime risk, not as a cyclical oilfield distributor. Across energy, utilities, manufacturing, and infrastructure, the economic penalty of downtime dwarfs the marginal cost of parts. When physical systems fail: pipelines, processing plants, power infrastructure, industrial facilities; the cost is measured in lost output, safety exposure, regulatory risk, and cascading operational disruption. DNOW’s business sits directly at this fault line. What DNOW actually sells is time certainty:

• The right part,

• in the right specification,

• at the right location,

• exactly when failure is most expensive.

This is a fundamentally different economic proposition than selling commoditized inputs. In this model, availability, logistics reliability, and workflow integration become the value drivers rather than unit pricing.

In 2025, this model became reinforced by an unusually favorable structural backdrop:

• U.S. industrial and manufacturing construction remains historically elevated.

• Policy-driven re-industrialization and tariff regimes are increasing supply-chain friction.

• Energy and midstream reinvestment is driven by reliability, not growth optimism.

• AI and data-center expansion is pulling forward power and infrastructure buildouts.

DNOW benefits from all of these without requiring a bullish view on any single commodity, election outcome, or GDP forecast.

The MRC Global combination materially strengthens the thesis. It expands DNOW’s network density, PVF category depth, purchasing leverage, and customer relevance, pushing the company closer to a supply-chain utility rather than a transactional distributor.

The core premise is simple but underappreciated:

As physical systems become more capital-intensive and less tolerant of failure, the value of being in-stock, on-time, and operationally embedded compounds.

That is the economic engine DNOW is building.

2. Catalysts & Narrative

DNOW’s story works because multiple independent narratives converge on the same operating mechanism: downtime avoidance. These narratives are:

A. Re-industrialization and the permanence of maintenance demand

The current U.S. manufacturing build cycle is not just about new construction. Every plant, terminal, and processing facility commissioned today creates a long tail of maintenance demand that often exceeds the initial build cost over the asset’s life.

DNOW participates in both phases:

• Build / commissioning: supplying PVF, flow control, safety equipment, and tooling.

• Operate / maintain: recurring MRO, replacement parts, and inventory programs.

The second phase is where the economics compound. Once DNOW is managing inventory, standards, and procurement workflows, it becomes operationally embedded. Switching suppliers becomes a risk decision, not a price decision. This dynamic makes DNOW less dependent on incremental construction starts and more tied to the installed base of physical capital, which is growing.

B. Tariffs, supply-chain friction, and the value of aggregation

The 2025 tariff environment matters less for its politics and more for its operational consequences.

Tariffs and trade friction increase:

• Lead-time uncertainty.

• Supplier fragmentation.

• Inventory risk.

Operators respond by:

• Localizing sourcing where possible.

• Holding buffer inventory.

• Consolidating suppliers to reduce complexity.

These behaviors disproportionately benefit scaled distributors that can aggregate supply, manage inventory across sites, and act as an outsourced procurement function. DNOW’s model becomes more valuable as supply chains grow more complex. This is a critical point: supply-chain friction increases distributor relevance when the distributor solves it.

C. Energy reliability over energy growth

DNOW does not need a new shale boom to work. Energy infrastructure, upstream, midstream, utilities, LNG, power, requires continuous reinvestment simply to remain operational and compliant. Maintenance is not discretionary, and downtime is not tolerated. Even as capital allocation in energy shifts toward electrification and decarbonization, the physical reality remains:

• Pipelines still need valves.

• Compressors still fail.

• Power systems still require redundancy.

• Regulatory standards continue to tighten.

DNOW’s exposure is to maintenance intensity. That distinction matters when cycles turn.

D. AI, data centers, and second-order infrastructure demand

AI and data centers do not buy parts from DNOW directly, but they reshape the physical economy underneath them. Data-center expansion pulls forward:

• generation capacity

• grid upgrades

• gas infrastructure

• cooling and redundancy systems

All of these are flow-control and MRO-intensive over time. DNOW’s participation is indirect but durable, and it reinforces the broader theme: as society leans harder on physical systems, downtime becomes more expensive.

E. The MRC Global integration as a structural catalyst

The MRC Global acquisition is the most important company-specific catalyst because it changes DNOW’s competitive geometry.

The combination delivers:

• materially higher network density

• expanded PVF category leadership

• improved purchasing leverage

• broader customer relevance across energy, utilities, and industrials

This matters for three reasons:

1. Service reliability improves with scale and inventory depth

2. Customer consolidation accelerates toward fewer, larger suppliers

3. Digital procurement leverage increases as workflows standardize

The strategic value is the reinforcement of DNOW’s moat where it actually matters: availability and fulfillment certainty.

3. Risks

• Integration execution risk:
  The MRC integration must preserve service levels. Any disruption to availability directly undermines DNOW’s value proposition.

• Energy activity downturns:
  DNOW is maintenance-oriented but not immune to sharp volume contractions in energy-related end markets.

• Policy volatility:
  Tariffs and industrial policy can raise costs as well as stimulate domestic investment. DNOW must maintain pricing discipline and execution to benefit net-net.

• Digital disintermediation risk:
  Digital procurement reduces friction, but it also lowers switching costs if DNOW fails to be the preferred platform. The bull case assumes DNOW deepens lock-in, not commoditization.

• Working-capital mismanagement:
  Inventory discipline during integration and demand shifts is critical. Poor execution here would pressure cash generation.

4. Conclusion

DNOW is best understood as industrial uptime infrastructure, not as a commodity distributor or a simple energy proxy.

Its economics are driven by:

• The cost of downtime.

• The value of availability.

• The difficulty of replacing an embedded supply-chain partner.

In a world of heavier physical capital, tighter supply chains, and lower tolerance for failure, those attributes become more valuable. The MRC Global combination materially strengthens DNOW’s position by widening its moat in the areas that matter most: inventory density, category breadth, and procurement integration. This is not a call on oil prices, GDP growth, or political outcomes. It is a call on a durable economic reality:

When downtime is expensive, the distributor who prevents it becomes indispensable.

That is the business DNOW is building.

Disclaimer:

This publication is for educational and informational purposes only. It reflects research opinions and illustrative examples, not investment advice or recommendations. Nothing herein constitutes an offer, solicitation, or advice to buy or sell any security. By reading, you agree to the full disclosures → Ridire Research Substack Disclaimer

Table of Contents

• 1. Investment Thesis

• 2. Quantitative Context

• 3. Catalysts & Narrative

• 4. Risks

• 5. Conclusion

Thesis Summary:

Coterra Energy (CTRA) is a diversified oil and natural gas producer with an exceptional free cash flow profile and a disciplined capital return strategy. Formed from a merger of premier shale operators, Coterra commands low-cost assets in both the Permian (oil) and Marcellus (gas) basins, allowing it to nimbly pivot investment to whichever commodity offers better returns. Trading at a value-investor price but delivering high margins and return of capital, CTRA offers a compelling opportunity as an “all-weather” energy play poised to outperform when gas prices recover and as its shareholder-friendly initiatives gain traction.

1.) Investment Thesis

Coterra’s investment case rests on superior business quality and optionality within the energy sector. The company boasts a high-quality, long-life asset base across three core regions – the Permian Basin of West Texas/New Mexico, the Marcellus Shale in Pennsylvania, and the Anadarko Basin in Oklahoma. These assets are top-tier in productivity and cost-efficiency, giving Coterra one of the lowest cost structures in the industry.

Management estimates Coterra’s corporate free cash flow breakeven at roughly $50/bbl WTI oil and $2.50/MMBtu Henry Hub gas, a remarkably low threshold that underscores its drilling prowess and geology.

In practice, this means Coterra can remain profitable (and even cover its dividend) through harsh downturns that would squeeze many peers off the field. As CEO Tom Jorden put it, the “durability of our high-quality asset portfolio shines throughout various price cycles,” driven by “the quality of the rock, our competitive drilling and completion costs, low cost structure and high margins”. This is a critical moat in a commodity business: Coterra sits low on the cost curve, enjoying high margins when prices are strong and still generating cash when prices are weak.

Diversification as a competitive advantage is the second pillar of the thesis. Unlike pure-play E&Ps, Coterra is a true oil and gas company, about half of its revenue comes from oil and liquids and half from natural gas, depending on price levels. This multi-basin, multi-commodity model gives Coterra flexibility to allocate capital to the highest-return projects at any given time.

For example, in 2023’s weak gas environment, Coterra leaned into its oil-rich Permian assets (running 9 rigs there) while scaling back activity in gas-focused Appalachia. Conversely, if gas prices surge, Coterra can ramp Marcellus drilling to capitalize. This dynamic approach maximizes returns and acts as a natural hedge: oil and gas fundamentals often diverge, and Coterra can benefit from whichever is favorable. Notably, an activist investor (Kimmeridge) has pressed Coterra to become a pure Permian oil player, but the company maintains that the “diversified strategy” unlocks more value by not “overlook[ing] the value of Marcellus gas assets”. We agree with management’s view: the gas segment is a strategic asset with significant long-term worth, and the diversification adds resilience. In short, Coterra has built-in optionality that most peers lack.

Crucially, Coterra couples this quality asset base with strong financial discipline and shareholder focus. The company runs a conservative reinvestment rate (about 50–55% of cash flow back into capex), which is far more restrained than shale drillers of the past and ensures hefty free cash flow. Indeed, at current strip prices Coterra expects ~$2.0 billion of free cash flow, roughly a 10% yield on the market cap. Rather than chase reckless growth, management prioritizes returning cash.

The stock’s valuation is mispricing these strengths, in our view. Despite its quality and cash generation, CTRA trades at a single-digit cash flow multiple and offers a high-single-digit to low-double-digit FCF yield at the current price.

Such a valuation implies skepticism either about commodity prices or about Coterra’s hybrid model.

This creates a classic asymmetry: Coterra is already highly profitable at today’s depressed gas prices, any improvement in pricing or sentiment could unlock outsized equity upside, whereas downside is cushioned by the company’s low cost base and ongoing buyback/dividend support. In effect, investors are “getting paid to wait,” collecting a ~3–4% base dividend (and additional buyback-induced EPS growth) while the thesis unfolds. Few E&Ps combine this level of income with torque to a recovery. In sum, Coterra represents a rare “quality-value” play in energy. It has the moats of low cost and diversified assets, the prudent capital allocation of a seasoned operator, and the shareholder orientation of a mature cash cow. Yet it’s “unloved and misunderstood” by some in the market (to borrow a recent description), a perception we expect will change as catalysts materialize.

2.) Quantitative Context

Under Ridire’s proprietary REC (Ridire Efficiency Composite) framework, Coterra screens as one of the most operationally efficient energy producers in our coverage universe. On this measure, CTRA ranks in the top decile of the sector, reflecting a business that consistently converts asset quality and capital discipline into durable cash outcomes.

CTRA’s REC strength is driven by its ability to sustain high free cash flow efficiency at current strip pricing without reliance on leverage, aggressive reinvestment, or favorable commodity conditions. The company demonstrates a repeatable capacity to self-fund operations, maintain production, and return capital through the cycle, a profile that distinguishes structurally efficient operators from cyclical beneficiaries.

Forward-looking indicators embedded in REC further reinforce this positioning. Coterra sits in the upper tier of large-cap E&Ps on operating durability, pairing strong margins with measured growth rather than volume-led expansion. This balance supports cash stability and limits downside sensitivity during weaker pricing environments.

Taken together, CTRA’s REC profile signals an efficiency advantage that is not fully reflected in market expectations. The stock is not mispriced because it is misunderstood on valuation, but because its operational efficiency tends to be under-appreciated during periods of commodity pessimism.

This gap between measured efficiency and prevailing sentiment is central to the CTRA thesis and frames the catalyst discussion that follows.

3.) Catalysts & Narrative

• Coterra is positioned for a constructive shift in its operating environment without requiring a single-point forecast. U.S. natural gas fundamentals are moving toward balance as export capacity expands and supply growth moderates, creating asymmetric upside for large, low-cost producers with embedded optionality. Coterra’s scale gas position and capital flexibility allow it to participate in this transition without sacrificing balance sheet integrity.

• The oil portfolio provides stability. Execution in the Permian continues to improve through efficiency gains and disciplined capital deployment, reinforcing cash durability at mid-cycle conditions and insulating returns from industry-wide growth deceleration.

• Capital returns remain a core lever. Coterra’s framework prioritizes balance sheet strength while preserving flexibility to increase shareholder distributions as visibility improves. This approach compounds downside protection and supports re-rating as cash flow consistency becomes more evident.

• Finally, the market narrative is evolving. What was once viewed as strategic ambiguity is increasingly recognized as resilience. As focus shifts toward efficiency, durability, and capital stewardship, Coterra’s diversified model and operating discipline are more likely to be rewarded.

4.) Risks

• Coterra remains exposed to oil and natural gas pricing. A prolonged period of weak demand or oversupply would pressure cash generation and constrain capital returns. While the company’s cost structure and flexibility mitigate downside relative to peers, hedging can also dampen upside participation in sharp commodity recoveries. The market largely prices this risk as persistent; our view assumes eventual normalization, but timing remains uncertain.

• Activist involvement introduces headline and strategic uncertainty. Pressure to pursue asset sales, structural changes, or strategic simplification could create execution risk or reduce diversification benefits if pursued opportunistically rather than cyclically. That said, increased scrutiny may also accelerate value recognition rather than impair it.

• Coterra’s forward profile assumes continued operational consistency and successful integration of recently acquired assets. Any shortfall in drilling performance, cost control, or inventory quality would weaken the efficiency thesis. The company’s track record reduces this risk, but it remains a key variable to monitor.

• Exposure to regulated basins introduces risks around permitting, environmental compliance, and infrastructure availability. These factors can limit growth optionality or reduce realized pricing, particularly for natural gas. Coterra’s conservative growth posture partially reflects this constraint.

• A core point of debate is whether Coterra’s diversified oil-and-gas model enhances resilience or suppresses valuation. Bears argue the company lacks the focus needed to earn premium multiples. Our view is that the market over-penalizes this structure during commodity troughs, despite evidence that diversification improves cash durability and risk-adjusted returns.

Overall, these risks are real but largely known. We believe they are more than reflected in current expectations, while the upside from improved conditions and sustained execution remains under-appreciated.

5.) Conclusion

Coterra Energy is a case study in fundamental value waiting to be recognized. The company’s unique combination of low-cost, diversified assets and prudent capital management has produced a cash flow juggernaut that the market has yet to fully appreciate. Our analysis, highlights that CTRA scores highly on both profitability and valuation metrics, an alignment rarely seen without a catch. In Coterra’s case, the “catch” has been negative sentiment around natural gas and a complex story, but those are precisely the factors we see turning into tailwinds. As the narrative shifts, aided by improving gas markets, consistent execution, and active capital returns, we expect Coterra’s high efficiency, high cash yield profile to be rewarded.

In essence, Coterra offers the best of both worlds: it’s an energy producer that can thrive in either oil or gas up-cycles, and it pays you well to own it in the meantime. The stock’s current mispricing provides a margin of safety, while the upcoming catalysts provide multiple shots for unlocking value. This is a high-quality business priced like a mediocre one, a discrepancy worth exploiting.

Disclaimer:

This publication is for educational and informational purposes only. It reflects research opinions and illustrative examples, not investment advice or recommendations. Nothing herein constitutes an offer, solicitation, or advice to buy or sell any security. By reading, you agree to the full disclosures → Ridire Research Substack Disclaimer

Ridire Research is not shutting down, slowing down, or changing direction.

The work continues. The funnel continues. The themes, frameworks, and cadence all remain the same. If anything, the research is becoming more focused and easier to evaluate.

What is changing is how accountability is expressed, and the reason is straightforward:

Beginning in January, I’ll be operating in a new professional role, one where the optics around aggregation, presentation, and interpretation of research outputs can reasonably be scrutinized more closely, even when those outputs are hypothetical and educational in nature. As responsibilities evolve, it makes sense to tighten structure before anything becomes ambiguous. This is a deliberate, preemptive refinement, not a reaction.

Retiring the RidIndex (and Only the RidIndex)

The RidIndex was created to make research more concrete, to express published ideas in a single, simplified construct so readers could see how narratives, valuation, and risk evolved together over time, including when things didn’t work.

It served that purpose well.

The idea itself wasn’t novel. Like many independent researchers, I borrowed a familiar presentation device used by some of the most successful finance publications: expressing ideas through a consolidated, hypothetical construct to enforce discipline and visibility.

Ironically, that same construct is also one of the most common points of criticism those publications receive. Aggregation can blur reasoning, overweight optics, and invite interpretation that goes beyond what research is meant to provide.

After running the RidIndex in practice, and watching how similar constructs are received elsewhere, it’s clear that the costs now outweigh the benefits.

As the publication has grown, maintaining a rolling, aggregated construct introduces diminishing returns. It can obscure why individual ideas worked or failed, and it can unintentionally suggest continuity or cohesion beyond what a research publication is designed to offer.

For that reason, the index will be formally retired. Nothing else changes. This is simply a tightening of structure to ensure clarity, for readers today and for how the work is interpreted over time.

What Replaces It: Per-Article Accountability

Going forward, accountability will be handled at the article level, not through an aggregate construct.

Each idea or theme will stand on its own, anchored to the date it was published. Follow-ups will focus on:

• What happened after publication

• What drove the outcome

• Which assumptions mattered

• Where the thesis held up, or didn’t

This avoids aggregation distortion and reflects how most readers actually engage with the work: one idea at a time. Research should be falsifiable. Per-article tracking does that more cleanly than a rolling composite ever could.

Introducing the Per-Article Tracking Spreadsheet

To support this shift, I’ll be publishing a simple, transparent Excel tracker that holds ideas accountable on a per-article basis.

This tracker will:

• List each article and its publication date

• Track hypothetical, point-to-point price changes from the time of publication to later review dates

• Avoid weights, aggregation, or portfolio construction

• Assume no interim rebalancing, trimming, exits, or optimization

Each row stands alone. There is no cumulative performance, no rolling construct, and no implied strategy. The purpose of the tracker is not to present a record or a system. It’s to answer a straightforward question in the cleanest possible way:

What happened after the idea was published?

This format keeps accountability explicit without implying continuity where none exists. You can download the latest copy here:

Ridire Research Article Tracker

14.7KB ∙ XLSX file

Download

Download

The Philosophy Remains the Same

Ridire Research exists to make thinking visible. That means:

• frameworks over forecasts

• clarity over complexity

• accountability over certainty

Retiring the RidIndex will actually increase transparency for most readers. Shifting to per-article tracking tightens evaluation without changing the substance of the work. The research remains public, iterative, and open to challenge. More soon.

Disclaimer:

This publication is for educational purposes only. Any performance shown is illustrative and tracked per article, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice or a solicitation. → Ridire Research Substack Disclaimer

Executive Summary

Rising system complexity and “prosumer” workflows are turning branded hardware and connectivity moats into recurring cash-flow engines. Each of these firms monetizes the interface between infrastructure and experience, where trust, data, and performance create lock-in.

• SNA is expanding beyond tools as diagnostic software and connected systems now outpace hardware growth, validating its shift toward subscription and workflow capture.

• LMN SW is compounding through curated travel packaging, converting curation and fulfillment into higher margins and cash build even in a volatile consumer backdrop.

• TMUS continues to leverage scale in network quality to lift ARPU and free cash flow through cross-sell (FWA, fiber) and cost-curve efficiency.

Across tools, travel, and telecom physical infrastructure becomes the substrate; recurring, data-rich monetization becomes the product.

Snap-on (SNA): Precision Tools Meet Recurring Workflow Capture

Thesis Summary:

• Snap-on has long dominated the professional tool market, but the company’s real transformation lies in its shift toward data-driven diagnostics and recurring software revenues. Its Repair Systems & Information (RS&I) division now leads the growth and margin profile of the business, building off a proprietary dataset that includes over 500 billion diagnostics records and 1.2 billion repair outcomes. In an era where vehicles are increasingly complex, electric drivetrains, ADAS sensors, encrypted ECUs, Snap-on provides not just physical tools but the essential software layer technicians rely on to solve problems quickly and accurately.

• The market still treats Snap-on like a cyclical industrial toolmaker, but it’s increasingly a tech-enabled platform embedded in automotive and heavy equipment maintenance workflows. The RS&I segment has shown 8.9% organic growth in Q3 2025, far outpacing the 1% Tools Group growth. Its diagnostic tools and repair subscriptions, sold on proprietary hardware, have become embedded in independent shops and OEM dealerships alike.

• Technicians now subscribe out of necessity, the RS&I software now covers 98% of vehicle types in the U.S., and its constant updates give Snap-on an edge in coverage and accuracy. This subscription model provides durable, high-margin recurring revenue (30%+ segment margin) and positions Snap-on as an irreplaceable node in the maintenance value chain.

Catalysts & Narrative:

• Near-term upside could come from multiple directions:

  • Further growth in EV diagnostics (where Snap-on already offers specialty tools for battery and high-voltage systems)

  • Increased subscription attach rates as new features roll out.

  • Macro recovery unlocking deferred capex among independent mechanics.

• There’s also a latent capital return angle, the company generates over $1B in annual FCF and maintains a strong balance sheet.

• With management guiding toward continued high-single-digit RS&I revenue growth and multiple new product launches slated through 2026, we expect software-led narrative momentum to strengthen.

Key Risks:

• EV repair mix could cannibalize some traditional tool demand over time.

• OEM restrictions on diagnostics or increasing competition from software-first repair platforms could also compress Snap-on’s data moat.

• In a macro downturn, tool purchases (especially big-ticket storage systems or lifts) may be delayed, which could drag on the legacy Tools segment even if RS&I proves resilient.

Lastminute.com (LMN SW): Curated Travel as Workflow Fulfillment

Thesis Summary:

Lastminute.com has repositioned itself as a travel fulfillment engine rather than a generic OTA. It does this by dynamically packaging flights, hotels, and ancillaries into bundled offerings that drive higher conversion, better margins, and stronger customer loyalty. With holiday packages now comprising more than 65% of revenue, LMN has turned curation into monetization, leveraging its legacy brand, a reengineered tech stack, and rising consumer demand for seamless value-focused travel.

Unlike OTAs that optimize for standalone flight or hotel inventory, LMN builds integrated bundles that abstract away the planning headache for customers. These packages have structurally higher take rates (~10%) and more pricing control. H1 2025 revenues were up 11% YoY, with Q3 revenue up 17% YoY and EBITDA up 35%. In addition, management has guided to continued margin expansion into 2026.

Strategically, the firm is broadening its channel mix through white-label deployments (ex. lastminute.ae in the Middle East) and enhancing its mobile stack to drive repeat usage. The recently installed CEO has stabilized governance post-controversy and laid out a clean multi-year roadmap.

Catalysts & Narrative:

• Peak season travel demand and continued mix-shift toward packages should support top-line upside in Q4.

• On the cost side, recent restructuring has already cut fixed costs by 5%:

  

• With the 2025 buyback program complete and balance sheet in a net cash position, reinstatement of shareholder returns could catalyze re-rating.

• Further expansion of loyalty offerings or mobile personalization could also reinforce customer lock-in and raise LTV.

Key Risks:

• LMN remains a small-cap European name with legacy baggage, past governance issues still create institutional hesitation.

• Travel remains macro-sensitive, especially for European discretionary spend.

• Competitive intensity from Booking, Expedia, or eDreams (subscription model) could also pressure CAC and margin.

T-Mobile US (TMUS): Network Moat, Cash Engine, Subscription Flywheel

Thesis Summary:

T-Mobile continues to turn its 5G spectrum scale into a cash compounder. In Q3 2025, it added over 2.3M net postpaid subscribers and raised full-year guidance across nearly every metric. More importantly, it’s transforming from a growth-through-subs model to an ARPU-expanding, multi-service subscription business via FWA, fiber, and enterprise. With $4.8B in Q3 FCF and aggressive buybacks underway, TMUS is monetizing network dominance into shareholder value at scale.

T-Mobile’s mid-band 5G network is materially ahead of peers in speed and coverage, and independent tests continue to confirm this. That network edge underpins customer acquisition, churn suppression, and now ARPU growth.

In parallel, T-Mobile is expanding its TAM via FWA (now 4M+ subs), and fiber (via partnerships with Lumos, Metronet). Meanwhile, enterprise wins and AI-driven CRM and pricing systems are enabling operating leverage.

This chart from Bloomberg Intelligence clearly illustrates how FWA has upended US broadband, intensifying competitive headwinds for cable operators:

Catalysts & Narrative:

• We see a high-probability path to FY26 guide-ups as integration costs fade, synergy capture accelerates, and ARPU expands via upsell.

• A further capital return announcement, or shift to a formal dividend growth policy, could expand the shareholder base.

• Near-term, expect margin tailwinds from AI-enabled service stack upgrades (post-$350M billing system impairment) and more efficient network scaling.

Key Risks:

• A potential price war (Verizon defensive moves) could pressure net adds and ARPU.

• Integration missteps (US Cellular or fiber expansion) could delay synergy realization.

• Regulators may scrutinize spectrum holdings if TMUS pursues more M&A or spectrum block wins.

Conclusion

This Tools & Interfaces basket (2% model portfolio weight, 0.66% each) targets recurring cash flows at the interface:

• Snap-on (SNA): Diagnostic content layered onto a legacy moat of branded tools and proprietary distribution.

• Lastminute.com (LMN SW): Curated travel packaging with defensible take-rates and strong conversion across bundles.

• T-Mobile US (TMUS): Network ARPU/ARPA flywheel, now boosted by US Cellular integration and adjacent fiber scale-up.

Each name compounds at the intersection of trust, infrastructure, and embedded monetization.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Table of Contents

• Executive Summary: Overview of the defense industrial cycle and Hard-Power Basket.

• Macro Context: The Industrialization of Deterrence: Global spending trends, NATO normalization, and supply-chain bottlenecks.

• Bristow Group (VTOL): Vertical-lift logistics and resilience infrastructure.

• Hyundai Rotem (064350 KS): Integrated armor and rail manufacturing.

• Creotech Instruments (CRI PW): Sovereign satellite and orbital systems.

• Conclusion: Equally weighted across air (VTOL), land (Rotem), and orbit (Creotech).

Executive Summary

Defense spending is entering an industrial phase. Across NATO and the Pacific, budgets are expanding and production lines are running at capacity. Foundries, avionics, and heavy-lift logistics are now the critical inputs for deterrence, and demand visibility stretches years ahead. The market is still focused on AI, but the more durable opportunity possibly sits in the companies rebuilding the physical infrastructure of defense.

Hard-Power Basket includes Bristow Group (VTOL), Hyundai Rotem (064350 KS), and Creotech Instruments (CRI PW), three firms positioned to compound through this defense industrial cycle. Each represents a different layer of the rebuild: air mobility, armored transport, and orbital communications.

Macro Context: The Industrialization of Deterrence

Rearmament has become a global capex cycle. Military expenditure reached $2.72 trillion as of 2024, up 9.4% yoy and 37% higher over the decade, the fastest sustained build-up in decades.

By the end of this year, all 32 members are expected to meet the 2% of GDP defense target, with Poland and the Baltic states above 3%, locking in multi-year procurement pipelines.

South Korea has become a key arsenal for Europe, delivering tanks, self-propelled howitzers, and rocket systems on tight schedules. Export volumes are tracking record highs this year.

Casting, avionics, railcar, and logistics suppliers are running near capacity. Lead times are stretching, and certified operators are beginning to gain pricing power as bottlenecks persist. In addition, defense logistics now overlaps with offshore wind, search-and-rescue, and satellite infrastructure, reducing cyclicality.

Our view: The “long defense” trade has moved past the primes. The alpha sits with Tier-2 enablers that turn sovereign policy into delivered capability, firms positioned at the intersection of manufacturing, logistics, and autonomy.

Bristow Group (VTOL)

Bristow operates one of the most advanced vertical-lift fleets in the world and remains the only independent operator with full global certification for government and offshore missions. Its competitive edge lies in scale, the world’s largest S-92 fleet, and in the hard infrastructure of trust: safety record, pilot training, and maintenance capability. The model is sticky; when a government contracts search-and-rescue, it stays with the same partner for decades. An example of this is the UKSAR2G rollout expanding Bristow’s footprint across the U.K. and Northern Europe, anchoring multi-year logistics revenue under government backing. At the same time, its offshore energy work is stabilizing as projects add to flight hours.

In addition, the partnership with Vertical Aerospace gives the company early exposure to eVTOL operations, a natural extension of its mission profile.

Essentially Bristow is evolving from an oilfield service legacy into the backbone of resilience logistics, emergency response, defense support, and offshore infrastructure. Few operators combine its regulatory clearances, pilot bench, and operational safety history. The next leg of growth comes from scaling these competencies into a global platform for industrial and sovereign missions.

Hyundai Rotem (064350 KS)

Rotem is Korea’s integrated manufacturer for both rail and armored systems, a dual capability that gives it a unique advantage as nations rebuild industrial capacity. The company produces the K2 main battle tank and high-speed rolling stock from a single engineering base, supported by the Hyundai and Hanwha industrial ecosystem. That combination of defense credibility and civilian manufacturing scale allows Rotem to deliver faster and at lower cost than European peers.

The landmark K2 program in Poland is now the anchor of Europe’s armor renewal. Localized production at Gliwice will embed Rotem inside Europe’s supply chain, creating a template for follow-on orders from other NATO members. Parallel wins in rail, including the record ONCF contract in Morocco, keep the company’s backlog balanced across sectors and geographies.

Rotem’s strength is in its ability to move quickly from design to delivery. Korea’s export model, government financing, proven equipment, and flexible transfer-of-technology, is giving it a structural foothold in markets once dominated by Western primes. As Europe re-industrializes its defense base, Rotem stands out as the supplier building both the tracks and the tanks.

Creotech Instruments (CRI PW)

Creotech is Poland’s leading satellite integrator and one of the few European firms capable of building complete small-sat systems, from electronics to ground control, under ESA certification. Its HyperSat platform is modular, flight-proven, and fully owned, positioning the company at the center of Europe’s push for strategic autonomy in space.

The CAMILA constellation and the MIKROGLOB defense program have turned Creotech into a sovereign supplier. Together, these contracts align the company with Europe’s own shift toward independent launch and observation capacity.

Creotech’s moat is technological sovereignty. It builds the subsystems Europe no longer wants to import, onboard computers, power units, and integration services for national constellations. As satellite demand moves to security, Creotech has already become one of the continent’s default providers.

Conclusion

The Hard-Power Basket holds Bristow (VTOL), Hyundai Rotem (064350 KS), and Creotech Instruments (CRI PW), operators building the air, land, and orbital layers of modern deterrence. The sleeve runs at 0.7% of NAV, sized for a cyclical but durable policy-driven uptrend. Positions are equally weighted (~0.23% each) to balance exposure across transport, armor, and space until the theme matures.

Disclaimer:

This publication is for educational and informational purposes only. Any performance referenced is illustrative and tracked on a per-article basis, not as part of a model portfolio or investment program. Nothing herein constitutes investment advice, a recommendation, or a solicitation. → Ridire Research Substack Disclaimer

Setup: 3% long sleeve of 11 rare-disease and specialty healthcare names (~0.27% each) vs. -3% short split XBI/PPH (≈50/50) for a near market-neutral expression.

Core thesis: In biotech/medtech, power accrues to bottlenecks: IP chokepoints, regulatory exclusivity, clinician workflow captivity, manufacturing scarcity, and distribution privileges. Own the bottlenecks, short the beta.

Model Portfolio Weightings:

How We Define “Moat” In This Context

• Regulatory protection: Orphan exclusivity, Breakthrough/PRV advantages, complex labeling that deters follow-on.

• IP choke points: Foundational patents (platforms, adjuvants, process IP) + freedom-to-operate barriers.

• Manufacturing scarcity: Biologics/biosimilars scale, high-purity proteins, aseptic complexity, or GMP-qualified capacity.

• Clinical workflow lock-in: Installed software/device bases, multi-year hospital contracts, training & data gravity.

• Channel & KOL control: Specialist prescriber concentration, advocacy groups, long-tail disease education.

• Capital discipline: Non-promotional OPEX, partner leverage, milestone funding, balanced risk budgets.

1) C4 Therapeutics (CCCC): Targeted Protein Degraders (TPD)

C4 Therapeutics sits at the intersection of precision oncology and chemical innovation. The company is one of the purest plays on targeted protein degradation (TPD), a modality designed to “tag” disease-causing proteins for destruction rather than inhibition. Where traditional small molecules block activity, degraders remove the protein entirely, offering potency and durability beyond conventional approaches.

C4’s differentiator is its E3 ligase platform chemistry, the cellular machinery that enables targeted degradation, paired with an evolving IP fortress and early proof-of-concept in orphan oncology indications. In a landscape crowded with discovery-stage imitators, C4 has turned platform potential into a replicable drug engine.

Moats

• Platform IP & know-how:
  C4’s intellectual property around E3 ligase binding and linker design represents a deep, defendable moat. The company’s proprietary TORPEDO platform (Target ORiented ProtEin Degrader Optimizer) provides rational degrader design and in silico screening capabilities, giving it a first-principles edge that shortens the optimization loop from years to months. These capabilities have already attracted blue-chip validation, including collaborations with Pfizer and Biogen, who recognized C4’s medicinal chemistry depth and scalable screening. The chemistry is not plug-and-play; ligase recruitment and linker optimization are empirically hard problems few labs can solve repeatedly.
  

• Orphan oncology focus:
  Unlike most TPD companies chasing broad oncology markets, C4 has concentrated on rare, genetically defined cancers, such as synovial sarcoma and multiple myeloma, where smaller, faster pivotal trials can lead to exclusivity-driven cash flow. Orphan drug designations for CFT8634 (BRD9 degrader) in synovial sarcoma and CFT7455 (IKZF1/3 degrader) in multiple myeloma not only confer 7 years of U.S. market exclusivity but also ensure regulatory support and pricing inelasticity. This rare-disease lens amplifies the fundamental advantages of the TPD platform, small, stratified patient populations, limited competition, and early commercial validation.
  

• Capital discipline:
  Unlike many peers that overbuild, C4 has kept its burn rate lean, targeting one to two INDs per year and leveraging partners for risk-sharing. Its deal structures with Pfizer and Biogen provide milestone capital and downstream royalties, a hybrid biotech model that extends runway and keeps ownership optionality.

Bottlenecks

• Ligase biology & medicinal chemistry:
  Protein degradation is deceptively complex. Potency, selectivity, and pharmacokinetics must balance within narrow ranges, and only a handful of ligases (e.g., CRBN, VHL) have proven tractable. C4’s team has mastered ligase-ligand engineering across multiple E3 ligases, an expertise that forms both a technological and personnel bottleneck. Very few companies possess comparable structure-based modeling and in vivo optimization data at this scale, making C4 one of the only independent pure-plays capable of serial degrader production.
  

• Trial access in ultra-rare tumors:
  With orphan oncology programs, KOL relationships and site readiness are strategic assets. Running efficient studies in rare tumor subtypes requires established referral networks, trial design expertise, and patient registries, resources C4 has already built through its sarcoma and myeloma collaborations. These networks serve as barriers to entry for newer entrants hoping to replicate the orphan model.
  

• Manufacturing and scale-up:
  While degraders are small molecules, they often possess complex linker chemistries that strain standard GMP processes. C4’s internal CMC knowledge and supply chain partnerships position it ahead of many TPD competitors that are still scaling pilot batches.

Trip-Wires / KPIs to Monitor

• Durable responses in orphan oncology cohorts, especially synovial sarcoma (CFT8634) and multiple myeloma (CFT7455): readouts confirming disease modification over inhibition.

• Combination data with standard-of-care (e.g., lenalidomide) validating safety and synergistic efficacy, unlocking broader usage.

• Partnership milestone cadence: revenue recognition from Pfizer/Biogen deals will serve as confidence indicators of external validation.

Variant Risk

• Class-wide toxicity: TPDs have flirted with IMiD-like or cereblon off-target effects, particularly in immune cells; adverse safety signals could reset investor confidence in the entire modality.

• Ligase resistance: Tumors may evolve ligase-binding site mutations or alternative degradation pathways, eroding durability.

• Platform crowding: Larger players (Arvinas, Kymera) could absorb capital attention, though their broader indications dilute focus.

Summary View

C4 Therapeutics exemplifies what Rare by Design looks like in early-stage innovation: a company that engineered both a molecular and strategic moat.

• Technological moat: Replicable degrader chemistry + platform IP.

• Market moat: Orphan oncology focus with exclusivity and limited competition.

• Operational moat: Partner funding and data-driven design that compound efficiency.

As the sector evolves, degraders will likely bifurcate, platform owners and product licensees. C4 is built to be the former. Its pipeline depth, orphan execution, and capital prudence make it a long-duration optionality trade within a space most investors treat as binary.

2) Alvotech (ALVO): Biosimilar Foundry with Rare-Disease Reach

Alvotech is quietly building what could become the TSMC of biologics, a fully integrated, globally compliant biosimilar manufacturer with the infrastructure, analytics, and regulatory credibility to operate as a capacity bottleneck in a post-patent world. Where most biotechs are single-asset narratives, Alvotech is a platform in reverse: it starts with proven biologics and competes on cost, quality, and speed at a global scale. Its moat isn’t just about price competition, it’s manufacturing orthodoxy, regulatory intimacy, and network distribution across dozens of payor regimes.

Moats

• End-to-end biologics capability:
  Alvotech is one of the few independents that controls the entire biosimilar value chain, from cell-line development to purification, analytics, and fill-finish, all within its single-site facility in Reykjavik, Iceland. This vertical control eliminates cross-contamination risk, reduces tech-transfer friction, and allows real-time process optimization. The result: faster global filings, lower COGS, and tighter compliance cycles. For complex molecules (monoclonal antibodies, fusion proteins), reproducibility is the gatekeeper, and Alvotech has proven it can consistently meet EMA and FDA biosimilarity standards, a technical feat most peers still struggle with.
  

• Regulatory moat:
  Alvotech’s CMC (chemistry, manufacturing, and controls) and analytics infrastructure rivals Big Pharma’s. It has already resolved FDA observations from 2022–23, re-establishing full GMP standing, a testament to quality governance discipline. This matters because biosimilar regulators are risk-averse; once a manufacturer demonstrates reliability, future approvals accelerate.Regulators trust repeat performers, and that trust compounds like credit history.
  

• Partner network as distribution flywheel:
  Alvotech doesn’t commercialize everything alone. Instead, it licenses commercialization rights regionally, e.g., Teva in the U.S., STADA in Europe, Fuji Pharma in Japan, Advanz in smaller markets. This model decentralizes commercial risk while preserving global penetration. In effect, Alvotech’s partners act as a multi-node sales force, embedding the company across payer systems and formularies. This creates a distribution moat, Alvotech’s partners are incentivized to keep pipelines full, ensuring repeat deals and sticky relationships.
  

• Rare- and specialty-bio overlap:
  Beyond the blockbuster biosimilars (Humira, Eylea), Alvotech’s pipeline includes biosimilar candidates for orphan and specialty indications. Through its Advanz Pharma collaboration, it’s developing copies of drugs like canakinumab (IL-1 inhibitor for rare autoinflammatory syndromes) and ofatumumab (B-cell therapy for multiple sclerosis). These target markets combine high biologic pricing and low patient counts, allowing biosimilars to enter rare-disease economics without the risk of true novelty R&D. In short: Alvotech leverages its scale into rare biology adjacencies, where pricing power and reimbursement stability mirror orphan-drug dynamics.
  

Bottlenecks

• CMC comparability analytics:
  The hardest moat to replicate is statistical similarity.Achieving equivalence across pharmacokinetics, potency, and glycosylation profiles requires proprietary assay systems and seasoned analysts. Alvotech’s analytical team has built internal libraries of reference product variability, allowing it to predict drift and adjust production proactively, a subtle but powerful edge in passing biosimilarity reviews.
  

• Sterile fill-finish and purification throughput:
  Global sterile fill-finish capacity remains the ultimate bottleneck in biologics.
  Alvotech’s integrated, high-yield line can process multiple biosimilars simultaneously, enabling it to time product launches precisely with patent cliffs.
  In practice, that means while competitors scramble for contract manufacturing slots, Alvotech hits the market on Day 1 of patent expiry, a margin timing advantage that compounds with every cycle.
  

• Global regulatory harmonization:
  Alvotech’s team has become fluent in multiple regulatory dialects, FDA, EMA, MHRA, PMDA, each with distinct analytical and validation standards. This multi-jurisdiction competence forms a human-capital bottleneck that can’t be easily poached. Few teams can synchronize filings across four continents while keeping CMC consistency, it’s a quiet, underappreciated moat.
  

Trip-Wires / KPIs to Monitor

• U.S. approval cadence: FDA reinspection milestones (particularly for AVT02, the Humira biosimilar) and speed of post-approval market share gains.

• Partner launch velocity: STADA and Advanz execution in Europe; visibility into pricing discipline under tender regimes.

• Biosimilar pipeline progression: Transition of canakinumab/ofatumumab programs toward pivotal stages, key to proving rare-disease leverage.

• Facility utilization: Degree of production line optimization and throughput increases post-FDA clearance.

Variant Risk

• Tender compression: Simultaneous price erosion across top molecules can squeeze blended margins, especially if payors shift faster than volume uptake.

• Regulatory reinspection: Any reemergence of compliance findings could reprice execution risk, given single-site dependence.

• Partner misalignment: Underperformance or strategy shifts by commercial partners could temporarily mute uptake in key geographies.

Summary View

Alvotech is an industrialized biology story: one site, global compliance, reproducible output. Its manufacturing-first moat creates optionality across molecules and geographies, and its rare-disease biosimilar pivot introduces upside in niche, high-margin categories. In a biotech landscape obsessed with discovery, Alvotech’s edge is execution at scale: control of every molecule, every batch, and every gatekeeper.
This is the antithesis of speculative biotech, tangible cash conversion from process scarcity. Own the factory everyone else must rent.

3) Gedeon Richter (RICHT) — CNS Royalty + Women’s Health

Gedeon Richter is Europe’s best-kept secret in specialty pharmaceuticals, a 120-year-old Hungarian firm that quietly built two enduring profit engines:

(1) a royalty stream from Vraylar (cariprazine), one of the world’s best-selling antipsychotics, and

(2) a deep, defensible franchise in women’s health built on decades of proprietary steroid chemistry.

Where most biotechs chase one molecule or one modality, Richter compounds through royalties, niche innovation, and global distribution. Its moat is structural: protected cash flows, high-margin chemistry, and patient trust built molecule by molecule.

Moats

• Blockbuster royalty annuity (CNS):
  Vraylar (cariprazine) is co-developed by Richter and Allergan (now AbbVie). It’s approved for schizophrenia, bipolar I disorder, and as an adjunctive treatment for depression, a triple label that has driven explosive adoption. In 2023, U.S. sales exceeded $2.7 billion (+35% YoY), putting it among the top 50 drugs globally. Richter earns a mid-teens royalty on these sales, translating into hundreds of millions in steady, non-dilutive cash annually. The compound’s complexity, cariprazine is a dopamine D3/D2 partial agonist with slow receptor kinetics, makes generic replication difficult. Patents stretch into 2028–2030, with lifecycle extensions likely to protect the U.S. franchise into the early 2030s.
  This royalty base functions like an internal bond portfolio, underwriting R&D and BD spend across the rest of the business.

• Steroid chemistry & women’s health mastery:
  Richter’s second moat is biochemical, not financial. The company has been a global leader in steroid chemistry since the 1950s, one of the few independents capable of producing API-grade synthetic hormones and selective progesterone receptor modulators (SPRMs) at scale. This legacy underpins its market-leading contraceptive and menopause products, as well as new-generation oral therapies for gynecological disorders. Its flagship, Ryeqo (relugolix combination), provides a non-surgical therapy for uterine fibroids and endometriosis, conditions that affect millions but remain under-treated. These franchises enjoy decade-long product cycles, sticky prescriber bases, and strong payer acceptance, all key ingredients for compounding.

• Dual-channel moat: Royalty + Operating Profit Engine:
  The Vraylar royalty stream smooths earnings volatility, while the women’s health division contributes recurring product revenue, a dual-channel model that gives Richter the financial elasticity to invest through downturns. Few mid-cap pharmas have such a balanced setup: one global royalty annuity (CNS) and one fully-owned cash cow (hormone-based therapies).

• Regulatory and geographic reach:
  Operating in 100+ countries, Richter’s in-house EU regulatory and manufacturing infrastructure allows it to launch and distribute without dependency on contract partners. In Europe, it owns its salesforce; in emerging markets, it leverages long-standing joint ventures. This self-sufficiency in both supply chain and regulatory execution creates resilience most small biopharmas lack. EU-specific know-how, navigating national price caps, HTA submissions, and tender cycles, is a competitive advantage in its own right.

• Balance sheet moat:
  Investment-grade rated, net-cash balance sheet, and prudent capital allocation. Richter is reinvesting royalty cash into de-risked adjacencies. The result is compounding without dilution.

Bottlenecks

• Neuropsychiatric KOL and payer inertia:
  Psychiatry has immense inertia. Once a molecule like Vraylar earns guideline inclusion and physician familiarity, switching costs become psychological as well as clinical. Prescribers and payers both resist disruption, especially in multi-indication therapies with established safety profiles. These entrenched relationships are hard to replicate and slow-moving, a behavioral bottleneck that sustains market share long after patent expiry anxiety begins.

• Regulatory positioning in women’s health:
  The ability to run multi-country trials in reproductive endocrinology, from patient recruitment to regulatory harmonization, is a rare skillset. Richter has built end-to-end regulatory and clinical operations across the EU, Russia, and emerging markets. That infrastructure forms an invisible moat: it’s much faster and cheaper for Richter to bring a new therapy to market in Europe than for a U.S. mid-cap trying to localize operations.

• API vertical integration:
  Richter manufactures its own active pharmaceutical ingredients (APIs), a strategic bottleneck in an industry now riddled with supply shocks. This ensures margin protection, quality control, and pricing leverage across both internal and partnered portfolios.

• Clinical development expertise in hormone modulation:
  Decades of cycle control data and real-world safety outcomes form a proprietary database that newer entrants can’t shortcut. It’s a time moat, 40 years of validated pharmacodynamics data that underpins regulator trust and prescriber confidence.

Trip-Wires / KPIs to Monitor

• Vraylar trajectory: Monitor AbbVie’s script growth and any early signs of generic strategy. Each new label expansion or add-on indication compounds the royalty stream’s duration.

• Women’s health pipeline: Track adoption curves of Ryeqo and label expansions in uterine fibroids/endometriosis; early physician uptake and reimbursement wins are critical.

• Royalty reinvestment rate: How much of the Vraylar cash is plowed into future compounding vs. returned as dividends.

• Geographic expansion: Progress in Asia-Pacific and LATAM markets where hormone therapy penetration remains low.

Variant Risk

• Patent expiry timing: Accelerated generic entry for Vraylar post-2030 could shorten the cash-flow runway, though complex chemistry reduces immediate threat.

• EU pricing pressure: Drug price negotiations across key EU markets could trim margins in the women’s health portfolio.

• Geopolitical exposure: Some emerging-market operations (Russia, CIS) introduce FX and regulatory volatility.

• Pipeline execution: Delays or underperformance in newer gynecologic products could slow offsetting growth as legacy contraceptives mature.

Summary View

Gedeon Richter is a rare compounder hiding in plain sight, a blend of royalty annuity, chemical craftsmanship, and geographic self-sufficiency.
Its “barbell model”, one side stable (royalties), the other innovative (hormone therapeutics), generates durable returns and cushions volatility. This is a business that monetizes time: the inertia of physicians, the longevity of patents, and the compounding of trust. In the basket, Richter serves as exposure to two secular themes: mental health and women’s wellness. In a market full of pre-revenue promises, Richter is the exception: a cash-flow engine priced like a cyclical, performing like a compounder.

4) CureVac (CVAC) — The mRNA Toll Road

CureVac is the non-U.S. mRNA platform with a credible shot at toll-road economics: foundational sequence/process IP that others may need to license, a refocused Gen-2 pipeline (with GSK) aimed at higher translational efficiency, and a multi-year cash runway to execute in a capital-scarce tape. The setup is asymmetric: IP outcomes + leaner R&D + partnered execution give multiple paths to value creation without chasing volume at any cost.

Moats

• Foundational IP & process know-how

  • Portfolio around sequence engineering (e.g., UTR/poly-A design), codon optimization, and templating that underpins antigen expression and durability.

  • The moat is a stack (sequence rules + manufacturing controls + QC analytics) that’s hard to replicate cleanly at scale.

• Manufacturing orthodoxy (process control as a moat)

  • mRNA output hinges on tight in-vitro transcription, capping, purification, and LNP formulation windows. CureVac’s internal playbooks target lower batch variability and COGS step-downs, critical for seasonal vaccines and global tenders.

  • Process reproducibility plus release analytics become the regulatory trust asset (and barrier for fast followers).

• Partnership leverage (GSK, EU ecosystem)

  • Co-development structure that shares wet-lab risk while preserving upside in infectious disease.

  • Proximity to European academic networks, trial infrastructure, and public health agencies shortens the path from lab → clinic → tenders.

• Runway = optionality

  • A multi-year cash buffer (post-restructuring) in a tight funding regime; the company can sequence milestones rather than sell optionality at a discount.

  • Lets CVAC run Gen-2 shots on goal (infectious disease + early oncology) while litigating/negotiating IP from a position of time.

Bottlenecks

• Sequence → expression translation

  • The hardest part of mRNA today is predictable in-cell expression across tissue contexts without excessive innate immune activation. CVAC’s rules-of-thumb for UTR/poly-A/codon usage are hard-earned and tacit, a human-capital moat not easily copied.

• Scale, purity, and LNP fit

  • High-throughput enzymatic steps, dsRNA removal, and particle uniformity remain non-commoditized. Fit-for-purpose LNPs (organ tropism, reactogenicity balance) are a rate limiter for many rivals; CureVac’s platform alignment is a hidden gate.

• IP navigation as a specialty

  • Global freedom-to-operate in mRNA is a maze. CVAC’s internal/extern counsel, claim strategy, and data room hygiene are a bottleneck capability, few teams can run offense (assert, settle) while keeping defense (FTO) intact across jurisdictions.

Trip-Wires / KPIs to Monitor

• IP milestones: Interim rulings, settlements, or royalty frameworks that monetize platform rights without protracted appeals.

• Gen-2 readouts: Early immunogenicity/neutralization vs first-gen baselines; translate into dose-sparing or durability advantages.

• COGS trajectory: Evidence of batch yield gains and release-test cycle time reduction (seasonal viability, tender competitiveness).

• Partner cadence: GSK co-dev milestones, new co-funded programs (respiratory, pandemic-preparedness), and regional tender wins.

• Oncology wedge: First-in-human tumor vaccine signals (antigen presentation, T-cell quality), even in small cohorts, proof of platform versatility.

Variant Risk

• Adverse IP outcomes: An unfavorable court sequence could defer or reduce toll-road monetization; optionality persists but timeline/value compresses.

• Modality fatigue: Post-pandemic mRNA apathy could weigh on demand narratives; requires COGS + convenience wins (e.g., combo shots) to re-ignite.

• Manufacturing shocks: Any CMC or LNP supply disruption would be disproportionately punitive given category perceptions.

• Partner concentration: Execution risk if a major partner reprioritizes or slows funding cadence.

• Competitive curves: Rivals’ self-amplifying RNA or next-gen delivery may reframe the efficiency frontier; CVAC must show delta, not parity.

Summary View

CureVac’s edge is platform law, not product lore: codified rules of sequence, process, and quality that can be monetized via toll-roads (IP), tenders (COGS), or translation (better Gen-2 data). With time on the balance sheet, credible partners, and a litigation/BD playbook, CVAC is positioned to harvest value from the plumbing of mRNA while keeping upside to category-expanding readouts. Own the mRNA toll-road: monetize the rules, scale the process, partner the products.

5) Protagonist Therapeutics (PTGX) — Peptides Become Products

Protagonist represents a rare bridge between biotech science and pharmaceutical discipline, a peptide engineering platform that has already delivered multiple clinical-stage assets and one nearing approval. Its lead program, rusfertide (PTG-300), has achieved Phase 3 success in polycythemia vera (PV) and secured both Breakthrough Therapy and Orphan Drug designations. With commercialization to be led by Takeda, the company is set to transition from R&D story to cash-flowing rare-disease player within two years. The broader moat lies not just in one molecule but in its proprietary peptide design engine, chemistry few competitors can match in scalability or stability.

Moats

• First-in-class hepcidin mimetic:

  • Rusfertide is the first injectable peptide that mimics hepcidin, the master regulator of iron homeostasis.

  • In PV, a chronic myeloproliferative disorder with too many red blood cells, rusfertide normalizes iron balance and reduces or eliminates the need for phlebotomy, the current standard of care.

  • This mechanistic innovation is defensible; it’s not a reformulation or me-too drug, but a new biological class that reprograms the body’s feedback loop on erythropoiesis.

• Orphan-drug economics:

  • PV affects roughly 100,000 patients globally, most inadequately controlled with outdated therapies.

  • With Orphan Drug and Breakthrough Therapy designations, rusfertide should secure 7 years of U.S. exclusivity (plus patent coverage into the mid-2030s) and premium pricing justified by chronic administration.

  • Its small, defined patient population makes it ideal for high-value specialty distribution, high-margin revenue with minimal sales infrastructure.

• Partnered launch with Takeda:

  • Takeda’s rare-disease salesforce, payer access, and manufacturing infrastructure give rusfertide a global launch platform without balance-sheet dilution.

  • This partnership transforms PTGX’s profile from binary biotech to royalty-bearing cash compounder, letting management allocate capital toward pipeline expansion rather than commercialization risk.

• Platform moat in peptide chemistry:

  • Beyond rusfertide, PTGX has engineered peptide scaffolds with drug-like half-lives, oral bioavailability, and tissue selectivity, solving one of biotech’s hardest problems.

  • This expertise, honed over a decade, enables the company to design peptides that combine biologic specificity with small-molecule pharmacokinetics, a “middle path” modality few can replicate.

  • The technology has already yielded validated assets, including an IL-23 receptor antagonist (JNJ-2113) that hit efficacy endpoints in psoriasis before Janssen returned rights (due to portfolio reprioritization, not data failure).

Bottlenecks

• Peptide discovery & CMC expertise:

  • Rational design of constrained peptides , balancing structure, stability, and absorption, is an art form.

  • PTGX’s structure-guided design algorithms and proprietary linker chemistries are trade secrets, built through trial, error, and data.

  • Manufacturing complexity (solid-phase synthesis, purification yields) creates natural scarcity; few CDMOs can handle it efficiently.

• Hematology KOL network:

  • PV is managed by a relatively small group of hematologists concentrated at academic and regional centers.

  • PTGX’s clinical team has spent years cultivating these networks through early-access programs and investigator-sponsored trials, relationships that act as a barrier to entry for any future hepcidin competitors.

• Clinical access bottleneck:

  • Running trials in rare hematologic disorders demands both registry access and diagnostic precision.

  • PTGX’s long-term collaboration with Takeda ensures global trial continuity, patient recruitment velocity, and regulatory advocacy across regions, logistical advantages that take years to reproduce.

Trip-Wires / KPIs to Monitor

• Regulatory milestones: NDA submission for rusfertide and acceptance by the FDA.

• Commercial launch prep: Takeda’s market-access work (payer formulary inclusion, distribution setup, patient-assistance programs).

• Label expansion: Exploratory trials in other erythrocytosis or iron-regulation disorders (e.g., β-thalassemia, hereditary hemochromatosis).

• Cash cadence: Quarterly burn trajectory and milestone inflows; confirmation of >18 months cash post-NDA without equity raise.

Variant Risk

• Safety & tolerability: Chronic injectable peptides can encounter injection-site reactions or long-term tolerability issues that require label mitigation.

• Competition: Other iron-modulating drugs could emerge from larger hematology players; differentiation must remain clear on efficacy and compliance.

• Regulatory timing risk: Any FDA data-request cycles could push out approval into 2027, deferring revenue inflection.

• Partner concentration: Takeda controls launch pacing and marketing focus; any reprioritization could slow adoption.

• Platform risk: Delays in pipeline partnering or setbacks in peptide oral delivery (e.g., PN-943) could limit diversification.

Summary View

Protagonist has out-engineered risk, de-risked clinical validation, orphan exclusivity, and a cash-rich partnership model that smooths the path from science to revenue.
The company now sits on the edge of its transition moment: from R&D cost center to rare-disease royalty machine, with pipeline optionality to follow. Its peptide platform is the kind of applied innovation moat Wall Street overlooks, chemically complex, capital-efficient, and scalable once the template is proven. Own the company turning peptides into a durable business model, first to market, first to cash flow, and first to repeat it.

6) RaySearch Laboratories (RAYB) — Software as Infrastructure

While most of healthcare innovation happens at the molecular level, RaySearch Laboratories built a fortress in bits and bytes, dominating the invisible layer of cancer treatment planning software that radiation oncologists use every day. Its flagship platform, RayStation, sits at the center of radiotherapy workflows, embedded across more than 1,000 cancer centers in 46 countries. Once installed, it becomes part of the hospital’s nervous system, impossible to rip out without retraining entire departments and rewriting decades of protocols.

RaySearch sells control over precision, safety, and reimbursement compliance in one of the highest-value, lowest-error-tolerance corners of medicine. It’s a mission-critical monopoly hiding in plain sight.

Moats

• Installed-base captivity (the real fortress wall):

  • RayStation and its companion system RayCare are deeply integrated into radiotherapy departments, linking linear accelerators (linacs), imaging systems, and hospital EHRs into a unified planning ecosystem.

  • Once deployed, the switching cost is massive: migrating away requires retraining clinicians, revalidating every treatment plan with regulators, and re-certifying billing workflows.

  • This results in decade-long customer relationships and near-100% renewal rates.

• Proton therapy dominance:

  • RaySearch has an 85% market share in proton therapy centers, the fastest-growing, highest-value modality in global radiotherapy.

  • Out of the 46 proton centers in the U.S. and Canada, 43 use RayStation as their planning backbone.

  • Proton therapy’s precision and cost require software that minimizes margin-of-error at the submillimeter level. RaySearch has become the regulatory default, the planning system every new proton center must prove compatibility with to get licensed.

• Cross-hardware interoperability:

  • RaySearch’s systems are vendor-agnostic, compatible with all major linac and imaging OEMs (Varian, Elekta, IBA, Mevion, Siemens).

  • This is crucial because many OEMs try to “bundle” their own proprietary software to lock in hardware sales. Hospitals, however, prefer flexibility, and RaySearch is the only truly multi-vendor-certified platform.

  • That means RaySearch sits in the middle of the radiotherapy stack, connecting devices from rival manufacturers that can’t easily talk to one another.

  • Every incremental OEM partnership strengthens this neutrality moat.

• R&D depth and regulatory flywheel:

  • With 20+ years of accumulated datasets, RaySearch continuously updates its dose-optimization algorithms, adaptive planning modules, and machine-learning contouring tools.

  • Its regulatory-clearance rhythm (FDA, EMA, Japan PMDA) gives it first-mover advantage in adopting new modalities (e.g., FLASH radiotherapy).

  • The result is an R&D cadence that compounds defensibility: every new clinical feature expands switching costs and drives recurring upgrade revenue.

• Recurring revenue and pricing power:

  • Software licenses are sold under multi-year contracts with ongoing support and maintenance fees.

  • As treatment complexity rises (AI planning, adaptive radiotherapy, hypofractionation), hospitals must keep systems current, giving RaySearch built-in recurring revenue with inflation-indexed pricing.

  • It’s a razor-and-blade model, sell the license once, monetize upgrades forever.

Bottlenecks

• Regulatory-cleared innovation:

  • Every algorithm, module, and interface in radiotherapy must be clinically validated and regulator-approved before deployment.

  • RaySearch’s in-house regulatory team has become an invisible moat, a global compliance engine fluent in FDA, CE, and PMDA pathways.

  • Competitors (including OEMs) can’t move at this pace because they lack dedicated regulatory bandwidth; RaySearch ships faster and scales globally.

• Integration inertia (workflow as gravity):

  • Radiotherapy departments are ecosystems with fixed workflows, staffing hierarchies, and treatment protocols.

  • Once RayStation defines those workflows, it becomes the standard of care within the institution, physicians are trained on it, templates are built around it, and billing codes reference it.

  • This inertia compounds adoption: when staff migrate to other hospitals, they advocate for the same system they already know.

• Data ownership and analytics lock:

  • RaySearch accumulates anonymized treatment data across modalities and centers, allowing machine-learning optimization unavailable to newcomers.

  • This growing data corpus is both an innovation engine and a defensive shield, no new entrant can replicate 20 years of annotated radiation-dose outcomes.

Trip-Wires / KPIs to Monitor

• Net new center wins: Growth in global radiotherapy footprint, particularly in emerging markets (India, China, Latin America) where new centers are being built from scratch.

• Module attach rates: Upgrades from planning-only (RayStation) to full workflow (RayCare) and analytics packages, a key driver of ARR growth.

• AI-enabled feature launches: Adoption of auto-contouring and adaptive planning modules; a leading indicator of long-term lock-in.

• Proton therapy expansion: New center openings using RayStation as the default; expansion into heavy-ion therapy planning could be the next catalyst.

• Recurring revenue mix: Monitor subscription vs perpetual license ratio; higher maintenance share = higher margin durability.

• R&D cadence: Regulatory approvals for FLASH or carbon-ion therapy planning, next-generation modalities that could open new markets.

Variant Risk

• Vendor bundling threats: Large OEMs (Varian/Siemens) could attempt to enforce tighter integration between their hardware and proprietary software.

  • However, hospitals value independence; RaySearch’s neutrality remains its best defense.

• Hospital budget pauses: Radiotherapy software is capital expenditure; prolonged macro tightening could delay upgrades, though maintenance renewals remain steady.

• Technological displacement risk: Long-term emergence of AI-native planning systems could disrupt parts of the workflow, though RaySearch is already embedding ML into its core engine.

Summary View

RaySearch is a critical-utility business inside oncology, with economic characteristics closer to enterprise software than biotech. It benefits from structural switching costs, cross-hardware compatibility, and regulatory entrenchment that make it almost impossible to displace once installed. While most investors chase molecules, RaySearch captures perpetual royalties on radiation therapy itself, not per dose, but per workflow. It’s the definition of a “mission-critical moat” in healthcare software: essential, invisible, and compounding. Own the picks-and-shovels of oncology, a global software monopoly on the infrastructure of precision cancer treatment.

7) Giant Biogene (2367 HK) — Collagen as an Enduring Franchise

Giant Biogene has quietly established itself as China’s recombinant collagen champion, commanding dominant share in medical-grade skincare, wound care, and aesthetic dermaceuticals. It’s a biotech manufacturer disguised as a consumer healthcare brand, combining IP, production scale, and clinical credibility into one of Asia’s most profitable healthcare franchises. Its moat stems from proprietary collagen synthesis technology, high regulatory barriers, and a unique dual exposure to medical and aesthetic markets that yield pricing power and diversification.

Moats

• Process IP & manufacturing scale:

  • Proprietary recombinant yeast-expression system for human collagen eliminates animal-derived inputs, giving Giant Biogene a purity and consistency advantage critical for medical-grade use.

  • The company owns hundreds of patents covering strains, purification, and formulation. Replicating this end-to-end process requires years of strain engineering and GMP validation.

• Dual-channel model (medical + aesthetic):

  • The company sells collagen wound dressings and gels through hospitals while also marketing high-end dermaceutical products for post-procedure recovery and sensitive skin.

  • Medical distribution provides stable, policy-backed revenue, while aesthetic skincare captures consumer-margin upside.

  • This mix reduces cyclicality, a rarity among Chinese health and beauty peers.

• Regulatory moat:

  • Operating in China’s tightly regulated medical device and cosmetics ecosystem, Giant Biogene has built first-mover licenses and quality certifications that take competitors years to replicate.

  • Its long relationship with provincial health bureaus ensures fast-track product approvals and hospital tender wins, an institutional moat beyond patents.

• Brand equity & trust:

  • The company’s products are prescribed by clinicians for wound healing and post-surgical recovery, conferring a halo of clinical legitimacy to its consumer line.

  • This “medicalized skincare” positioning commands premium pricing in a crowded cosmetic market.

Bottlenecks

• Strain reproducibility:

  • Consistent recombinant yield requires proprietary bioprocessing controls; not all CDMOs can replicate the same expression levels or purity.

• Clinical tender access:

  • China’s hospital system is relationship- and documentation-heavy; the company’s established KOL network acts as a gatekeeper for new entrants.

• Regulatory cadence:

  • Each new product class demands fresh local clinical validation, a process where experience and data archives become competitive armor.

Trip-Wires / KPIs

• Hospital penetration: Number of new tenders/hospitals added per quarter; proxy for share expansion in wound care.

• Export pipeline: Entry into Southeast Asian and Middle Eastern markets through licensing; optionality for revenue diversification.

• Margin stability: Maintaining 80%+ gross margins as consumer mix rises; a test of pricing power and product loyalty.

Variant Risk

• Policy-driven price compression: Centralized tenders could lower medical collagen ASPs.

• Macro sensitivity: Aesthetic skincare may soften during consumption slowdowns.

• Regulatory drift: Stricter cosmetics oversight could delay new SKU launches.

Summary View

Giant Biogene owns the collagen supply chain end to end, from proprietary yeast strains to hospital distribution. It’s less a cosmetics play than a regulated biotech franchise monetizing medical-grade IP at consumer multiples. With entrenched hospital ties, unmatched margins, and a hybrid revenue model, the company epitomizes “rare by design” in Asia’s healthcare landscape. Own the collagen monopoly, biotech precision, consumer scale, medical trust.

8) Microbot Medical (MBOT) — Disposable Robotics, Infinite Leverage

Microbot Medical is pioneering the first fully disposable endovascular micro-robotic system, a concept that could democratize interventional care the way single-use laparoscopic tools transformed surgery. Its flagship device, LIBERTY, is designed to perform remote, minimally invasive vascular procedures without large capital robots or on-site specialists. The opportunity is binary but asymmetric: if FDA clearance arrives on schedule, MBOT could own the intellectual and regulatory ground floor of a new medical device category.

Moats

• Category-creating IP:

  • LIBERTY’s broad patent estate covers mechanical design, navigation algorithms, and disposable robotic actuation, effectively blocking fast followers from entering the same design space.

  • The concept merges robotic precision with single-use economics, addressing infection control, setup time, and capital cost barriers that limit robotic surgery adoption today.

• Regulatory first-mover advantage:

  • LIBERTY holds FDA Breakthrough Device designation, enabling priority review and streamlined clinical dialogue.

  • Being first through the FDA pathway creates a de facto regulatory moat, future entrants must conform to the standards MBOT sets.

• Workflow moat (access expansion):

  • By eliminating bulky consoles and infrastructure, LIBERTY allows small hospitals and rural centers to perform neurovascular and peripheral interventions remotely.

  • This expands the TAM rather than cannibalizing existing robotics players like Intuitive Surgical or Corindus (Siemens).

Bottlenecks

• Human-factors reliability:

  • Single-use robotics must prove consistency across thousands of disposables; scaling precision manufacturing and QC is a nontrivial engineering challenge.

• Reimbursement coding:

  • The path to adoption depends on CPT/DRG code assignment — without it, hospitals can’t bill. MBOT’s early engagement with payors is essential.

• Capital access:

  • As a pre-revenue microcap, progress hinges on bridge financing or strategic partnerships post-FDA clearance.

Trip-Wires / KPIs

• Pivotal trial milestones: Enrollment completion and top-line data in 2025.

• FDA submission/decision: Potential 2025–26 approval under Breakthrough review track.

• Partnership announcements: OEM alliances or distribution deals with major medtechs.

• Cash runway: At least 12 months post pivotal readout.

Variant Risk

• Execution risk: Manufacturing scale-up or trial complications could defer clearance.

• Dilution risk: Additional capital raises likely pre-launch.

• Competitive re-entry: Larger device makers may respond with semi-disposable systems once the category proves viable.

Summary View

Microbot is a convex bet on procedural access: one FDA win could unlock a multibillion-dollar procedural TAM with modest capital intensity. It’s speculative but structurally original, a disposable robotics model that could define a new subfield. First to file, first to clear, first to scale, own the blueprint for disposable surgical robotics.

9) Avanos Medical (AVNS) — The Quiet Fortress in Pain & Care

Avanos is a steady compounder hiding inside healthcare’s most entrenched infrastructure, pain management and enteral feeding systems. Spun out of Kimberly-Clark, it operates in slow-moving, regulation-heavy niches where safety, clinician familiarity, and reimbursement stability create natural barriers to entry. It’s not a growth rocket; it’s a formulary fortress that compounds through procedural inertia and steady policy tailwinds away from opioids.

Moats

• Formulary & training lock:

  • Avanos’s Coolief radiofrequency ablation system and On-Q pain pumps are embedded in hospital pain protocols nationwide.

  • These devices are included in standard-of-care guidelines and bundled reimbursement codes, once adopted, switching costs span retraining, credentialing, and new approvals.

  • In enteral feeding, its Corpak brand commands trust among dietitians and ICU staff, cemented by years of safe-use data.

• Regulatory & brand credibility:

  • Medical device regulation favors incumbents. Coolief was the first FDA-cleared RF system for osteoarthritis pain, and that regulatory first-mover status sustains payer recognition and physician loyalty.

  • The company’s reliability in high-risk care settings (ICU, post-op, long-term feeding) gives it a brand moat built on safety, not marketing.

• Macro tailwinds:

  • The global shift toward non-opioid pain interventions and aging demographics expands demand for Avanos’s core offerings.

  • Hospitals value predictability and compliance more than disruption, a structural advantage for incumbents like Avanos.

Bottlenecks

• Clinical inertia:

  • Procedures and device preferences in pain management evolve slowly; this inertia preserves Avanos’s installed base.

• Procurement friction:

  • Hospital supply contracts renew infrequently and require vendor audits, creating long replacement cycles that insulate market share.

Trip-Wires / KPIs

• Coolief utilization growth across orthopedic and spine centers.

• Gross margin trajectory as product mix shifts toward higher-margin pain therapies.

• Recall-free operation, execution quality is the moat’s daily test.

Variant Risk

• Pricing pressure: Hospital procurement could push for incremental discounts.

• Volume stagnation: If elective procedures slow, near-term utilization softens.

• Acquisition premium risk: Larger medtechs could buy Avanos before market fully prices in its stability.

Summary View

Avanos is quietly monetizing the status quo of safe, reimbursed, repeatable care. It adds stability and low beta to the RAREDIS² sleeve, balancing the higher-volatility biotech names. In a sector chasing novelty, Avanos compounds by being the brand hospitals don’t replace. Own the pain franchise no one wants to switch from, a steady earner in an opioid-averse world.

10) Niagen Bioscience (NAGE) — Patented Longevity in a Capsule

Niagen Bioscience (formerly ChromaDex) is the purest intellectual-property play on NAD⁺ biology, the cellular coenzyme tied to energy metabolism, aging, and repair. Its patented compound, nicotinamide riboside (NR), branded as Niagen®, is the only FDA-vetted NAD⁺ precursor with GRAS status and a clean human-safety dossier. Unlike speculative “longevity” plays, Niagen already sells a profitable product line and supplies ingredient partnerships to major CPG and nutrition brands. It’s a cash-generating moat built on regulatory legitimacy and scientific credibility.

Moats

• Ingredient IP + safety dossier:

  • Niagen holds composition-of-matter and use patents around NR production and absorption pathways, defended successfully against multiple challengers.

  • It is the only NAD⁺ precursor recognized as Generally Recognized as Safe (GRAS) by the FDA, a regulatory barrier competitors can’t easily breach.

  • That certification allows Niagen to sell into both nutraceutical and pharmaceutical channels without re-validation.

• Science & credibility moat:

  • Backed by over 100 peer-reviewed studies and 25+ clinical trials, NR’s effects on mitochondrial efficiency, muscle recovery, and metabolic health make it the benchmark compound in the NAD⁺ category.

  • Competitors like NMN and NRH remain unapproved or untested in humans, giving Niagen category authority among physicians and researchers.

• Dual-channel monetization:

  • Operates a hybrid model: B2B ingredient supply (to Nestlé and Thorne) and direct-to-consumer brand (Tru Niagen).

  • This structure compounds margin leverage, ingredient sales scale with partners, while the DTC channel captures premium brand value.

  • Gross margins above 60% and consistent free cash flow make NAGE a profitable outlier in biotech-adjacent wellness.

• Distribution & brand moat:

  • Years of consumer education, FDA correspondence, and supply reliability have created channel lock-in with retailers and supplement partners.

  • Shelf space and brand trust in the supplement sector are slow-cycle assets, once established, they rarely change hands.

Bottlenecks

• Manufacturing purity:

  • Pharmaceutical-grade NR requires high-precision crystallization and stability control; only Niagen’s facility and contracted GMP partners can consistently meet specs.

• Scientific validation cadence:

  • Each new claim (e.g., cognitive health, metabolic support) requires multi-year trials, Niagen’s existing safety data accelerates this loop, forming a time-based moat competitors can’t shortcut.

Trip-Wires / KPIs

• New B2B launches with global CPG partners expanding beyond the U.S.

• Clinical readouts confirming therapeutic potential in rare mitochondrial or aging-related disorders (e.g., Cockayne syndrome).

• Margin resilience as ingredient volumes scale faster than marketing spend.

• Regulatory posture: Continued FDA acceptance of NR as supplement-safe amid tightening oversight on NMN.

Variant Risk

• Category confusion: Shifting consumer interest toward unregulated NMN compounds could divert near-term retail demand.

• Policy risk: Changes to supplement-drug classification could raise compliance costs.

• Science perception: A failed or inconclusive longevity trial could momentarily dampen investor sentiment.

Summary View

Niagen Bioscience monetizes aging science without the binary risk, a patented molecule, proven safety, and growing consumer adoption. It’s a compounder of trust: recurring ingredient royalties, expanding DTC margins, and embedded regulatory advantage. NAGE provides low-beta, cash-positive exposure to a megatrend, cellular rejuvenation, anchored by real IP and real profits. Own the only longevity molecule with patents, profits, and permission.

11) Novavax (NVAX) — The Protein Vaccine Countertrade

Novavax remains one of the few independent vaccine makers with a proven, scalable alternative to mRNA, a recombinant protein platform paired with its proprietary Matrix-M adjuvant. Post-COVID, it has refocused on sustainable markets: combination respiratory vaccines, global booster contracts, and adjuvant licensing. Beneath the volatility, Novavax owns a rare asset trifecta, a validated antigen production process, a differentiated adjuvant with external royalties, and an FDA-approved manufacturing network. The story now is less redemption, more re-industrialization of vaccines.

Moats

• Adjuvant IP (Matrix-M):

  • Derived from Quillaja saponaria, Matrix-M enhances immune response at lower antigen doses.

  • It is already licensed into Oxford/Serum Institute’s malaria vaccine, generating royalties and giving Novavax credibility as a technology provider, not just a manufacturer.

  • Only a handful of adjuvants are globally approved; this is one of them — a toll-road asset other vaccine developers must rent.

• Platform flexibility:

  • Protein subunit vaccines have simpler storage, better thermostability, and lower reactogenicity than mRNA, critical for global tenders.

  • The same core process can produce COVID, flu, RSV, or combination vaccines by swapping antigens, a modular manufacturing moat with minimal retooling costs.

• Manufacturing scale & regulatory goodwill:

  • After ramping during the pandemic, Novavax owns FDA-approved, WHO-qualified facilities and validated global supply chains.

  • That infrastructure is costly to rebuild; many peers are outsourcing or mothballing. Novavax now rents its excess capacity, turning fixed cost into optionality.

• Non-mRNA market positioning:

  • As skepticism toward mRNA’s side-effect profile persists in parts of the world, Novavax captures vaccine-hesitant and government diversification demand.

  • This creates durable niche demand even in a post-pandemic market.

Bottlenecks

• Regulatory dependency:

  • Respiratory vaccine cycles hinge on annual strain selection; regulatory coordination is a timing bottleneck.

• Working-capital sensitivity:

  • Inventory and tender schedules create short-term balance-sheet swings; disciplined production planning is key.

• Adjuvant scaling:

  • Matrix-M’s natural raw materials and extraction complexity limit how fast capacity can expand.

Trip-Wires / KPIs

• Combo COVID-Flu (CIC) trial readouts, proof of platform breadth.

• RSV Phase 3 data and regulatory filings in adults.

• Adjuvant licensing deals beyond malaria; royalties are the cleanest margin.

• Cash balance trajectory, maintaining positive free cash flow post restructuring.

• Global procurement contracts for 2026-27 seasonal vaccines.

Variant Risk

• Demand volatility: COVID booster orders remain unpredictable; any mismatch between production and tenders hits cash flow.

• Execution risk: Repeated delays or manufacturing miscues could re-ignite credibility concerns.

• Competition: Combined vaccines from Pfizer/Moderna could crowd the respiratory space.

• Policy exposure: Government tender pacing drives quarter-to-quarter earnings volatility.

Summary View

Novavax is evolving from pandemic boom-bust to steady platform operator: a royalty-earning adjuvant supplier, lean vaccine producer, and optional call on new outbreaks.
It’s under-owned, cash-positive, and uncorrelated to both mRNA hype and biotech beta, an asymmetric recovery trade inside a proven global infrastructure. Own the anti-mRNA toll road, a proven adjuvant, modular vaccine platform, and balance-sheet leverage to the next respiratory cycle.

Why Short Both XBI and PPH (50/50)

• XBI (equal-weight biotech)

  • What we hedge: Pre-revenue churn, clinical blow-ups, meme squeezes, factor rotations.

  • Equal-weighting forces buy/hold of lower-quality tails; rebalance mechanics buy losers.

  • Offsets sector-wide drawdowns that do not impair our moats.

• PPH (mega-cap pharma/biotech)

  • What we hedge: Crowded mega-cap narratives (GLP-1, Alzheimer’s) + drug-pricing regimes.

  • Top-heavy baskets can unwind sharply on single trial or policy shock.

  • Lower beta than XBI dampens hedge vol while catching policy/pricing risk.

• Our longs span software, devices, orphan therapies, IP toll-roads, low overlap with both ETFs. The pair neutralizes junk beta and crowded mega-cap beta simultaneously.

Conclusion

This index concentrates on companies that control bottlenecks: IP toll roads, orphan exclusivity, installed clinical software, and specialized manufacturing and hedges sector noise with XBI/PPH shorts. This construct seeks repeatable alpha from durable moats while muting macro/policy beta and ETF factor churn.

Basket Weighting Recap:

Disclaimer:
Ridire Research is an independent research publication operated by Ridire Research LLC and affiliated with a private fund, an Exempt Reporting Adviser under the U.S. Investment Advisers Act of 1940. Ridire Research is not registered as an investment adviser and does not provide personalized investment, legal, accounting, or tax advice.

Informational & Educational Purpose Only

All materials—including text, charts, model portfolios, and explicit labels such as “Buy,” “Sell,” “Hold,” “Long,” or “Short”—are published solely for general informational and educational purposes. They reflect the author’s views at the time of writing, derived from publicly available data, proprietary frameworks, and market analysis, and are not tailored to any reader’s specific objectives, financial situation, or risk tolerance. Subscription to this Substack does not create an adviser–client relationship with the affiliated private fund or its principals.

No Offer or Solicitation

Nothing herein constitutes (i) an offer to sell or the solicitation of an offer to buy any security or other instrument, (ii) a recommendation to participate in any investment strategy, or (iii) a solicitation for investment advisory services. Any references to trades, allocations, or vehicles should be viewed as hypothetical model illustrations only. Offers, if ever made, will be made solely by confidential offering documents and only to qualified investors in jurisdictions where permitted.

Potential Conflicts of Interest

The affiliated private fund, its affiliates, employees, and related accounts may hold, increase, decrease, initiate, or exit positions, long or short, in securities or digital assets discussed, without notice or obligation to update disclosures. Such positions may be inconsistent with views expressed in this publication. The affiliated private fund, related entities, and personnel may initiate, modify, or exit positions in any mentioned security before or after publication without further notice. We maintain internal policies, including trading blackout windows and conflict reviews, to mitigate potential conflicts of interest.

Accuracy & Forward-Looking Statements

Although we strive for accuracy and analytical rigor, information may become outdated and may contain errors or omissions. Forward-looking statements, projections, or target prices are inherently uncertain and may differ materially from actual results. No warranty, express or implied, is given as to completeness, accuracy, or reliability.

Risk Acknowledgment

Investing involves substantial risk, including the potential for complete loss of capital. Past performance, whether actual, indicated by back-tests, or modeled, is not indicative of future results. Securities, derivatives, and digital assets mentioned may be illiquid, highly volatile, or subject to regulatory change.

Reader Responsibility

Readers should conduct their own due diligence, consider their personal circumstances, and consult a licensed financial professional before acting on any information contained herein. By reading this publication you agree that Ridire Research LLC, the affiliated private fund, and their affiliates accept no liability for any direct or consequential loss arising from reliance on the information presented. This research is not directed at persons in jurisdictions where such distribution would be contrary to local law.

Before I lose half of you at the headline, let me be clear: this is highly speculative. This is a framework review rather than a call. What follows is the first attempt to map out the ideas circulating around what I’m going to call the “Hash-Energo Dollar.” I’m not advocating it, just outlining the logic and the players behind it. Personally, I’m exposed to both “systems”, the hash/energy-anchored assets and the gold/BRICS complex, and I don’t particularly care which one wins. My base case: it’s slightly better than a coin-flip that some version of this structure quietly takes shape within five to ten years. I’ve heard variations of it whispered for a while now, and it keeps resurfacing. It still sounds ridiculous at first, especially if you can’t get past the “crypto is a scam” reflex, but the plumbing is starting to look real. That being said, let’s dive in.

Table of Contents

1. The Hash-Energo Dollar Hypothesis

2. Why This Exists & Campbell’s Asymmetry: The Decoupling Backdrop

3. Mechanics That Already Work, Mechanics That Could Work

4. The Pigeon Framework vs. Softwar

5. Incentive Alignment and the Stablecoin Flywheel

6. Financial Weaponization: Two Systems, Two Logics

7. From Geopolitics to Balance Sheets

8. Trump and Musk: Policy, Optics, and Execution

9. Implementation Phases

10. What the Outcome Looks Like

11. Tracking the Trades: The Two Horses

The Hash-Energo Dollar Hypothesis

Thesis in brief:

• Move the dollar’s second anchor from abstract confidence to measurable energy productivity and Bitcoin hashpower.

• Pull global crypto liquidity into Treasuries, keep custody and miners on U.S. rails, and let the reserve architecture emerge from the grid.

• The objective is straightforward: reinforce dollar primacy while decoupling from China and blunting the optics of a BRICS gold lane.

Why This Exists

Treasuries still sit at the core of the system, but reserve prestige erodes at the margin. Gold lifts our adversaries. China’s banking system is running a structural loss machine: $5-10T in property-related losses against roughly $3T in bank equity, plus something on the order of $1.1T per year to hide the damage. That is called a capacity constraint. The United States needs a second pillar that rests on physics and metered output, rather than narrative alone.

Campbell’s Decoupling 2017-2045 gives the macro backdrop. He outlines how China’s extend-and-pretend property regime bleeds liquidity and traps the PBOC in an impossible trilemma: defend the currency, recapitalize banks, or preserve social stability. Time, demographics, and energy dependence all push in one direction, structural asymmetry that widens each year.

His key insight: after 2027, U.S. rare-earth and energy independence close the loop, leaving Beijing exposed to dollar system chokepoints it cannot replicate.

The Hash-Energo Dollar is what I believe fills that vacuum: the mechanism through which U.S. energy and computation become reserve credibility, while China’s capital base dissolves into hidden losses.

Campbell’s decoupling framework is the backdrop. China faces a trilemma it cannot solve cleanly: defend the currency, recap banks, or preserve social stability. Choose two at best, often one. The leverage window narrows into 2027 to 2030 as U.S. rare-earth independence rises, demographics worsen in China, Taiwan politics move, and leadership succession risk increases. The asymmetry grows with time, so this is the window to shift the plumbing.

Mechanics That Already Work

• Bitcoin miners already earn $1b to $2b per year from ERCOT to provide flexible load. They are paid to throttle when the grid needs headroom. In practice, these sites behave like controllable demand that absorbs volatility and helps renewables scale.

• Immersion cooling can improve efficiency 20 - 40%.

• U.S. miners control on the order of 40% of global hash rate, roughly two hundred exahash per second.

Mechanics that could work:

Tie issuance to verified energy output and proof of work. Start small, 1 - 2 billion of capacity, scale to 10 to-20 as contracts, measurement, and custody mature. Energy-backed instruments could probably print 5 - 10% yields while delivering grid services. Liquidity lives around the clock. Bitcoin trades roughly $200b per day. DeFi flows can reach $500b to $1T by 2030. That outpaces gold’s cash turnover and gives the dollar a continuous settlement rail that moves at market speed.

The Pigeon Framework vs. Softwar

This is where the Pigeon Framework departs from Softwar. Softwar imagined Bitcoin as a digital battlespace, essentially hash as deterrence. Pigeon treats hash as collateral. Instead of militarizing the network, it monetizes it and miners become flexible infrastructure. Under Pigeon logic, the U.S. doesn’t need to dominate global hash to win; it only needs to host enough of it to link computation, grid balance, and dollar liquidity under its legal system.

Softwar’s frame casts Bitcoin as a non-kinetic power system, a new military domain to be contested like cyber or space. The Pigeon view is less theatrical and more useful. Bitcoin is a reserve release valve running on U.S. rails. It extends the dollar’s reach precisely when pure Treasuries lose some reserve shine and gold starts funding rivals. The neutrality of the asset is not the point. Jurisdiction over custody, ETFs, banking access, and miner share is the point. Washington is not fighting Bitcoin, this is clear.

In short, Softwar gives the metaphor while Pigeon gives the plumbing, and Campbell provides the strategic rationale. Together they describe a state that no longer needs to announce standards; it shapes them through infrastructure. Hashpower, custody, and energy policy become instruments of macro strategy, the invisible hand of the state moving through open-source rails.

Incentive Alignment and the Stablecoin Flywheel

• Miners monetize downtime, earn curtailment revenue, and upgrade to immersion without praying for bull markets.

• Grids get a programmable cushion that makes an 80% renewable target by 2030 more realistic and more stable.

• Investors get liquid, yield-bearing exposure to U.S. energy infrastructure.

• Treasury gains a scalable collateral channel that does not require a treaty or a new Bretton Woods.

The stablecoin flywheel is the quiet engine:

• Credible stablecoins will hold 100% T-Bills.

• Tether already sits among the largest Treasury holders. Each on-chain dollar becomes a structural bid for U.S. debt.

• Our $30T+ T-Bill pool is the natural sink for global crypto savings. You are not browbeating foreign central banks to buy paper.

Here the feedback loop becomes geopolitical:

• Every stablecoin minted with full T-Bill backing is a private-sector extension of U.S. debt monetization.

• The same mechanism that critics call “crypto” effectively crowds in global dollar demand.

• The United States gets a permanent, algorithmic buyer base that is permissionless in front-end form but sovereign in custody. It is the quiet mirror image of China’s ghost banking loop, except this one earns real yield, in real dollars.

Financial Weaponization: Two Systems, Two Logics

The U.S. model weaponizes liquidity through openness: stablecoins collateralized by Treasuries, miners stabilizing renewables, and energy converted into yield. It turns productive capacity into collateral and keeps global capital tied to U.S. rails.

The BRICS model weaponizes exclusion: gold, commodities, and bilateral settlement meant to bypass the dollar. It’s defensive and finite, stores value but doesn’t scale or compound.

The gap is simple: one system monetizes electrons, the other hoards metal. One exports liquidity, the other traps it. The Hash-Energo Dollar sits in between, anchoring credibility in measurable output.

From Geopolitics to Balance Sheets

BRICS are building a gold lane that is static and finite. The United States is building an energy lane that scales with innovation. One hoards metal. The other monetizes electrons and computation with better custody, law, liquidity, and hardware.

Campbell’s asymmetry maps neatly into this plumbing:

• China needs the dollar system, advanced chips, allied markets, and U.S. software.

• The United States needs Chinese rare-earth processing for a limited window that closes as domestic projects come online.

• The financial hostage logic is simple. China holds roughly 2.5 trillion in U.S. financial assets that can be frozen, inflated away, or bought back with a balance-sheet expansion. U.S. firms in China hold physical assets that are far harder to weaponize at scale.

• Immediate decoupling hurts them catastrophically and us temporarily. You do not have to pull the trigger for the deterrent to work. Markets price the option.

Trump and Musk: Policy, Optics, and Execution

Trump’s posture is pro-energy and pro-crypto with a mixed-strategy approach to China. Build domestic hash first, normalize ETFs, keep policy optionality on seizures and strategic reserves, and declare the standard only after the infrastructure exists.

Musk’s view of flexible power offloading is the engineering layer. Miners already behave like virtual batteries next to Powerpacks. They get paid to curtail, they stabilize frequency, they capture waste heat.

The optics are coherent: energy independence, American custody, continuous markets, and a real plan to scale renewables without brownouts.

The historical rhyme is obvious. Nixon moved the dollar from gold to oil to regain maneuvering room. The modern move shifts from oil to energy plus computation to regain credibility without gifting the narrative to gold. Build the infrastructure first. Announce the standard later.

Expect the administration’s messaging to stay ambiguous. Publicly, it’s “energy security” and “innovation.” Privately, it’s a quiet re-anchoring of monetary credibility. The politics play as jobs and grid stability; the macro outcome is a harder dollar without a single policy speech. Musk’s engineering credibility gives it narrative cover: renewables, batteries, flexible load, while Trump’s chaos strategy keeps opponents guessing which part is policy vs bluff.

Implementation Phases

• Phase one builds hash capacity near stranded or intermittent generation and hardens ERCOT-style contracts in multiple ISOs.

• Phase two tightens the custody perimeter with ETFs, qualified custodians, surveillance-sharing, and clean hygiene around seized reserves.

• Phase three tokenizes T-Bills, validates energy output, references hash metrics in issuance, and opens a narrow pilot window of one to two billion that can scale to ten to twenty. The Strategic Bitcoin Reserve at 127,000 BTC is a signaling tool. Used sparingly, it hardens optics without telegraphing a peg.

What the Outcome Looks Like

A dollar with a second anchor. Energy output and proof of work provide reserve credibility. Stablecoin standards create a constant bid for Treasuries. U.S. custody binds global flows to U.S. law. Miners make renewables easier to finance and operate.

China’s extend-and-pretend meets a hard floor. The BRICS gold optic loses altitude because the growth asset is not metal rather it is productive capacity you can meter.

The standard does not need a grand unveiling. It will show up first as capacity auctions, curtailment receipts, ETF flows, tokenized bills that settle in seconds, and grid dashboards that look strangely like monetary dashboards. When the plumbing is built, the announcement writes itself.

Tracking the Trade: The Two Horses

To track the thesis in real time, I’ve built two equal-weight baskets: two “horses” racing the monetary transition.

HASHBACK: Hash/Energy System → QQQ + IBIT + MNRS
A proxy for the emerging U.S. architecture: tech compute, Bitcoin reserve absorption, and domestic mining infrastructure integrated with the grid.

GOLDBACK: BRICS/Gold System → KWEB + GLD + GDX
A proxy for the alternative bloc: China’s digital and capital-market exposure via KWEB, paired with physical gold and gold miners to represent the static, metal-backed reserve model centered on BRICS and commodity collateral.

Performance since Liberation Day+1 (04/03/2025):

The spread between the two serves as a live decoupling gauge. When HASHBACK outperforms, it implies markets are leaning into the energy-anchored regime, stronger Treasury demand via stablecoins, healthy compute CAPEX, tighter U.S. credit spreads, and confidence in renewable buildout economics. It would theoretically align with a firmer dollar and fading gold beta.

When GOLDBACK leads, it signals rotation toward the BRICS and gold safety complex, capital flight from risk assets, policy or custody stress, rising term premium, or geopolitical pressure that favors tangible stores of value. It would theoretically coincide with softer U.S. liquidity conditions, EM outflows, and widening credit spreads.

Over time, the spread’s direction offers more than a trade, it’s a readout of which monetary operating system the market believes in: the energy-backed, compute-native dollar or the gold-and-commodity collateral bloc.

I’m exposed to both systems. I’m not making a directional bet on which global monetary system wins, I’m positioned to benefit (or at least observe cleanly) either outcome. My goal isn’t to predict, it’s to track which regime the market is migrating toward.

Disclaimer:
Ridire Research is an independent research publication operated by Ridire Research LLC and affiliated with a private fund, an Exempt Reporting Adviser under the U.S. Investment Advisers Act of 1940. Ridire Research is not registered as an investment adviser and does not provide personalized investment, legal, accounting, or tax advice.

Informational & Educational Purpose Only

All materials, including text, charts, model portfolios, and explicit labels such as “Buy,” “Sell,” “Hold,” “Long,” or “Short”, are published solely for general informational and educational purposes. They reflect the author’s views at the time of writing, derived from publicly available data, proprietary frameworks, and market analysis, and are not tailored to any reader’s specific objectives, financial situation, or risk tolerance. Subscription to this Substack does not create an adviser–client relationship with the affiliated private fund or its principals.

No Offer or Solicitation

Nothing herein constitutes (i) an offer to sell or the solicitation of an offer to buy any security or other instrument, (ii) a recommendation to participate in any investment strategy, or (iii) a solicitation for investment advisory services. Any references to trades, allocations, or vehicles should be viewed as hypothetical model illustrations only. Offers, if ever made, will be made solely by confidential offering documents and only to qualified investors in jurisdictions where permitted.

Potential Conflicts of Interest

The affiliated private fund, its affiliates, employees, and related accounts may hold, increase, decrease, initiate, or exit positions, long or short, in securities or digital assets discussed, without notice or obligation to update disclosures. Such positions may be inconsistent with views expressed in this publication. The affiliated private fund, related entities, and personnel may initiate, modify, or exit positions in any mentioned security before or after publication without further notice. We maintain internal policies, including trading blackout windows and conflict reviews, to mitigate potential conflicts of interest.

Accuracy & Forward-Looking Statements

Although we strive for accuracy and analytical rigor, information may become outdated and may contain errors or omissions. Forward-looking statements, projections, or target prices are inherently uncertain and may differ materially from actual results. No warranty, express or implied, is given as to completeness, accuracy, or reliability.

Risk Acknowledgment

Investing involves substantial risk, including the potential for complete loss of capital. Past performance, whether actual, indicated by back-tests, or modeled, is not indicative of future results. Securities, derivatives, and digital assets mentioned may be illiquid, highly volatile, or subject to regulatory change.

Reader Responsibility

Readers should conduct their own due diligence, consider their personal circumstances, and consult a licensed financial professional before acting on any information contained herein. By reading this publication you agree that Ridire Research LLC, the affiliated private fund, and their affiliates accept no liability for any direct or consequential loss arising from reliance on the information presented. This research is not directed at persons in jurisdictions where such distribution would be contrary to local law.

The thesis is simple: the United States is pushing aggressively to rebuild its semiconductor manufacturing base, driven by the recognition that technological self-sufficiency has become a matter of national security. The government is deploying vast resources to ensure that critical components for defense, communications, and industry are produced domestically and shielded from external risk. Within this push, two symbols have emerged, the Quiet Foundry, quietly executing on Washington’s mandate with steady precision, and the Flagship Mirage, celebrated in headlines yet still racing to deliver on its promise.

The trade: long GFS, short INTC (Adding this trade to the Ridindex at a 2% gross vol adjusted allocation: long GFS at 1.14% weight, short INTC -0.86%). This trade positions on the difference between policy-driven momentum and proven strategic relevance.

INTC stands at the center of America’s political effort to reclaim chipmaking capacity. It has received major federal awards and broad public attention as the symbol of national resurgence. Yet the challenge before it is immense: The company must rebuild process competitiveness, execute new foundry operations, and deliver high-volume production to external customers, all while sustaining unprecedented capital expenditures.

GFS operates at a quieter but more essential layer of the same reshoring movement. It is one of the few Department of Defense–designated trusted foundries (fun fact, it inherited this status when it acquired IBM’s microelectronics business in 2015), supplying secure chips for aerospace, communications, and military systems. Its core manufacturing spans RF, power management, and automotive semiconductors, technologies that underpin defense and infrastructure but have long depended on overseas suppliers.

Federal policy is explicitly supporting this capacity, with GFS receiving more than $1.5 billion in CHIPS Act funding and additional loan backing to expand U.S. fabs. Most of its production is already secured through long-term agreements with government and industrial customers, giving it reliable cash flow and visibility.

This alignment with Washington’s goals gives the trade a clear footing in reality rather than rhetoric. GFS is already doing the work the policy was designed to encourage, producing secure chips on U.S. soil for defense and industry. INTC, despite its prominence, is still building toward that role.

The pair trade captures that difference in timing: one company delivering on the mandate today, the other still racing to catch up.

Disclaimer:
Ridire Research is an independent research publication operated by Ridire Research LLC and affiliated with a private fund, an Exempt Reporting Adviser under the U.S. Investment Advisers Act of 1940. Ridire Research is not registered as an investment adviser and does not provide personalized investment, legal, accounting, or tax advice.

Informational & Educational Purpose Only

All materials, including text, charts, model portfolios, and explicit labels such as “Buy,” “Sell,” “Hold,” “Long,” or “Short”, are published solely for general informational and educational purposes. They reflect the author’s views at the time of writing, derived from publicly available data, proprietary frameworks, and market analysis, and are not tailored to any reader’s specific objectives, financial situation, or risk tolerance. Subscription to this Substack does not create an adviser–client relationship with the affiliated private fund or its principals.

No Offer or Solicitation

Nothing herein constitutes (i) an offer to sell or the solicitation of an offer to buy any security or other instrument, (ii) a recommendation to participate in any investment strategy, or (iii) a solicitation for investment advisory services. Any references to trades, allocations, or vehicles should be viewed as hypothetical model illustrations only. Offers, if ever made, will be made solely by confidential offering documents and only to qualified investors in jurisdictions where permitted.

Potential Conflicts of Interest

The affiliated private fund, its affiliates, employees, and related accounts may hold, increase, decrease, initiate, or exit positions, long or short, in securities or digital assets discussed, without notice or obligation to update disclosures. Such positions may be inconsistent with views expressed in this publication. The affiliated private fund, related entities, and personnel may initiate, modify, or exit positions in any mentioned security before or after publication without further notice. We maintain internal policies, including trading blackout windows and conflict reviews, to mitigate potential conflicts of interest.

Accuracy & Forward-Looking Statements

Although we strive for accuracy and analytical rigor, information may become outdated and may contain errors or omissions. Forward-looking statements, projections, or target prices are inherently uncertain and may differ materially from actual results. No warranty, express or implied, is given as to completeness, accuracy, or reliability.

Risk Acknowledgment

Investing involves substantial risk, including the potential for complete loss of capital. Past performance, whether actual, indicated by back-tests, or modeled, is not indicative of future results. Securities, derivatives, and digital assets mentioned may be illiquid, highly volatile, or subject to regulatory change.

Reader Responsibility

Readers should conduct their own due diligence, consider their personal circumstances, and consult a licensed financial professional before acting on any information contained herein. By reading this publication you agree that Ridire Research LLC, the affiliated private fund, and their affiliates accept no liability for any direct or consequential loss arising from reliance on the information presented. This research is not directed at persons in jurisdictions where such distribution would be contrary to local law.

Executive Summary

Theme: Own the platforms that structurally profit from trading and investment activity.
Basket (equal-weight, long-only, 2% model portfolio allocation):

• Monex Group (8698 JP)

• iFAST (IFAST SP)

• MarketAxess (MKTX US)

• Intercontinental Exchange (ICE US)

• IG Group (IGG LN)

These primary five companies are the casino owners of finance. They don’t speculate; they monetize volume, flow, and balances through fees, spreads, and subscriptions. Their moats are built on network effects, regulatory licenses, sticky client relationships, and scale infrastructure. Growth comes from electronification, retail adoption, new asset classes, and platform expansion.

Owning this basket is a way to consistently collect the “house edge” of global speculation and investing.

Bonus mentions: HYPE and CARDS.

Intercontinental Exchange (ICE): The All-Weather Operator

• Moat: ICE combines exchange franchises, exclusive listings, and clearinghouses with a global data subscription business. Its NYSE listings are defensible because issuers value prestige, liquidity, and index inclusion; rivals can’t replicate that network. Clearinghouses create regulatory and capital moats, once a firm clears through ICE, switching is impractical. The data arm is sticky: risk managers, banks, and asset managers embed ICE’s pricing/indices into workflows, paying recurring fees regardless of volumes.

• Why it’s “own the casino”: Every trade on ICE futures, every stock listed on NYSE, every data feed consumed, ICE collects a toll. It thrives in any market regime: volatility drives futures/derivatives activity, while calmer markets still pay for data, listings, and mortgages tech. ICE earns the casino rake whether traders win, lose, or sit on data subscriptions.

• Growth opportunity: Digitization of mortgages (multi-trillion-dollar U.S. market), expansion in ESG/Carbon markets, and broadening fixed-income execution. ICE isn’t just the house, it’s building new casinos in adjacencies where it can transplant its model.

MarketAxess (MKTX): Network Effects in Bond Trading

• Moat: MKTX’s moat is its liquidity network. By pioneering all-to-all credit trading, it became the natural venue where dealers and asset managers meet. Liquidity attracts liquidity, once open interest builds, switching costs are high because clients need depth, not just low fees. The platform is also a data monopoly in certain bonds: its pricing feeds are embedded across buy-side risk systems.

• Why it’s “own the casino”: MKTX doesn’t take bond risk; it skims a commission on every match. It benefits from the structural electronification of a $30T+ market that is still <50% electronic. As volumes migrate, MKTX’s “take rate” applies to a growing pie. The house here is the digital bond pit, the more players enter, the more indispensable MKTX becomes.

• Growth opportunity: Expansion in portfolio trading (bond baskets), emerging markets, and Treasuries. Each adds a new “game” to the casino, widening its rake. Its data and post-trade services reinforce stickiness, giving MKTX multiple ways to monetize participants.

IG Group (IGG LN): The Retail Trading House

• Moat: IG benefits from regulatory licenses, risk management systems, and brand scale that are hard for new entrants to replicate. Its moat is statistical: most retail CFD and spread-bet traders lose money over time, but IG earns consistently from spreads, financing charges, and fees. Its technology stack and global licenses (20+ jurisdictions) create both barriers and trust.

• Why it’s “own the casino”: IG is the literal casino in retail trading. It prices the tables (spreads), sets leverage caps, and manages risk. While some clients win occasionally, the aggregate flow reliably yields profits. Like a sportsbook or poker room, IG always takes its cut, and its risk systems hedge outliers.

• Growth opportunity: Expanding in the U.S. (tastytrade options), onboarding younger equity investors via Freetrade, and upselling them into leveraged products. More games, more players, same house edge.

iFAST (IFAST SP): AUA-Based Fee Machine

• Moat: iFAST’s moat is recurring AUA-based fees and sticky advisor relationships. Once assets are custodied on iFAST, moving them is cumbersome for advisors and clients. Its pension administration (Hong Kong ePension) locks in decades-long contracts. The platform also now embeds a digital bank, capturing cash balances with regulatory protection.

• Why it’s “own the casino”: iFAST is the casino cage, every dollar of client assets generates a predictable “cut” via platform fees and fund trailers. Whether clients gain or lose on investments, iFAST earns the toll on custody, admin, and services. With pensions and banking, it extends this edge deeper into the financial stack.

• Growth opportunity: Scaling Asian wealth flows, leveraging the HK ePension mandate, and building banking into a second profit engine. As more chips sit in the cage, iFAST automatically takes its cut.

Monex Group (8698 JP): Brokerage with Crypto Optionality

• Moat: Monex has a diversified brokerage base in Japan/US and a stake in crypto exchange Coincheck. Its moat comes from licenses, existing client relationships, and distribution partnerships (e.g. NTT Docomo). While crypto revenues are cyclical, Monex’s traditional brokerage provides a stable fee floor.

• Why it’s “own the casino”: Monex collects fees on retail stock trades, FX trades, and crypto activity. Especially in crypto, where most retail traders churn capital, Coincheck’s fee rake is textbook “house” economics. Monex itself doesn’t gamble on direction; it earns whether the client wins or loses.

• Growth opportunity: Upside comes if crypto trading volumes rebound. A new bull cycle would dramatically lift Coincheck, giving Monex a high-beta boost layered on top of stable brokerage rake.

Common Traits Across the Basket

• They sell shovels in a gold rush: volume, activity, or AUA expansion = higher fees, regardless of client outcome.

• Structural moats: network effects (MKTX), regulatory licenses (IG, ICE, Monex), sticky platforms (iFAST).

• Growth by adding new tables to the casino: new asset classes, new geographies, adjacent workflows.

• Defensive compounding: high margins, recurring revenue, strong cash returns.

Bonus: On-Chain “Casinos”: HYPE & CARDS

• HYPE (Hyperliquid): A perp DEX where ~97% of fees are recycled into daily token buybacks. Trader fees and losses become permanent buy pressure, making HYPE a direct claim on the casino rake. What’s amazing is this trades at a low single digit (currently 4x) supply weighted P/E.

When you look at net trader P&L the thesis becomes obvious: most gamblers lose, so own the casino:

• CARDS (Collector Crypt): A gacha model for Pokémon cards. Players sell back pulls at 85–90% of value; the 10–15% spread is the house edge used to buy/burn CARDS tokens. Player “losses” are systematically funneled into tokenholder gains.

  • For a thorough writeup on this token I recommend you read this piece by 0xKyle:

    0xKyle's Research

    TCGs & Collector Crypt

    First things first - some disclaimers…

    Read more

    7 months ago · 9 likes · 2 comments · 0xkyle

Both mirror the equities: activity → protocol rake → owner returns.

The risk: crypto cycles and regulatory scrutiny.
The lesson: whether regulated exchanges or on-chain casinos, the house wins.

Conclusion

Owning this basket means owning the economic infrastructure of speculation. Each company has a defensible moat ensuring it can keep charging fees, and clear growth vectors to expand its rake. In equities, bonds, retail trading, or crypto, the gambler may lose, but the house always collects.

Disclaimer:
Ridire Research is an independent research publication operated by Ridire Research LLC and affiliated with a private fund, an Exempt Reporting Adviser under the U.S. Investment Advisers Act of 1940. Ridire Research is not registered as an investment adviser and does not provide personalized investment, legal, accounting, or tax advice.

Informational & Educational Purpose Only

All materials—including text, charts, model portfolios, and explicit labels such as “Buy,” “Sell,” “Hold,” “Long,” or “Short”—are published solely for general informational and educational purposes. They reflect the author’s views at the time of writing, derived from publicly available data, proprietary frameworks, and market analysis, and are not tailored to any reader’s specific objectives, financial situation, or risk tolerance. Subscription to this Substack does not create an adviser–client relationship with the affiliated private fund or its principals.

No Offer or Solicitation

Nothing herein constitutes (i) an offer to sell or the solicitation of an offer to buy any security or other instrument, (ii) a recommendation to participate in any investment strategy, or (iii) a solicitation for investment advisory services. Any references to trades, allocations, or vehicles should be viewed as hypothetical model illustrations only. Offers, if ever made, will be made solely by confidential offering documents and only to qualified investors in jurisdictions where permitted.

Potential Conflicts of Interest

The affiliated private fund, its affiliates, employees, and related accounts may hold, increase, decrease, initiate, or exit positions, long or short, in securities or digital assets discussed, without notice or obligation to update disclosures. Such positions may be inconsistent with views expressed in this publication. The affiliated private fund, related entities, and personnel may initiate, modify, or exit positions in any mentioned security before or after publication without further notice. We maintain internal policies, including trading blackout windows and conflict reviews, to mitigate potential conflicts of interest.

Accuracy & Forward-Looking Statements

Although we strive for accuracy and analytical rigor, information may become outdated and may contain errors or omissions. Forward-looking statements, projections, or target prices are inherently uncertain and may differ materially from actual results. No warranty, express or implied, is given as to completeness, accuracy, or reliability.

Risk Acknowledgment

Investing involves substantial risk, including the potential for complete loss of capital. Past performance, whether actual, indicated by back-tests, or modeled, is not indicative of future results. Securities, derivatives, and digital assets mentioned may be illiquid, highly volatile, or subject to regulatory change.

Reader Responsibility

Readers should conduct their own due diligence, consider their personal circumstances, and consult a licensed financial professional before acting on any information contained herein. By reading this publication you agree that Ridire Research LLC, the affiliated private fund, and their affiliates accept no liability for any direct or consequential loss arising from reliance on the information presented. This research is not directed at persons in jurisdictions where such distribution would be contrary to local law.

Structure, Sizing and Basket Chart

• Long leg: OTEX CN (0.25%), KD (0.25%), DOX (0.25%), CGY CN (0.25%) = +1.00% gross

• Short leg: SNOW (-0.25%), CNDT (-0.25%), CVO CN (-0.25%), IAS (-0.25%) = -1.00% gross

Why We’re Long

• OTEX: Cloud bookings +32%, EBITDA margin 34.5%, record $683M capital return. Dividend +5%, buybacks active, durable ARR and TSR support.

• KD: EBITDA up 16% YoY, $725M annualized savings from automation, shifting to higher-margin scopes. Cheap EV/EBITDA with active buyback.

• DOX: $4.15B 12-month backlog (+3% cc), double-digit TSR target, deep Tier-1 telco integration.

• CGY: $1.5B+ backlog, 61% recurring revenue, ~80% FCF conversion. Guidance withdrawal sets up re-rate if execution holds.

Why We’re Short

• SNOW: FY26 product revenue guide $4.325B, NRR now 124% vs prior highs. EV/S ~17x, priced for perfection.

• CNDT: Revenue –9% YoY, EBITDA margin 5%, –$30M FCF. Structural ceiling on margins.

• CVO: FY25 revenue +6%, partner-dependent growth; strong GM (79–82%) but modest scale.

• IAS: 35% margin with raised guidance, but tied to ad-spend cycles.

The Trade Setup

• Longs: High-quality cash flow, backlog/ARR visibility, capital return, single-digit to low-teens EV/EBITDA.

• Shorts: Cyclical or valuation-stretched, thin margins, or platform dependence.

• Catalysts: KD margin expansion, OTEX cloud ramp, DOX backlog conversion vs. SNOW multiple risk, CNDT cash burn, and CVO/IAS cyclicality.

Conclusion

This is a spread trade on quality and valuation, long defensive compounders that can grind higher on earnings and buybacks, short names where expectations are stretched or structural issues limit upside. The valuation gap is wide and fundamentals are diverging.

Disclaimer:
Ridire Research is an independent research publication operated by Ridire Research LLC and affiliated with a private fund, an Exempt Reporting Adviser under the U.S. Investment Advisers Act of 1940. Ridire Research is not registered as an investment adviser and does not provide personalized investment, legal, accounting, or tax advice.

Informational & Educational Purpose Only

All materials—including text, charts, model portfolios, and explicit labels such as “Buy,” “Sell,” “Hold,” “Long,” or “Short”—are published solely for general informational and educational purposes. They reflect the author’s views at the time of writing, derived from publicly available data, proprietary frameworks, and market analysis, and are not tailored to any reader’s specific objectives, financial situation, or risk tolerance. Subscription to this Substack does not create an adviser–client relationship with the affiliated private fund or its principals.

No Offer or Solicitation

Nothing herein constitutes (i) an offer to sell or the solicitation of an offer to buy any security or other instrument, (ii) a recommendation to participate in any investment strategy, or (iii) a solicitation for investment advisory services. Any references to trades, allocations, or vehicles should be viewed as hypothetical model illustrations only. Offers, if ever made, will be made solely by confidential offering documents and only to qualified investors in jurisdictions where permitted.

Potential Conflicts of Interest

The affiliated private fund, its affiliates, employees, and related accounts may hold, increase, decrease, initiate, or exit positions, long or short, in securities or digital assets discussed, without notice or obligation to update disclosures. Such positions may be inconsistent with views expressed in this publication. The affiliated private fund, related entities, and personnel may initiate, modify, or exit positions in any mentioned security before or after publication without further notice. We maintain internal policies, including trading blackout windows and conflict reviews, to mitigate potential conflicts of interest.

Accuracy & Forward-Looking Statements

Although we strive for accuracy and analytical rigor, information may become outdated and may contain errors or omissions. Forward-looking statements, projections, or target prices are inherently uncertain and may differ materially from actual results. No warranty, express or implied, is given as to completeness, accuracy, or reliability.

Risk Acknowledgment

Investing involves substantial risk, including the potential for complete loss of capital. Past performance, whether actual, indicated by back-tests, or modeled, is not indicative of future results. Securities, derivatives, and digital assets mentioned may be illiquid, highly volatile, or subject to regulatory change.

Reader Responsibility

Readers should conduct their own due diligence, consider their personal circumstances, and consult a licensed financial professional before acting on any information contained herein. By reading this publication you agree that Ridire Research LLC, the affiliated private fund, and their affiliates accept no liability for any direct or consequential loss arising from reliance on the information presented. This research is not directed at persons in jurisdictions where such distribution would be contrary to local law.

Table of Contents

• Model Portfolio Action

• Company Profiles & Context

• Investment Thesis

• Growth & Moat Analysis

• Conclusion

Model Portfolio Action

Long Side (1% portfolio allocation, 0.33% each): Oddity Tech (ODD US), Beiersdorf AG (BEI GY) and Milbon Co. (4919 JT).

Short Side (-1% portfolio weight): Estée Lauder (EL US).

Company Profiles

Oddity Tech (ODD) — an Israeli-US digital beauty platform that owns IL MAKIAGE and SpoiledChild. Everything sells 100% direct-to-consumer, allowing Oddity to own 40m first-party consumer profiles and a training set of 1bn+ skin images. Q225 revenue reached $268m (+27% YoY) and H1 cash flow hit $99m.